<SEC-DOCUMENT>0001628280-23-013558.txt : 20230427
<SEC-HEADER>0001628280-23-013558.hdr.sgml : 20230427
<ACCEPTANCE-DATETIME>20230427160036
ACCESSION NUMBER:		0001628280-23-013558
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		15
FILED AS OF DATE:		20230427
DATE AS OF CHANGE:		20230427

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cardiff Oncology, Inc.
		CENTRAL INDEX KEY:			0001213037
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				272004382
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35558
		FILM NUMBER:		23856570

	BUSINESS ADDRESS:	
		STREET 1:		11055 FLINTKOTE AVENUE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-952-7570

	MAIL ADDRESS:	
		STREET 1:		11055 FLINTKOTE AVENUE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Trovagene, Inc.
		DATE OF NAME CHANGE:	20130304

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TrovaGene Inc.
		DATE OF NAME CHANGE:	20110830

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XENOMICS INC
		DATE OF NAME CHANGE:	20040719
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>crdf-20230427.htm
<DESCRIPTION>DEF 14A
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:d60d8c77-ec40-464e-a25d-a3547cb6d562,g:838ee74e-ea21-4773-8d7d-e22a95cb2f30,d:6eaaaa0344f74a9caae5f17960d0edec--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2022q4" xmlns:crdf="http://www.cardiffoncology.com/20230427" xmlns:ecd="http://xbrl.sec.gov/ecd/2022q4" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>crdf-20230427</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ie01d1de15b9444b183272d5953f012c0_D20220101-20221231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NTYvZnJhZzpmNWMwYTdiY2YxNTM0NjNmOTZkZDY5YzYyOWZkZjIxZC90YWJsZTphNDNhNmExNWZhN2Q0OGVlYjBlNWI3OTMwZTg3MDliNC90YWJsZXJhbmdlOmE0M2E2YTE1ZmE3ZDQ4ZWViMGU1Yjc5MzBlODcwOWI0XzItMS0xLTEtNDc3NTc_ce97fa7d-e0be-4805-b3cf-f1f9012d1ce4">0001213037</ix:nonNumeric><ix:nonNumeric contextRef="ie01d1de15b9444b183272d5953f012c0_D20220101-20221231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NTYvZnJhZzpmNWMwYTdiY2YxNTM0NjNmOTZkZDY5YzYyOWZkZjIxZC90YWJsZTphNDNhNmExNWZhN2Q0OGVlYjBlNWI3OTMwZTg3MDliNC90YWJsZXJhbmdlOmE0M2E2YTE1ZmE3ZDQ4ZWViMGU1Yjc5MzBlODcwOWI0XzMtMS0xLTEtNDc3NTc_8a1cc244-3da2-40b4-89c9-02063ad0b5ee">DEF 14A</ix:nonNumeric><ix:nonNumeric contextRef="ie01d1de15b9444b183272d5953f012c0_D20220101-20221231" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NTYvZnJhZzpmNWMwYTdiY2YxNTM0NjNmOTZkZDY5YzYyOWZkZjIxZC90YWJsZTphNDNhNmExNWZhN2Q0OGVlYjBlNWI3OTMwZTg3MDliNC90YWJsZXJhbmdlOmE0M2E2YTE1ZmE3ZDQ4ZWViMGU1Yjc5MzBlODcwOWI0XzQtMS0xLTEtNDc3NTc_0b590f9d-8e90-436a-a5c3-b7b8da117087">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="crdf-20230427.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ie01d1de15b9444b183272d5953f012c0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i162e015e217c4d45bddc31b5744d6c17_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6c039ead809495cae54a5ab4e87a488_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:DeductionForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f35b7ba98ca4879b389a1204541bc1f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:DeductionForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i808f413dd8bd4a038c815bd31cf674bb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:DeductionForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67ff1600b4c246b2ab359a056db81b0a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:DeductionForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86619fe2a4904a08839c9a77d4598f63_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:IncreasedecreaseForTheInclusionOfRule402vEquityValuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icafd16b4fdca433ab80e693f2728fc6c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:IncreasedecreaseForTheInclusionOfRule402vEquityValuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i099dab0c3dfb4ba08b9f1e8273c73b43_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:IncreasedecreaseForTheInclusionOfRule402vEquityValuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48bde130657f4d60a3c8729859ad4a54_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:IncreasedecreaseForTheInclusionOfRule402vEquityValuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia69205d3273d42cfa5b47e45431f4273_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:EquityAwardsYearEndFairValueOfEquityAwardsGrantedDuringYearThatRemainedUnvestedAsOfLastDayOfYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i222ba39e2bff496a82ec7ce575a3569c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:EquityAwardsYearEndFairValueOfEquityAwardsGrantedDuringYearThatRemainedUnvestedAsOfLastDayOfYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa076cb47d104183826cd32c0caf6c74_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:EquityAwardsYearEndFairValueOfEquityAwardsGrantedDuringYearThatRemainedUnvestedAsOfLastDayOfYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1374971d2a224cd48aec91e78ac8bd8b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:EquityAwardsYearEndFairValueOfEquityAwardsGrantedDuringYearThatRemainedUnvestedAsOfLastDayOfYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bcd6aa3ae8a4718aaa3527feb1a9750_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:EquityAwardsChangeInFairValueFromLastDayOfPriorYearToLastDayOfYearOfUnvestedEquityAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacbe2ef0043b41eca3c977825b71bcc7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:EquityAwardsChangeInFairValueFromLastDayOfPriorYearToLastDayOfYearOfUnvestedEquityAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6423de9d56142b9894e5e2217b5c134_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:EquityAwardsChangeInFairValueFromLastDayOfPriorYearToLastDayOfYearOfUnvestedEquityAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia51f311be92445049c84ed71423fc1ac_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:EquityAwardsChangeInFairValueFromLastDayOfPriorYearToLastDayOfYearOfUnvestedEquityAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4757a2404ced49b79c5f7734d44d691d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:EquityAwardsAddAwardsThatAreGrantedAndVestInTheSameYearTheFairValueAsOfTheVestingDateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i424d110c9c7447cf8d86db48ddc56f09_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:EquityAwardsAddAwardsThatAreGrantedAndVestInTheSameYearTheFairValueAsOfTheVestingDateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac46fe9783ba4350948ac1b50c0f82e8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:EquityAwardsAddAwardsThatAreGrantedAndVestInTheSameYearTheFairValueAsOfTheVestingDateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b2e7c637d8641d0ab07136fac2ce541_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:EquityAwardsAddAwardsThatAreGrantedAndVestInTheSameYearTheFairValueAsOfTheVestingDateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6097bc48663442fa8090165e5ebaafcf_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:EquityAwardsChangeInFairValueOfPriorYearsEquityAwardsThatVestedDuringTheYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56212971324f4fd1bdfe65dd27e611ab_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:EquityAwardsChangeInFairValueOfPriorYearsEquityAwardsThatVestedDuringTheYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i388d394b3cb749cca54ab1a0e0ad8209_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:EquityAwardsChangeInFairValueOfPriorYearsEquityAwardsThatVestedDuringTheYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35341a6be28048239380a00aa3e164a4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:EquityAwardsChangeInFairValueOfPriorYearsEquityAwardsThatVestedDuringTheYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c34c7e022294fe4aeb274e2e44b75ef_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:EquityAwardsChangeInValueOfPriorYearsEquityAwardsThatForfeitedDuringTheYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d89663085a84502b34c2da05d99e96e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:EquityAwardsChangeInValueOfPriorYearsEquityAwardsThatForfeitedDuringTheYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i101ba4e616204ee3a06df10ad6050ef9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:EquityAwardsChangeInValueOfPriorYearsEquityAwardsThatForfeitedDuringTheYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18bc58d898e84d1cae4dc8e8325704b9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:EquityAwardsChangeInValueOfPriorYearsEquityAwardsThatForfeitedDuringTheYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i6eaaaa0344f74a9caae5f17960d0edec_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:115%">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Washington, D.C. 20549</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:115%">SCHEDULE 14A</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.     )</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.399%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Filed by the Registrant x</span></div></td></tr><tr style="height:11pt"><td colspan="12" style="padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Filed by a Party other than the Registrant o</span></div></td></tr><tr style="height:11pt"><td colspan="12" style="padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Check the appropriate box:</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%">o</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Preliminary Proxy Statement</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%">o</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%">x</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Definitive Proxy Statement</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%">o</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Definitive Additional Materials</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%">o</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Soliciting Material under &#167;240.14a-12</span></div></td></tr><tr style="height:9pt"><td colspan="12" style="padding:0 1pt"></td></tr><tr><td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="ie01d1de15b9444b183272d5953f012c0_D20220101-20221231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY18xL2ZyYWc6ZmFlMDAwMGQ3YzNiNGYxY2EwNjg0NmMwMjIxOTBhN2QvdGFibGU6NjllOWYyZWZiYTExNDhiZGE0MTIxNWYwMDQ4YTAwYjEvdGFibGVyYW5nZTo2OWU5ZjJlZmJhMTE0OGJkYTQxMjE1ZjAwNDhhMDBiMV8xMS0wLTEtMS00Nzc1OQ_90969a3e-be7a-408c-98fa-d8f25972d094">Cardiff Oncology, Inc.</ix:nonNumeric></span></div></td></tr><tr><td colspan="12" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Name of Registrant as Specified In Its Charter)</span></div></td></tr><tr style="height:9pt"><td colspan="12" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="12" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="12" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Name of Person(s) Filing Proxy Statement, if other than the Registrant)</span></div></td></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Payment of Filing Fee (Check the appropriate box):</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%">x</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">No fee required.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%">o</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Title of each class of securities to which transaction applies:</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Aggregate number of securities to which transaction applies:</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(3)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(4)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Proposed maximum aggregate value of transaction:</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(5)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total fee paid:</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%">o</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fee paid previously with preliminary materials.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%">o</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1)</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amount Previously Paid:</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2)</span></div></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Form, Schedule or Registration Statement No.:</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(3)</span></div></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Filing Party:</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(4)</span></div></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date Filed:</span></div></td></tr></table></div><div id="i6eaaaa0344f74a9caae5f17960d0edec_4"></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Cardiff Oncology, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">11055 Flintkote Avenue</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">San Diego, CA 92121</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">NOTICE OF ANNUAL MEETING OF STOCKHOLDERS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">To Be Held on June 15, 2023</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dear Stockholder:</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are pleased to invite you to attend the annual meeting of stockholders (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Annual Meeting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;) of Cardiff Oncology, Inc. (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Cardiff</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; or the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;), which will be held on June 15, 2023 at 9:00 a.m. local time at our offices, located at 11055 Flintkote Avenue, San Diego, CA 92121, for the following purposes:</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1. To elect seven (7) members to our Board of Directors;</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2. To ratify the appointment of BDO USA, LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2023;</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3. To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers;</span></div><div style="text-align:justify;text-indent:48.95pt"><span><br/></span></div><div style="text-align:justify;text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4. To approve, on an advisory basis, the compensation of the Company&#8217;s named executive officers; and</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5. To transact such other matters as may properly come before the Annual Meeting and any adjournment or postponement thereof.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cardiff Oncology's Board of Directors has fixed the close of business on April 24, 2023 as the record date for a determination of stockholders entitled to notice of, and to vote at, the Annual Meeting or any adjournment or postponement thereof.</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">If You Plan to Attend</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Please note that space limitations make it necessary to limit attendance of the Annual Meeting to our stockholders. Registration and seating will begin at 8:30 a.m. Shares of common stock can be voted at the Annual Meeting only if the holder thereof is present in person or by valid proxy.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For admission to the Annual Meeting, each stockholder may be asked to present valid picture identification, such as a driver&#8217;s license or passport, and proof of stock ownership as of the record date, such as the enclosed proxy card or a brokerage statement reflecting stock ownership. Cameras, recording devices and other electronic devices will not be permitted at the Annual Meeting. If you do not plan on attending the Annual Meeting, please vote, date and sign the enclosed proxy and return it in the business envelope provided. Even if you do plan to attend the Annual Meeting, we recommend that you vote your shares at your earliest convenience in order to ensure your representation at the Annual Meeting. Your vote is very important.</span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">If you have any questions or need assistance voting your shares, please call Kingsdale Advisors at:</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Strategic Shareholder Advisor and Proxy Solicitation Agent</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">745 Fifth Avenue, 5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Floor, New York, NY 10151</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">North American Toll Free Phone:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1-(866)-581-1514</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Email: contactus@kingsdaleadvisors.com</span></div><div style="text-align:center;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Call Collect Outside North America: +1 (917) 722-1504</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting to Be Held on June 15, 2023 at 9:00 a.m. local time at 11055 Flintkote Avenue, San Diego, CA 92121.</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The proxy statement and annual report to stockholders are available at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">http://www.annualgeneralmeetings.com/crdf2023.</span></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"><tr><td style="width:1.0%"></td><td style="width:62.806%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By the Order of the Board of Directors</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ Dr. Rodney S. Markin MD, Ph.D.</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dr. Rodney S. Markin MD, Ph.D.</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Chairman of the Board of Directors</span></div></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dated: April 27, 2023</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Whether or not you expect to attend the Annual Meeting in person, we urge you to vote your shares at your earliest convenience. This will ensure the presence of a quorum at the Annual Meeting. Promptly voting your shares will save Cardiff Oncology the expenses and extra work of additional solicitation. An addressed envelope for which no postage is required if mailed in the United States is enclosed if you wish to vote by mail. Submitting your proxy now will not prevent you from voting your shares at the Annual Meeting if you desire to do so, as your proxy is revocable at your option. Your vote is important, so please act today!</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i6eaaaa0344f74a9caae5f17960d0edec_463"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:87.755%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.045%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_10">CORPORATE GOVERNANCE STANDARDS AND DIRECTOR INDEPENDENCE</a></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_10">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_13">PROPOSAL 1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_13">: </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_13">ELECTION OF DIRECTORS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_13">13</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_46">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_46"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_46">AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_46">18</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_49">PROPOSAL</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_49"> 2: </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_49">RATIFICATION OF THE APPOINTMENT OF OUR INDEPENDENT</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_49"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_49">REGISTERED PUBLIC ACCOUNTING FIRM FOR FISCAL YEAR ENDING</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_49"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_49">DECEMBER 31, 2023</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_49">19</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_478">PROPOSAL 3: ADVISORY VOTE ON THE FREQUENCY OF HOLDING AN ADVISORY VOTE ON EXECUTIVE COMPENSATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_478">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_64">PROPOSAL 4: APPROVAL OF THE COMPENSATION OF THE NAMED EXECUTIVE OFFICERS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_64">23</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_28">EXECUTIVE COMPENSATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_28">24</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_451">SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_451">41</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_67">TRANSACTIONS WITH RELATED PERSONS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_67">41</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_70">OTHER MATTERS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_70">42</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_73">ADDITIONAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_73">42</a></span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_463">Table of Contents</a></span></div></div><div><span><br/></span></div><div id="i6eaaaa0344f74a9caae5f17960d0edec_7"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cardiff Oncology, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11055 FLINTKOTE AVENUE</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">SAN DIEGO, CA 92121</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">PROXY STATEMENT FOR THE</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023 ANNUAL MEETING OF STOCKHOLDERS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">TO BE HELD ON JUNE 15, 2023</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Board of Directors (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Board</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;) of Cardiff Oncology, Inc. (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Cardiff</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; or the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;) is soliciting your proxy to vote at the Annual Meeting of Stockholders (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Annual Meeting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;) to be held at our offices, located at 11055 Flintkote Avenue, San Diego, CA 92121, on June 15, 2023, at 9:00 a.m. local time, including at any adjournments or postponements of the Annual Meeting. You are invited to attend the Annual Meeting to vote on the proposals described in this proxy statement. However, you do not need to attend the Annual Meeting to vote your shares. Instead, you may simply complete, sign and return the enclosed proxy card if you received paper copies of the proxy materials, or follow the instructions below to submit your proxy over the Internet.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In accordance with rules and regulations adopted by the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;), we have elected to provide our beneficial owners and stockholders of record access to our proxy materials over the Internet. Beneficial owners are stockholders whose shares of our common stock are held in the name of a broker, bank or other agent (i.e., in &#8220;street name&#8221;). Accordingly, a Notice of Internet Availability of Proxy Materials (the &#8220;Notice&#8221;) will be mailed on or about May 1, 2023 to our beneficial owners and stockholders of record who owned our common stock at the close of business on April 24, 2023. Beneficial owners and stockholders of record will have the ability to access the proxy materials on a website referred to in the Notice or request that a printed set of the proxy materials be sent to them by following the instructions in the Notice. Beneficial owners and stockholders of record who have previously requested to receive paper copies of our proxy materials will receive paper copies of the proxy materials instead of a Notice.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">QUESTIONS AND ANSWERS ABOUT THIS PROXY MATERIAL AND VOTING</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Why did I Receive a Notice of Internet Availability of Proxy Materials in the Mail instead of a Full Set of Proxy Materials?</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are pleased to take advantage of the SEC rule that allows companies to furnish their proxy materials over the Internet. Accordingly, we have sent to our stockholders of record a Notice of Internet Availability of Proxy Materials. Instructions on how to access the proxy materials over the Internet free of charge or to request a paper copy may be found in the Notice. Our stockholders may request to receive proxy materials in printed form by mail or electronically on an ongoing basis. A stockholder&#8217;s election to receive proxy materials by mail or electronically will remain in effect until the stockholder changes the stockholder&#8217;s election.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">What Does it Mean if I Receive More than One Notice?</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If you receive more than one Notice, your shares may be registered in more than one name or in different accounts. Please follow the voting instructions on each Notice to ensure that all of your shares are voted.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">How do I attend the Annual Meeting?</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Annual Meeting will be held on June 15, 2023, at 9:00 a.m. local time at our offices, located at 11055 Flintkote Avenue, San Diego, CA 92121. Directions to the Annual Meeting may be found at the back of this Proxy Statement. Information on how to vote in person at the Annual Meeting is discussed below.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Who May Attend the Annual Meeting?</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Only record holders and beneficial owners of our common stock, or their duly authorized proxies, may attend the Annual Meeting. If your shares of common stock are held in street name, you will need to bring a copy of a brokerage statement or other documentation reflecting your stock ownership as of the Record Date.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Who is Entitled to Vote?</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_463">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Board has fixed the close of business on April&#160;24, 2023 as the record date (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Record Date</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;) for the determination of stockholders entitled to notice of, and to vote at, the Annual Meeting or any adjournment or postponement thereof. On the Record Date, there were 44,677,169 shares of common stock outstanding. Each share of common stock represents one vote that may be voted on each proposal that may come before the Annual Meeting.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">What is the Difference Between Holding Shares as a Record Holder and as a Beneficial Owner (Holding Shares in Street Name)?</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If your shares are registered in your name with our transfer agent, Pacific Stock Transfer Company, you are the &#8220;record holder&#8221; of those shares. If you are a record holder, these proxy materials have been provided directly to you by the Company.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If your shares are held in a stock brokerage account, a bank or other holder of record, you are considered the &#8220;beneficial owner&#8221; of those shares held in &#8220;street name.&#8221; If your shares are held in street name, these proxy materials have been forwarded to you by that organization. The organization holding your account is considered to be the stockholder of record for purposes of voting at the Annual Meeting. As the beneficial owner, you have the right to instruct this organization on how to vote your shares.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">What am I Voting on?</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There are four (4) matters scheduled for a vote:</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1. To elect seven (7) members to our Board of Directors;</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2. To ratify the appointment of BDO USA, LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2023; </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3. To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers; and</span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4. To approve, on an advisory basis, the compensation of the Company's named executive officers.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">What if another matter is properly brought before the Annual Meeting?</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Board knows of no other matters that will be presented for consideration at the Annual Meeting. If any other matters are properly brought before the Annual Meeting, it is the intention of the persons named in the accompanying proxy to vote on those matters in accordance with their best judgment.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">How Do I Vote?</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Stockholders of Record</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For your convenience, record holders of our common stock have three methods of voting:</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Vote by Internet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The website address for Internet voting is on your proxy card.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Vote by mail</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Mark, date, sign and promptly mail the enclosed proxy card (a postage-paid envelope is provided for mailing in the United States).</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Vote in person</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Attend and vote at the Annual Meeting.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Beneficial Owners of Shares Held in Street Name</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For your convenience, beneficial owners of our common stock have three methods of voting:</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Vote by Internet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The website address for Internet voting is on your vote instruction form.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_463">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Vote by mail</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Mark, date, sign and promptly mail your vote instruction form (a postage-paid envelope is provided for mailing in the United States).</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Vote in person</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Obtain a valid legal proxy from the organization that holds your shares and attend and vote at the Annual Meeting.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If you vote by Internet, please DO NOT mail your proxy card.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All shares entitled to vote and represented by a properly completed and executed proxy received before the Annual Meeting and not revoked will be voted at the Annual Meeting as instructed in a proxy delivered before the Annual Meeting. If you do not indicate how your shares should be voted on a matter, the shares represented by your properly completed and executed proxy will be voted as the Board recommends on each of the enumerated proposals, with regard to any other matters that may be properly presented at the Annual Meeting and on all matters incident to the conduct of the Annual Meeting. If you are a registered stockholder and attend the Annual Meeting, you may deliver your completed proxy card in person. If you are a street name stockholder and wish to vote at the Annual Meeting, you will need to obtain a proxy form from the institution that holds your shares. All votes will be tabulated by the inspector of elections appointed for the Annual Meeting, who will separately tabulate affirmative and negative votes, abstentions and broker non-votes.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">We provide Internet proxy voting to allow you to vote your shares online, with procedures designed to ensure the authenticity and correctness of your proxy vote instructions. However, please be aware that you must bear any costs associated with your Internet access, such as usage charges from Internet access providers and telephone companies.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">How Many Votes do I Have?</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On each matter to be voted upon, you have one vote for each share of common stock you own as of the close of business on the Record Date.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Is My Vote Confidential?</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Yes, your vote is confidential. Only the inspector of elections, individuals who help with processing and counting your votes and persons who need access for legal reasons will have access to your vote. This information will not be disclosed, except as required by law.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">What Constitutes a Quorum?</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To carry on business at the Annual Meeting, we must have a quorum. A quorum is present when a majority of the shares entitled to vote as of the Record Date, are represented in person or by proxy. Thus, 22,083,585 shares must be represented in person or by proxy to have a quorum at the Annual Meeting. Your shares will be counted towards the quorum only if you submit a valid proxy (or one is submitted on your behalf by your broker, bank or other nominee) or if you vote in person at the Annual Meeting. Abstentions and broker non-votes will be counted towards the quorum requirement. Shares owned by us are not considered outstanding or considered to be present at the Annual Meeting. If there is not a quorum at the Annual Meeting, either the chairperson of the Annual Meeting or our stockholders entitled to vote at the Annual Meeting may adjourn the Annual Meeting.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">How Will my Shares be Voted if I Give No Specific Instruction?</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We must vote your shares as you have instructed. If there is a matter on which a stockholder of record has given no specific instruction but has authorized us generally to vote the shares, they will be voted as follows:</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1. &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">FOR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; the election of each of the seven (7) members to our Board of Directors;</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2. &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">FOR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; the ratification of the appointment of BDO USA, LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2023; </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3. &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">ONE YEAR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; for future, on an advisory basis, votes on the compensation of the Company's named executive officers; and</span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4. &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">FOR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; approval, on an advisory basis, of the compensation of the Company&#8217;s named executive officers.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_463">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This authorization would exist, for example, if a stockholder of record merely signs, dates and returns the proxy card but does not indicate how its shares are to be voted on one or more proposals. If other matters properly come before the Annual Meeting and you do not provide specific voting instructions, your shares will be voted at the discretion of the proxies.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If your shares are held in street name, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">What is a Broker Non-Vote</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">?&#8221; below regarding the ability of banks, brokers and other such holders of record to vote the uninstructed shares of their customers or other beneficial owners in their discretion.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">How are Votes Counted?</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Votes will be counted by the inspector of election appointed for the Annual Meeting, who will separately count, for the election of directors, &#8220;FOR,&#8221; &#8220;WITHHOLD&#8221; and broker non-votes; and, with respect to the other proposals, votes &#8220;FOR,&#8221; &#8220;AGAINST,&#8221; &#8220;ABSTAIN,&#8221; and broker non-votes.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">What is a Broker Non-Vote?</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If your shares are held in street name, you must instruct the organization who holds your shares how to vote your shares. If you sign your proxy card but do not provide instructions on how your broker should vote on &#8220;routine&#8221; proposals, your broker will vote your shares as recommended by the Board. If you do not provide voting instructions, your shares will not be voted on any &#8220;non-routine&#8221; proposals. This vote is called a &#8220;broker non-vote.&#8221; Because broker non-votes are not considered under Delaware law to be entitled to vote at the Annual Meeting, broker non-votes will not be included in the tabulation of the voting results of any of the proposals and, therefore, will have no effect on these proposals.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Brokers cannot use discretionary authority to vote shares on the election of directors if they have not received instructions from their clients. Please submit your vote instruction form so your vote is counted.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">What is an Abstention?</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">An abstention is a stockholder&#8217;s affirmative choice to decline to vote on a proposal. Under Delaware law, abstentions are counted as shares present and entitled to vote at the Annual Meeting. However, our By-Laws provide that an action of our stockholders (other than the election of directors) is only approved if a majority of the number of shares of stock present and entitled to vote thereat vote in favor of such action.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">How Many Votes are Needed for Each Proposal to Pass?</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.315%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.170%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Proposal</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Vote Required</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Election of each of the seven (7) members to our Board of Directors</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Plurality of the votes cast (the seven directors receiving the most &#8220;FOR&#8221; votes). Our Board of Directors, acting through the Corporate Governance/Nominating Committee, will make a determination whether or not to request the resignation of an incumbent director who failed to receive a majority of the vote cast. We will publicly disclose our Board of Directors' decision and reasoning.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Ratification of the Appointment of BDO USA, LLP as our Independent Registered Public Accounting Firm for our Fiscal Year Ending December 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A majority of the votes entitled to vote thereon and present at the Annual Meeting</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A majority of the votes entitled to vote thereon and present at the Annual Meeting</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Approval, on an advisory basis, of the compensation of the Company&#8217;s named executive officers</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A majority of the votes entitled to vote thereon and present at the Annual Meeting</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_463">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">What Are the Voting Procedures?</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In voting by proxy with regard to the election of directors, you may vote in favor of all nominees, withhold your votes as to all nominees, or withhold your votes as to specific nominees. With regard to other proposals, you may vote in favor of or against the proposal, or you may abstain from voting on the proposal. You should specify your respective choices on the accompanying proxy card or your vote instruction form.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Is My Proxy Revocable?</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">You may revoke your proxy and reclaim your right to vote at any time before your proxy is voted by giving written notice to the Secretary of Cardiff Oncology, by delivering a properly completed, later-dated proxy card or vote instruction form or by voting in person at the Annual Meeting. All written notices of revocation and other communications with respect to revocations of proxies should be addressed to: Cardiff Oncology, Inc., 11055 Flintkote Avenue, San Diego, CA 92121, Attention: Secretary, or by facsimile at 858-952-7571. Your most current proxy card or Internet proxy is the one that will be counted.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Who is Paying for the Expenses Involved in Preparing and Mailing this Proxy Statement?</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All of the expenses involved in preparing, assembling and mailing these proxy materials and all costs of soliciting proxies will be paid by us. In addition to the solicitation by mail, proxies may be solicited by our officers and other employees by telephone or in person. Such persons will receive no compensation for their services other than their regular salaries. Arrangements will also be made with brokerage houses and other custodians, nominees and fiduciaries to forward solicitation materials to the beneficial owners of the shares held of record by such persons, and we may reimburse such persons for reasonable out of pocket expenses incurred by them in forwarding solicitation materials. We have retained Kingsdale Advisors as our strategic shareholder advisor and proxy solicitation agent in connection with the solicitation of proxies for the Meeting. If you have any questions or require any assistance with completing your proxy, please contact Kingsdale Advisors by telephone (toll-free within North America) at 1-(866)-581-1514 or (call collect outside North America) at +1 (917)-722-1504 or by email at contactus@kingsdaleadvisors.com.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Do I Have Dissenters&#8217; Rights of Appraisal?</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our stockholders do not have appraisal rights under Delaware law or under our governing documents with respect to the matters to be voted upon at the Annual Meeting.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">How can I Find out the Results of the Voting at the Annual Meeting?</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Preliminary voting results will be announced at the Annual Meeting. In addition, final voting results will be disclosed in a Current Report on Form 8-K that we expect to file with the SEC within four business days after the Annual Meeting. If final voting results are not available to us in time to file a Form 8-K with the SEC within four business days after the Annual Meeting, we intend to file a Form 8-K to publish preliminary results and, within four business days after the final results are known to us, file an additional Form 8-K to publish the final results.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">When are Stockholder Proposals Due for the 2024 Annual Meeting?</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any appropriate proposal submitted by a stockholder and intended to be presented at the 2024 Annual Meeting of Stockholders (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024 Annual Meeting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) must be submitted in writing to our Secretary at 11055 Flintkote Avenue, San Diego, CA 92121, and received no later than December 26, 2023, to be includable in our proxy statement and related proxy for the 2024 Annual Meeting. However, if the date of the 2024 Annual Meeting is convened more than 30 days before, or delayed by more than 30 days after, June 15, 2024, to be considered for inclusion in proxy materials for our 2024 Annual Meeting, a stockholder proposal must be submitted in writing to our Secretary at 11055 Flintkote Avenue, San Diego, CA 92121, a reasonable time before we begin to print and send our proxy materials for the 2024 Annual Meeting. A stockholder proposal will need to comply with the SEC regulations under Rule 14a-8 of the Securities Exchange Act of 1934, as amended (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exchange Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), regarding the inclusion of stockholder proposals in company-sponsored proxy materials. Although the Board will consider stockholder proposals, we reserve the right to omit from our proxy statement, or to vote against, stockholder proposals that we are not required to include under the Exchange Act, including Rule 14a-8.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If you wish to submit a proposal that is not to be included in the proxy materials for the 2024 Annual Meeting, your proposal must be submitted in writing to our Secretary at 11055 Flintkote Avenue, San Diego, CA 92121 by December 26, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_463">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023. However, if the date of the 2024 Annual Meeting is convened more than 30 days before, or delayed by more than 30 days after, June 15, 2024, to be brought before our 2024 Annual Meeting, a stockholder proposal must be submitted in writing to the Company&#8217;s Secretary at 11055 Flintkote Avenue, San Diego, CA 92121, a reasonable time before we begin to print and send our proxy materials for the 2024 Annual Meeting.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Do the Company&#8217;s Officers and Directors have an Interest in Any of the Matters to Be Acted Upon at the Annual Meeting?</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Members of the Board have an interest in Proposal 1, the election to the Board of the seven (7) director nominees set forth herein. Members of the Board and executive officers of Cardiff Oncology do not have any interest in Proposal 2, the ratification of the appointment of our independent registered public accounting firm. Members of the Board and the executive officers of Cardiff Oncology do have an interest in Proposal 3, to the extent such proposal is on a non-binding advisory basis. Members of the Board and executive officers of Cardiff Oncology do have an interest in Proposal 4, to the extent such proposal is on a non-binding advisory basis.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div id="i6eaaaa0344f74a9caae5f17960d0edec_10"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CORPORATE GOVERNANCE STANDARDS AND DIRECTOR INDEPENDENCE</span></div><div style="text-align:center"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to good corporate governance practices. These practices provide an important framework within which our Board of Directors and management pursue our strategic objectives for the benefit of our stockholders.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Governance Guidelines</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors has adopted Corporate Governance Guidelines that set forth expectations for directors, director independence standards, Board committee structure and functions, and other policies for the governance of the company. Our Corporate Governance Guidelines are available without charge on the investor relations section of our website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.cardiffoncology.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Board Composition and Leadership Structure</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The positions of Chief Executive Officer and Chair of our Board of Directors are held by two different individuals (Dr. Mark Erlander and Dr. Rodney Markin, respectively). This structure allows our Chief Executive Officer </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to focus on our day-to-day business while our Chair leads our Board of Directors in its fundamental role of providing advice to and independent oversight of management. Our Board of Directors believes such separation is appropriate, as it enhances the accountability of the Chief Executive Officer to the Board of Directors and strengthens the independence of the Board of Directors from management.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Board&#8217;s Role in Risk Oversight</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors believes that open communication between management and the Board of Directors is essential for effective risk management and oversight. Our Board of Directors meets with our Chief Executive Officer and other members of the senior management team at quarterly Board of Director meetings, where, among other topics, they discuss strategy and risks in the context of reports from the management team and evaluate the risks inherent in significant transactions. While our Board of Directors is ultimately responsible for risk oversight, our Board committees assist the Board of Directors in fulfilling its oversight responsibilities in certain areas of risk. The Audit Committee assists our Board of Directors in fulfilling its oversight responsibilities with respect to risk management in the areas of major financial risk exposures, internal control over financial reporting, disclosure controls and procedures, legal and regulatory compliance and cybersecurity and data privacy. The Compensation Committee assists our Board of Directors in assessing risks created by the incentives inherent in our compensation policies. The Corporate Governance/Nominating Committee assists our Board of Directors in fulfilling its oversight responsibilities with respect to the management of corporate, legal and regulatory risk.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Director Independence</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is listed on the Nasdaq Capital Market. Under the rules of the Nasdaq Stock Market, independent directors must constitute a majority of a listed company&#8217;s Board of Directors. In addition, the rules of the Nasdaq Stock Market require that, subject to specified exceptions, each member of a listed company&#8217;s Audit, Compensation and Corporate Governance/Nominating Committees must be an &#8220;independent director.&#8221; Under the rules of the Nasdaq Stock Market, a director will only qualify as an &#8220;independent director&#8221; if, in the opinion of that company&#8217;s Board of Directors, that person does </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_463">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. Additionally, Compensation Committee members must not have a relationship with the listed company that is material to the director&#8217;s ability to be independent from management in connection with the duties of a Compensation Committee member.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Audit Committee members must also satisfy the independence criteria set forth in Rule 10A-3 under the Securities Exchange Act of 1934, as amended (Exchange Act). In order to be considered independent for purposes of Rule 10A-3, a member of an Audit Committee of a listed company may not, other than in his or her capacity as a member of the Audit Committee, the Board of Directors or any other Board committee: (i) accept, directly or indirectly, any consulting, advisory or other compensatory fee from the listed company or any of its subsidiaries or (ii) be an affiliated person of the listed company or any of its subsidiaries.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors has undertaken a review of the independence of each director and considered whether each director has a material relationship with us that could compromise his or her ability to exercise independent judgment in carrying out his or her responsibilities. As a result of this review, our Board of Directors determined that Drs. Armitage, Markin, Mohindru, Pace, Tannenbaum and Ms. White representing six of our seven incumbent directors, are &#8220;independent directors&#8221; as defined under the applicable rules and regulations of the SEC and the listing requirements and rules of the Nasdaq Stock Market. In making these determinations, our Board of Directors reviewed and discussed information provided by the directors and us with regard to each directors&#8217; business and personal activities and relationships as they may relate to us and our management, including the beneficial ownership of our capital stock by each non-employee director and any affiliates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Committee of our Board of Directors</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors has established an Audit Committee, a Compensation Committee and a Corporate Governance/Nominating Committee, each of which has the composition and responsibilities described below. Members serve on these committees until their resignation or until otherwise determined by our Board of Directors. Each of these committees has a written charter, copies of which are available without charge on our website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">http://cardiffoncology.investorroom.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/ under &#8220;Corporate Governance'</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Audit Committee</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee&#8217;s responsibilities include, among other things: </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">selecting and retaining an independent registered public accounting firm to act as our independent auditors, setting the compensation for our independent auditors, overseeing the work done by our independent auditors and terminating our independent auditors, if necessary; </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">periodically evaluating the qualifications, performance and independence of our independent auditors; </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pre-approving all auditing and permitted non-audit services to be provided by our independent auditors; </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing with management and our independent auditors our annual audited financial statements and our quarterly reports prior to filing such reports with the SEC, including the results of our independent auditors&#8217; review of our quarterly financial statements; </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing with management and our independent auditors significant financial reporting issues and judgments made in connection with the preparation of our financial statements; and </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">review the processes utilized by management for identifying, evaluating, and mitigating strategic, financial, operational, regulatory, and external risks inherent in the Company&#8217;s business, including but not limited to, cybersecurity. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee also prepares the Audit Committee report that is required to be included in our annual proxy statement pursuant to the rules of the SEC.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Audit Committee consisted of L&#226;le White, chair of the Audit Committee, Dr. Rodney S. Markin and Dr. Mani Mohindru. Under the applicable rules and regulations of Nasdaq, each member of a company&#8217;s audit committee must be considered independent in accordance with Nasdaq Listing Rule 5605(c)(2)(A)(i) and (ii) and Rule 10A-3(b)(1) under the Exchange Act. The Board has determined that all of the members are &#8220;independent&#8221; as that term is defined under applicable Nasdaq and SEC rules. Ms. White is our audit committee financial expert. </span></div><div><span><br/></span></div><div><span id="i623122299d3d48bc9cd79b7029019f79_43537"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation Committee</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purpose of the Compensation Committee is to discharge the Board&#8217;s responsibilities relating to compensation of our directors and executive officers. The Compensation Committee has responsibility for, among other things: </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_463">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recommending to the Board for approval the overall compensation philosophy for our company and periodically reviewing the overall compensation philosophy for all employees to ensure it is appropriate and does not incentivize unnecessary and excessive risk taking; </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing annually and making recommendations to the Board for approval, as necessary or appropriate, with respect to our compensation plans;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">based on an annual review, determining and approving, or at the discretion of the Compensation Committee, recommending to the Board for determination and approval, the compensation and other terms of employment of each of our officers;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing and making recommendations to the Board with respect to the compensation of directors;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing feedback from our shareholders and engaging with shareholders on as needed basis;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">overseeing our regulatory compliance with respect to compensation matters;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing and discussing with management, prior to the filing of our annual proxy statement or annual report on Form 10-K, our disclosure relating to executive compensation, including our executive and director compensation tables as required by SEC rules and, if required, our Compensation Discussion and Analysis; and</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preparing any required annual report regarding executive compensation for inclusion in our annual proxy statement or our annual report on Form 10-K. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee has the power to form one or more subcommittees, each of which may take such actions as may be delegated by the Compensation Committee.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The charter of the Compensation Committee grants the Compensation Committee authority to select, retain, compensate, oversee and terminate any compensation consultant to be used to assist in the evaluation of director, chief executive officer, officer and our other compensation and benefit plans and to approve the compensation consultant&#8217;s fees and other retention terms. The Compensation Committee is directly responsible for the appointment, compensation and oversight of the work of any internal or external legal, accounting or other advisors and consultants retained by the Compensation Committee. The Compensation Committee may also select or retain advice and assistance from an internal or external legal, accounting or other advisor as the Compensation Committee determines to be necessary or advisable in connection with the discharge of its duties and responsibilities and will have the direct responsibility to appoint, compensate and oversee any such advisor. Currently, the Compensation Committee engages the Human Capital Solutions subdivision of Aon plc (&#8220;Aon&#8221;), as its compensation consultant. The Compensation Committee regularly evaluates the services Aon provides and has final authority to engage and terminate their services. Our Compensation Committee has assessed Aon's independence consistent with Nasdaq listing standards and has concluded that the engagement of Aon does not raise any conflict of interest. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Compensation Committee consisted of Dr. Renee Tannenbaum, chair of the Compensation Committee, Dr. Gary W. Pace and Dr. Rodney S. Markin. The Board has determined that all of the members are &#8220;independent&#8221; under Nasdaq Listing Rule 5605(a)(2).</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Corporate Governance/Nominating Committee</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Corporate Governance/Nominating Committee has responsibility for assisting the Board in, among other things: </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effecting Board organization, membership and function, including identifying qualified board nominees;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effecting the organization, membership and function of the committees of the Board, including the composition of the committees of the Board and recommending qualified candidates for the committees of the Board;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">evaluating and providing successor planning for the chief executive officer and our other executive officers;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">identifying and evaluating candidates for director in accordance with certain general and specific criteria;  </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developing and recommending to the Board Corporate Governance Guidelines and any changes thereto, setting forth the corporate governance principles applicable to us, and overseeing compliance with the Corporate Governance Guidelines;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> reviewing potential conflicts of interest involving directors and determining whether such directors may vote on issues as to which there may be a conflict; and</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">oversees corporate environmental and social responsibility matters as they pertain to the Company&#8217;s business and long-term strategy and identify and bring to the attention of the full Board emerging Environmental, Social, and Corporate Governance ("ESG") trends and issues that may affect the business operations, performance, external stakeholder relationships or reputation of the Company.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_463">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Corporate Governance/Nominating Committee consisted of Dr. Gary W. Pace, chair of the Corporate Governance/Nominating Committee, Dr. James O. Armitage and Dr. Mani Mohindru. The Board has determined that all of the members are &#8220;independent&#8221; under Nasdaq Listing Rule 5605(a)(2). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Code of Business Conduct and Ethics</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a formal Code of Business Conduct and Ethics applicable to all Board members, officers and employees. Our Code of Business Conduct and Ethics can be found on our website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.cardiffoncology.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. A copy of our Code of Business Conduct and Ethics may be obtained without charge upon written request to Secretary, Cardiff Oncology, Inc., 11055 Flintkote Avenue, San Diego, California 92121. If we make any substantive amendments to our Code of Business Conduct and Ethics or grant any waiver from a provision of the Code of Business Conduct and Ethics to any executive officer or director, we will promptly disclose the nature of the amendment or waiver on our website (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.cardiffoncology.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and/or in our public filings with the SEC.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Anti-hedging</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted an Insider Trading Policy that applies to all of our employees, officers and directors, including our Chief Executive Officer and other executive officers, which prohibits such individuals from purchasing financial instruments (including prepaid variable forward contracts, equity swaps, collars and exchange funds), or otherwise engaging in transactions, that hedge or offset, or are designed to hedge or offset, any decrease in market value of our common stock, such as zero cost collars and forward sales contracts and exchange funds.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Family Relationships and Other Arrangements</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no family relationships among our directors and executive officers. There are no arrangements or understandings between or among our executive officers and directors pursuant to which any director or executive officer was or is to be selected as a director or executive officer.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation Committee Interlocks and Insider Participation</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2022, Drs. Markin, Pace and Tannenbaum served on our Compensation Committee. None of our current executive officers has served as a member of the Board of Directors, or as a member of the Compensation Committee or similar committee, of any entity that has one or more executive officers who served on our Board of Directors or Compensation Committee during the fiscal year ended December 31, 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Board and Committee Meetings and Attendance</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors and its committees meet regularly throughout the year and also hold special meetings and act by written consent from time to time. During fiscal year 2022, the Board of Directors held 8 meetings including telephonic meetings; the Audit Committee held 4 meetings; the Compensation Committee held 7 meetings; and the Corporate Governance/Nominating Committee held 4 meetings. During fiscal year 2022, none of the directors attended fewer than 90% of the aggregate of the total number of meetings held by the Board of Directors during his or her tenure and the total number of meetings held by all committees of the Board of Directors on which such director served during his or her tenure. The independent members of the Board of Directors also meet separately without management directors on a regular basis to discuss such matters as the independent directors consider appropriate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Board Attendance at Annual Stockholders&#8217; Meeting</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invite and encourage each member of our Board of Directors to attend our annual meetings of stockholders. We do not have a formal policy regarding attendance of our annual meetings of stockholders by the members of our Board of Directors.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_463">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Communication with Directors</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders and interested parties who wish to communicate with our Board of Directors, non-management members of our Board of Directors as a group, a committee of the Board of Directors or a specific member of our Board of Directors (including our Chair) may do so by letters addressed to:</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiff Oncology, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c/o Secretary</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11055 Flintkote Ave.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Diego, California, 92121</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All communications by letter addressed to the attention of our Secretary will be reviewed by the Secretary and provided to the members of the Board of Directors unless such communications are unsolicited items, sales materials and other routine items and items unrelated to the duties and responsibilities of the Board of Directors.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Considerations in Evaluating Director Nominees</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Corporate Governance/Nominating Committee is responsible for identifying, considering and recommending candidates to the Board of Directors for Board membership. A variety of methods are used to identify and evaluate director nominees, with the goal of maintaining and further developing a diverse, experienced and highly qualified Board of Directors. Candidates may come to our attention through current members of our Board of Directors, professional search firms, stockholders or other persons.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Corporate Governance/Nominating Committee will recommend to the Board of Directors for selection all nominees to be proposed by the Board of Directors for election by the stockholders, including approval or recommendation of a slate of director nominees to be proposed by the Board of Directors for election at each annual meeting of stockholders, and will recommend all director nominees to be appointed by the Board of Directors to fill interim director vacancies.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors encourages selection of directors who will contribute to the company&#8217;s overall corporate goals. The Corporate Governance/Nominating Committee may from time to time review and recommend to the Board of Directors the desired qualifications, expertise and characteristics of directors, including such factors as breadth of experience, knowledge about our business and industry, willingness and ability to devote adequate time and effort to the Board of Directors, ability to contribute to the Board of Directors&#8217; overall effectiveness, and the needs of the Board of Directors and its committees. Exceptional candidates who do not meet all of these criteria may still be considered. In evaluating potential candidates for the Board of Directors, the Corporate Governance/Nominating Committee considers these factors in the light of the specific needs of the Board of Directors at that time.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under our Corporate Governance Guidelines, a director is expected to spend the time and effort necessary to properly discharge such director&#8217;s responsibilities. Accordingly, a director is expected to regularly attend meetings of the Board of Directors and committees on which such director sits, and to review prior to meetings material distributed in advance for such meetings. Thus, the number of other public company boards and other boards (or comparable governing bodies) on which a prospective nominee is a member, as well as his or her other professional responsibilities, will be considered. Also, under our Corporate Governance Guidelines, there are no limits on terms that may be served by a director. However, in connection with evaluating recommendations for nomination for reelection, the Corporate Governance/Nominating Committee considers director tenure. We value diversity on a company-wide basis but have not adopted a specific policy regarding Board diversity.</span></div><div><span><br/></span></div><div id="i6eaaaa0344f74a9caae5f17960d0edec_13"></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_463">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">PROPOSAL 1</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">ELECTION OF DIRECTORS</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At the Annual Meeting, the stockholders will elect seven (7) directors to hold office until the 2023 Annual Meeting. Directors are elected by a plurality of votes cast by stockholders. In the event the nominees are unable or unwilling to serve as directors at the time of the Annual Meeting, the proxies will be voted for any substitute nominees designated by the present Board or the proxy holders to fill such vacancy, or for the balance of the nominees named without nomination of a substitute, or the size of the Board will be reduced in accordance with the Bylaws of the Company. The Board has no reason to believe that the persons named below will be unable or unwilling to serve as nominees or as directors if elected. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Assuming a quorum is present, the seven (7) nominees receiving the highest number of affirmative votes of shares entitled to be voted for such persons will be elected as directors of the Company to serve for a one-year term. Unless marked otherwise, proxies received will be voted &#8220;FOR&#8221; the election of the nominees named below. In the event that additional persons are nominated for election as directors, the proxy holders intend to vote all proxies received by them in such a manner as will ensure the election of the nominees listed below, and, in such event, the specific nominees to be voted for will be determined by the proxy holders. Our Board of Directors, acting through the Corporate Governance/Nominating Committee, will make a determination whether or not to request the resignation of an incumbent director who failed to receive a majority of the vote cast. We will publicly disclose our Board of Directors' decision and reasoning.</span></div><div><span><br/></span></div><div id="i6eaaaa0344f74a9caae5f17960d0edec_16"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Information with Respect to Director Nominees</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Listed below are the current directors who are nominated to hold office until their successors are elected and qualified, and their ages as of April 24, 2023.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.502%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Committee Memberships</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Age</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Audit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Compensation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Governance/Nominating</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. James O. Armitage, M.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark Erlander, Ph.D.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr.&#160;Rodney S. Markin, M.D., Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mani Mohindru, Ph.D.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gary W. Pace, Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renee P. Tannenbaum, Pharm.D.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">L&#226;le White</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt;text-indent:11.25pt"><span><br/></span></div><div id="i6eaaaa0344f74a9caae5f17960d0edec_19"></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dr. James O. Armitage, M.D. - Independent Director</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Armitage has been a director of our company since April 2020. Dr. Armitage has been a Professor of Internal Medicine in the division of Hematology and Oncology at the University of Nebraska Medical Center since 2003, after having served as Chairman of the Department of Internal Medicine, Dean of the College of Medicine, and in various other capacities since joining the Center in 1982. He also holds a hospital appointment at The Nebraska Medical Center. Dr. Armitage has authored or co-authored more than 600 articles, 108 book chapters and edited or co-edited 27 textbooks. He has previously served as President of the American Society of Clinical Oncology ("ASCO"), and as a member of the ASCO Board of Directors. Dr. Armitage received a bachelor of science degree from the University of Nebraska and a medical degree from the University of Nebraska Medical Center and completed his post-graduate training at the University of Nebraska Medical Center and the University of Iowa Hospitals and Clinics. The Board believes that Dr. Armitage's training as a physician, his research, clinical and administrative experience, and his previous service as a director of a publicly traded biopharmaceutical company provide him with the qualifications and skills to serve as a director.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mark Erlander, Ph.D. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chief Executive Officer and Director</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Erlander has been our Chief Executive Officer since May 2020 and a director since June 2020. Dr. Erlander was our Chief Scientific Officer from March 2013 to April 2020. Dr. Erlander has more than 18 years of experience directing and leading research and development for gene discovery, with a strong focus on molecular diagnostics. Prior to joining Cardiff Oncology, he was Chief Scientific Officer at bioTheranostics, (a bioM&#233;rieux company,) a molecular diagnostic testing company that is focused on clinical applications in oncology, from 2008 to February 2013. Previously Dr. Erlander was a Group Leader and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_463">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsequently Research Fellow at the R. W. Johnson Pharmaceutical Research Institute (Johnson &amp; Johnson). He was also an assistant member and Postdoctoral Fellow at The Scripps Research Institute in the Department of Molecular Biology. Dr. Erlander holds a B.S. degree in Biochemistry from the University of California, Davis; an M.S. degree in Biochemistry from Iowa State University; and a Ph.D. in Neuroscience from the University of California, Los Angeles. Dr. Erlander is an accomplished researcher with 32 issued U.S. patents and 38 U.S. patent applications, and is a lead or contributing author on more than 70 scientific articles. The Board believes that Dr. Erlander&#8217;s research and clinical experience qualifies him to serve as a director of our company.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dr.&#160;Rodney S.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Markin, M.D., Ph.D. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chair of the Board &amp; Independent Director</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Markin has been Chairman of the Board of our company since December 2020 and a Director since February 2014. Dr. Markin has served as Chief Operating Officer of The University of Nebraska since August 2017. Dr. Markin has served as Chief Technology Officer and Associate Vice Chancellor for Business Development at The University of Nebraska Medical Center since 2011; as Professor of Pathology and Microbiology since 1985; as David T. Purtilo Distinguished Professor Pathology and Microbiology since 2005; as Courtesy Professor of Surgery since 1990 and as Courtesy Professor of Psychiatry since 2013. Dr. Markin is also a director on the Board of Children's Hospital and Medical Center Foundation, on the Board of Trustees for Keck Graduate Institute, on the Board of the Make-A-Wish Foundation and on the Board of PerceptiMed since July 2015. Dr. Markin served on the Board of Directors for Transgenomic, Inc. from March 2007 to December 2014. The Board believes that Dr. Markin&#8217;s valuable executive experience in the healthcare business qualifies him to serve as a director and Chairman of the Board of our company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mani Mohindru, Ph.D. - Independent Director</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Mohindru is currently the CEO of Novasenta, an early-stage biotech company. In addition to Cardiff Oncology, she also serves as a director of CytomX Therapeutics, Inc., a public biotechnology company. From October 2020 to May 2021, she served as a director of SAB Biotherapeutics, a then private biotech company. From December 2019 to October 2020, Dr. Mohindru served as Chief Executive Officer of CereXis, a biotechnology company. Dr. Mohindru served as Chief Financial Officer and Chief Strategy Officer of Cara Therapeutics, Inc., a public biotechnology company, from August 2017 until December 2019. From March 2016 to July 2017, Dr. Mohindru served as the Chief Strategy Officer at Curis, Inc., a public biotechnology company. From April 2015 to February 2016, Dr. Mohindru served as Senior Vice President of Corporate Strategy and Investor Relations and from June 2013 to March 2015, Dr. Mohindru served as Vice President of Corporate Strategy and Investor Relations, each at Curis, Inc. In 2012, Dr. Mohindru co-founded ImmTox, Inc., a small private biotechnology company. From June 2011 to September 2012, Dr. Mohindru was a Senior Biotechnology Analyst at ThinkEquity, LLC, a research and investment banking firm. Previously, from June 2009 to May 2011, Dr. Mohindru was a Partner at Axon Healthcare Company, a strategic pharmaceutical and biotechnology consultancy firm that she co-founded. Dr. Mohindru was also a Managing Director at Capstone Investments in its investment banking division, a Vice President at Credit Suisse, and an Associate Research Analyst at global financial services firm, UBS. Dr. Mohindru completed her Ph.D. in Neurosciences at Northwestern University and she received both her B.S. in Human Biology and Masters in Biotechnology from the All India Institute of Medical Sciences, New Delhi, India. The Board believes that Dr. Mohindru&#8217;s years of biopharmaceutical industry leadership as well as Wall Street experience provides her with the qualifications and skills to serve as a director.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Gary W. Pace, Ph.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Independent Director</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Pace has been a director of our company since April 2020. In addition, Dr. Pace has been a Director of Pacira Biosciences, Inc. since 2008, as well as a director of several private companies. He previously served on the board of Antisense Therapeutics from 2015 to 2022, Simavita Ltd. from 2016 to 2021, ResMed Inc. from 1994 to 2018, Transition Therapeutics Inc. from 2002 to 2016 and QRxPharma Ltd. from 2001 to 2013. Dr. Pace is a seasoned biopharmaceutical executive with over 40 years of experience in the industry. He has co-founded several early stage life science companies, where he built products from the laboratory to commercialization. Dr. Pace has contributed to the development of the biotechnology industry through honorary university appointments and industry and government committees. In 2003, he was awarded a Centenary Medal by the Australian Government &#8220;for service to Australian society in research and development&#8221; and was recognized as the 2011 Director of the Year (corporate governance) by the San Diego Directors Forum. He is also a fellow of the Australian Academy of Technological Sciences and Engineering. Dr. Pace holds a B.Sc. (Hons I) from the University of New South Wales and a Ph.D. from the Massachusetts Institute of Technology where he was a Fulbright Fellow and General Foods Scholar. The Board believes that Dr. Pace&#8217;s years of experience providing strategic advisory services to complex organizations, including as a public company director provides him with the qualifications and skills to serve as a director.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_463">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Renee P. Tannenbaum, Pharm.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">- Independent Director</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Tannenbaum currently serves as an independent consultant and strategic advisor to several biopharmaceutical, diagnostic and device companies. Most recently she served as Vice President of Global Partnering at Halozyme, Inc., where she was responsible for leading the team that executes business development activities and the company&#8217;s alliances through partnerships and collaborations. Dr. Tannenbaum was previously Head of Global Customer Excellence at AbbVie from October 2012 to January 2016, where she was responsible for building commercial capabilities for the organization. Previously, Dr. Tannenbaum served as President of Myrtle Potter &amp; Company, LLC, a global life sciences consulting and advisory firm from April 2011 to October 2012 and Executive Vice President and Chief Commercial Officer at Elan Pharmaceuticals, Inc., from May 2009 to January 2011, where she was responsible for revenue generation for Elan&#8217;s marketed products, preparing for the commercialization of the company&#8217;s pipeline, including its Alzheimer&#8217;s portfolio, and strengthening the company&#8217;s overall commercial capabilities. Prior to her role at Elan, Dr. Tannenbaum was at Novartis Pharma AG for three years, where she led the Global Commercial Operations organization. Prior to that, Dr. Tannenbaum spent nine years at Bristol Myers Squibb and 16 years at Merck and Company, Inc. where she held a variety of leadership positions in operations and general management. Dr. Tannenbaum serves on the Board of Directors for ANI Pharmaceuticals since March 2022. She served as a director of Zogenix, Inc. from February 2015 to March 2022.  Dr. Tannenbaum served as a director to Nordic Nanovector ASA, a publicly-traded company in Norway, and Cipher Pharmaceuticals, Inc. a Canadian publicly-traded company, from April to August 2016, Sharps Compliance Inc. from November 2012 to November 2014 and Immune Pharmaceuticals, Inc., a privately-held company, from August 2011 to October 2012. Dr. Tannenbaum received her Doctor of Pharmacy degree from the Philadelphia College of Pharmacy and Sciences, her MBA from Temple University, and her Bachelor of Science degree in Pharmacy from the University of Connecticut. The Board believes that Dr. Tannenbaum&#8217;s extensive experience in the biopharmaceutical industry, including providing strong executive leadership to numerous biopharmaceutical companies provides her with the qualifications and skills to serve as a director.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">L&#226;le White - Independent Director</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ms. White has been a director of our company since April 2020. Ms. White is the Chief Executive Officer of XIFIN, Inc., a financial cloud computing company, with over 25 years of experience in information systems development and medical billing. She lectures extensively on these topics and has consulted for major laboratories and laboratory associations throughout the U.S. Ms. White worked with HCFA and the U.S. Office of the Inspector General to develop the first OIG Model Compliance Program. She is a longstanding member of the California Clinical Lab Association, where for the last eight years she has chaired the state and federal contractor committees that work with the Medicare Administrative Contractors and the Department of Health and Human Services. Ms. White was previously Vice President of Finance of Laboratory Corporation of America, one of the largest clinical reference laboratories in the U.S., and its predecessor National Health Laboratories, where she led the software development of several accounts receivable, inventory, cost accounting and financial management systems for the laboratory industry. Ms. White previously was on the Board of bioTheranostics while it was a BioMerieux subsidiary and CombiMatrix Corporation, until its acquisition by Invitae Corporation in 2017. Ms. White has a BA in finance and an MBA from Florida International University. The Board believes that Ms. White&#8217;s significant executive experience with the strategic, financial, and operational requirements of health care organizations, particularly in the area of billing and reimbursement provides her with the qualifications and skills to serve as a director.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="i6eaaaa0344f74a9caae5f17960d0edec_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_463">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Board Diversity</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following Board Diversity Matrix presents our Board diversity statistics in accordance with Nasdaq Rule 5606, as self-disclosed by our directors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.276%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Board Diversity Matrix as of April 24, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total number of directors</span></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Part 1: Gender Identity</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Female</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Male</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Binary</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decline to Disclose</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Directors</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Part 2: Demographic Background</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Female</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Male</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Binary</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decline to Disclose</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">African American or Black</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alaskan Native or Native American</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asian</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hispanic or Latinx</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Native Hawaiian or Pacific Islander</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">White</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Two or More Races or Ethnicities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LGBTQ+</span></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Did Not Disclose Demographic Background</span></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div id="i6eaaaa0344f74a9caae5f17960d0edec_25"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Board Recommendation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">THE BOARD RECOMMENDS THAT YOU VOTE &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">FOR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8221; EACH OF THE NOMINEES TO THE BOARD SET FORTH IN THIS PROPOSAL 1.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_463">Table of Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div id="i6eaaaa0344f74a9caae5f17960d0edec_46"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth certain information regarding beneficial ownership of shares of our common stock as of April&#160;24, 2023 by (i)&#160;each person known to beneficially own more than&#160;5% of our outstanding common stock, (ii)&#160;each of our directors, (iii)&#160;each of our named executive officers, and (iv)&#160;all of our directors and executive officers as a group. Except as otherwise indicated, the persons named in the table below have sole voting and investment power with respect to all shares beneficially owned, subject to community property laws, where applicable.</span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:71.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.272%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.605%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name&#160;of&#160;Beneficial&#160;Owner</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares&#160;of&#160;Common<br/>Stock Beneficially Owned</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage (2)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Executive officers and directors(1):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. James O. Armitage</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,036&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark Erlander, Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">734,895&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James Levine</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr.&#160;Rodney S. Markin, M.D., Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mani Mohindru, Ph.D.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gary W. Pace, Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738,357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(8)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tod Smeal, Ph.D.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(9)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renee P. Tannenbaum, Pharm.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,134&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(10)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">L&#226;le White</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(11)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All Officers and Directors as a Group (11 persons)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,809,638&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5% Stockholders:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfizer, Inc.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,411,575&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(12)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.198%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*less than 1%</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The address of each person is c/o Cardiff Oncology,&#160;Inc., 11055 Flintkote Avenue, San Diego, CA 92121 unless otherwise indicated herein.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The calculation in this column is based upon&#160;44,677,169 shares of common stock outstanding on April&#160;24, 2023. Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to the subject securities. Shares of common stock that are currently exercisable or exercisable within&#160;60&#160;days of April&#160;24, 2023 are deemed to be beneficially owned by the person holding such securities for the purpose of computing the percentage beneficial ownership of such person, but are not treated as outstanding for the purpose of computing the percentage beneficial ownership of any other person.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Includes 93,546 shares of common stock issuable upon exercise of stock options that are exercisable within 60 days after April&#160;24, 2023. Dr. Armitage has direct ownership of 14,490 shares of common stock, and indirect ownership of 13,000 shares of Common Stock through the Shirley Young Revocable Trust, Shirley Young is the wife of Dr. Armitage. </span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Includes 710,414 shares of common stock issuable upon exercise of stock options that are exercisable within 60 days after April&#160;24, 2023.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Includes 240,005 shares of common stock issuable upon exercise of stock options that are exercisable within 60 days after April&#160;24, 2023.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Includes 124,627&#160;shares of common stock issuable upon exercise of stock options that are exercisable within 60 days after April&#160;24, 2023. Dr. Markin has direct ownership of 7,181 shares of common stock, and indirect ownership of 23,879 shares of Common Stock through Prairie Ventures LLC. </span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Includes 56,134&#160;shares of common stock issuable upon exercise of stock options that are exercisable within 60 days after April&#160;24, 2023.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_463">Table of Contents</a></span></div></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Includes 93,546&#160;shares of common stock issuable upon exercise of stock options that are exercisable within 60 days after April&#160;24, 2023.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Includes 97,427&#160;shares of common stock issuable upon exercise of stock options that are exercisable within 60 days after April&#160;24, 2023.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.34pt">Includes 56,134&#160;shares of common stock issuable upon exercise of stock options that are exercisable within 60 days after April&#160;24, 2023.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.34pt">Includes 64,688&#160;shares of common stock issuable upon exercise of stock options that are exercisable within 60 days after April&#160;24, 2023.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.34pt">Based on a Schedule 13G filed with the SEC on November 19, 2021, reporting beneficial ownership as of November 18, 2021. Pfizer, Inc. has sole voting and dispositive power over all 2,411,575 shares. The address of Pfizer, Inc. is 235 East 42nd Street, New York, New York 10017.</span></div><div><span><br/></span></div><div id="i6eaaaa0344f74a9caae5f17960d0edec_438"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">DELINQUENT SECTION 16(a) REPORTS</span></div><div style="text-align:center"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Section 16(a) of the Securities Exchange Act of 1934, or Exchange Act, requires our directors, officers and holders of more than 10% of our common stock to file with the SEC initial reports of ownership and reports of changes in ownership of common stock and other of our equity securities. Based solely on our review of copies of Section 16(a) reports furnished to us and representations made to us, we believe that during the year ended December 31, 2022, our officers, directors and holders of more than 10% of our common stock complied with all Section 16(a) filing requirements, with the exception of the late filing by Dr. James Armitage of a Form 4 due September 20, 2022, which was filed on October 11, 2022, due to administrative error.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i6eaaaa0344f74a9caae5f17960d0edec_49"></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_463">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">PROPOSAL 2</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">RATIFICATION OF THE APPOINTMENT OF OUR INDEPENDENT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">REGISTERED PUBLIC ACCOUNTING FIRM FOR FISCAL YEAR ENDING</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">DECEMBER 31, 2023</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i6eaaaa0344f74a9caae5f17960d0edec_52"></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Board has appointed BDO USA, LLP (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">BDO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;) to serve as our independent registered public accounting firm for the year ending December 31, 2023. BDO has acted as our principal accountant since April 5, 2007 and served as our independent registered public accounting firm for the fiscal year ended December 31, 2022.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A representative of BDO is expected to be present via telephone conference at the Annual Meeting. He or she will have the opportunity to make a statement if desired and is expected to be available to respond to appropriate questions.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our Audit Committee retains our independent registered public accounting firm and approves in advance all audit and non-audit services performed by this firm and any other auditing firms. Although management has the primary responsibility for the financial statements and the reporting process including the systems of internal control, the Audit Committee consults with management and our independent registered public accounting firm regarding the preparation of financial statements and the adoption and disclosure of our critical accounting estimates and generally oversees the relationship of the independent registered public accounting firm with Cardiff Oncology. The independent registered public accounting firm is responsible for expressing an opinion on the conformity of those audited financial statements with generally accepted accounting principles, relating to their judgments as to the quality, not just the acceptability, of Cardiff Oncology's accounting principles, and such other matters as are required to be discussed with the Audit Committee under generally accepted auditing standards.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">It is the responsibility of our management to determine that our financial statements and disclosures are complete and accurate and in accordance with generally accepted accounting principles. It is the responsibility of our independent registered public accounting firm to conduct the audit of our financial statements and disclosures. In giving its recommendation to the Board that our audited financial statements for the year ended December 31, 2022 be included in our Annual Report on Form 10-K for the year ended December 31, 2022, the Audit Committee has relied on: (1) management&#8217;s representation that such financial statements have been prepared with integrity and objectivity and in conformity with generally accepted accounting principles in the United States; and (2) the report of our independent registered public accounting firm with respect to such financial statements.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div id="i6eaaaa0344f74a9caae5f17960d0edec_55"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principal Accountant Fees and Services</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate fees billed to us by BDO, our independent registered public accounting firm, for the indicated services for each of the last two fiscal years were as follows:</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audit fees (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341,370&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax fees (2)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,659&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,609&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485,836&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349,979&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.198%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Audit fees consist of fees for professional services performed by BDO for the audit and review of our financial statements, preparation and filing of our registration statements, including issuance of comfort letters.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Tax fees consist of fees for professional services performed by BDO with respect to tax compliance.</span></div><div><span><br/></span></div><div id="i6eaaaa0344f74a9caae5f17960d0edec_58"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Policy on Audit Committee Pre-Approval of Audit and Permissible Non-Audit Services of Independent Auditors</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Consistent with SEC policies and guidelines regarding audit independence, the Audit Committee is responsible for the pre-approval of all audit and permissible non-audit services provided by our independent registered public accounting firm on a case-by-case basis. Our Audit Committee has established a policy regarding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">approval of all audit and permissible non-audit services provided by our principal accountants. Our Audit Committee pre-approves these services by category and service. Our Audit Committee has pre-approved all of the services provided by our independent registered public accounting firm.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_463">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Vote Required</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The selection of our independent registered public accounting firm is not required to be submitted to a vote of our stockholders for ratification. However, we are submitting this matter to the stockholders as a matter of good corporate governance. Even if the appointment is ratified, the Board may, in its discretion, appoint a different independent registered public accounting firm at any time during the year if it determines that such a change would be in the best interests of us and our stockholders. If the appointment is not ratified, the Board will reconsider whether or not to retain BDO.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The affirmative vote of a majority of the shares (by voting power) present in person at the Annual Meeting or represented by proxy and entitled to vote at the Annual Meeting is required to approve the ratification of the appointment of BDO USA, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Board Recommendation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">THE BOARD RECOMMENDS A VOTE &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">FOR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8221; RATIFICATION OF THE APPOINTMENT OF BDO USA, LLP AS THE COMPANY&#8217;S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2023.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">AUDIT COMMITTEE REPORT</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following Audit Committee Report shall not be deemed to be &#8220;soliciting material,&#8221; deemed &#8220;filed&#8221; with the SEC or subject to the liabilities of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exchange Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8221;). Notwithstanding anything to the contrary set forth in any of the Company&#8217;s previous filings under the Securities Act of 1933, as amended, or the Exchange Act that might incorporate by reference future filings, including this Proxy Statement, in whole or in part, the following Audit Committee Report shall not be incorporated by reference into any such filings.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee is comprised of three independent directors (as defined under Nasdaq Listing Rule 5605(a)(2)). The Audit Committee operates under a written charter, which is available on our website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">http://cardiffoncology.com/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under &#8220;Corporate Governance.&#8221;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reviewed and discussed with management and the Company&#8217;s auditors, the Company&#8217;s audited financial statements as of and for the fiscal year ended December 31, 2022.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have discussed with BDO USA, LLP, the Company&#8217;s independent registered public accounting firm, the matters as required to be discussed by the Public Company Accounting Oversight Board (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PCAOB</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) Auditing Standard No. 1301 (Communications with Audit Committees).</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received the written disclosures and the letter from BDO USA, LLP required by applicable requirements of the PCAOB regarding BDO USA, LLP&#8217;s communications with the Audit Committee concerning independence, and have discussed with BDO USA, LLP, their independence from management and the Company.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the review and discussions referred to above, we recommended to the Board that the financial statements referred to above be included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 for filing with the Securities and Exchange Commission.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Submitted by the Audit Committee</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;L&#226;le White, Chair</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dr. Rodney S. Markin</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Mani Mohindru</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_463">Table of Contents</a></span></div></div><div><span><br/></span></div><div id="i6eaaaa0344f74a9caae5f17960d0edec_478"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROPOSAL 3</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">ADVISORY VOTE ON THE FREQUENCY OF HOLDING AN ADVISORY VOTE ON EXECUTIVE COMPENSATION</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In addition to the advisory approval of the Company's executive compensation program, Cardiff Oncology is also holding a non-binding advisory vote by stockholders on the frequency with which stockholders would have an opportunity to hold an advisory vote on the Company's executive compensation program. The Company has included this proposal among the items to be considered at the Annual Meeting pursuant to the requirements of Section 14A of the Exchange Act. The Company is providing stockholders the option of selecting a frequency of one, two or three years, or abstaining. For the reasons described below, the Company recommends that Cardiff Oncology's stockholders select a frequency of one year in order to provide investors with an annual opportunity to opine on our compensation program.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">While Cardiff Oncology's executive compensation program is designed to support long-term value creation, in recent years we have conducted in-depth reviews of the Company's executive compensation with outside consultants on a yearly basis. Accordingly, an annual vote will coincide with these review. Setting a one-year period for holding the stockholder vote will enhance ongoing stockholder communication by providing a clear, simple means for us to obtain information on investor sentiment every year about our executive compensation matters. The Company therefore recommends that Cardiff Oncology stockholders select &#8220;One Year&#8221; when voting on the frequency of advisory votes on executive compensation. Although the advisory vote is non-binding, Cardiff Oncology's Board will review the results of the vote and take them into account in making a determination concerning the frequency of future advisory votes on executive compensation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Vote Required</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%">As described above, the affirmative vote of a majority of shares having voting power present in person or represented by proxy at the annual meeting, where a quorum is present, will constitute a non-binding, advisory approval of this Proposal 3. If none of the frequency options receive a majority vote, the option that receives the highest number of votes cast will be considered the frequency selected by stockholders. Nonetheless, if two or more frequency alternatives receive a similar level of votes and thus there is no clear mandate from stockholders, the Board may determine that it is in the best interests of the stockholders of the Company to hold a &#8220;say-on-pay&#8221; vote more or less frequently than the frequency option receiving the highest number of votes. You may abstain from voting on this proposal. Abstentions will have no effect on the outcome of the advisory vote. Brokers do not have discretion to vote on this proposal without your instruction. If you do not instruct your broker how to vote on this proposal, your broker will deliver a non-vote on this proposal.</span></div><div style="text-indent:23.4pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:117%">THE BOARD RECOMMENDS THAT YOU VOTE FOR A ONE-YEAR FREQUENCY FOR HOLDING AN ADVISORY VOTE ON EXECUTIVE COMPENSATION</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:117%">.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_463">Table of Contents</a></span></div></div><div style="text-indent:22.5pt"><span><br/></span></div><div id="i6eaaaa0344f74a9caae5f17960d0edec_64"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROPOSAL 4</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APPROVAL OF THE COMPENSATION OF THE NAMED EXECUTIVE OFFICERS</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (the &#8220;Dodd-Frank Act&#8221;), our stockholders are entitled to vote to provide advisory approval of the compensation of our named executive officers as disclosed in this proxy statement pursuant to the compensation disclosure rules of the SEC. In accordance with these requirements, at our 2019 Annual Meeting of Stockholders, a majority of our stockholders voted in favor of holding an advisory vote to approve executive compensation every three years. At that time, our Board of Directors considered the voting results on that proposal and determined to hold future advisory votes on the compensation of our named executive officers every three years. Pursuant to the Dodd-Frank Act, the stockholder vote on executive compensation is an advisory vote only, and it is not binding on us or our Board of Directors. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We last held this advisory vote at our 2022 annual meeting. In 2022 we received a negative vote on this proposal for our executive compensation. Subsequently the Compensation Committee engaged in a dialog with stockholders to gather feedback. The results from this outreach are described on page </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88ddd4b8b6a341349c266961c1a5d35f_112760">26</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of this proxy statement. Additionally, our Board of Directors has recommended (as discussed in Proposal 3) that future advisory votes on the compensation of our named executive officers should be held every year as opposed to every three years in order to provide investors with an annual opportunity to opine on our compensation program.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Compensation Committee continually reviews the compensation programs for our executive officers to ensure they achieve the desired goals of aligning our executive compensation structure with stockholders' interests and current market practices. Our executive compensation program is designed to attract, retain and motivate individuals with superior ability, experience and leadership capability to deliver on our annual and long-term business objectives necessary to create stockholder value. Our executive officers are compensated for the achievement of annual goals established by our Compensation Committee in our performance-based annual cash incentive program and through stock option grants that are at risk of having no value unless our stock price appreciates. The Executive Compensation section of this proxy statement provides additional details about our 2022 executive compensation program, including information about the 2022 compensation of our named executive officers.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee and the Board of Directors believe that our executive compensation program fulfills the above-described goals and is reasonable, competitive, and aligned with our performance and the performance of our executives.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are asking our stockholders to indicate their support for our named executive officer compensation as described in this proxy statement. This proposal, commonly known as a &#8220;say-on-pay&#8221; proposal, gives our stockholders the opportunity to express their views on our named executive officers&#8217; compensation. This vote is not intended to address any specific item of compensation, but rather the overall compensation of our named executive officers and the philosophy, policies and practices described in this proxy statement. Although the vote is non-binding, our Compensation Committee and Board of Directors value the opinions of the stockholders and will consider the outcome of the vote when making future compensation decisions.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, we ask that our stockholders vote &#8220;FOR&#8221; the following resolution:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;RESOLVED, that Cardiff Oncology, Inc.&#8217;s stockholders approve, on an advisory basis, the compensation of the named executive officers, as disclosed in Cardiff Oncology, Inc.&#8217;s Proxy Statement for the 2022 Annual Meeting of Stockholders, pursuant to the compensation disclosure rules of the SEC, including the Executive Compensation, the Summary Compensation Table and the other related tables and disclosure.&#8221;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vote Required</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The affirmative vote of a majority of the shares (by voting power) present in person at the Annual Meeting or represented by proxy and entitled to vote at the Annual Meeting will be required to approve the advisory vote regarding the compensation of the named executive officers. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Board Recommendation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OUR BOARD OF DIRECTORS RECOMMENDS THAT STOCKHOLDERS VOTE "FOR" THE APPROVAL OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS AS DISCLOSED IN THIS PROXY STATEMENT PURSUANT TO THE COMPENSATION DISCLOSURE RULES OF THE SEC.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_463">Table of Contents</a></span></div></div><div><span><br/></span></div><div id="i6eaaaa0344f74a9caae5f17960d0edec_28"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXECUTIVE COMPENSATION</span></div><div><span><br/></span></div><div id="i6eaaaa0344f74a9caae5f17960d0edec_472"></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Compensation Practices</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This summary of compensation practices explains the strategy, design, and decision-making related to our compensation programs and practices for our Principal Executive Officer and our other executive officers. This section is intended to provide perspective on the information contained in the tables that follow this discussion.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For fiscal 2022, our Principal Executive Officer and our other named executive officers were:</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.371%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Age</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Position</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark Erlander; Ph.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer, PEO</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James Levine</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer, non PEO NEO</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tod Smeal, Ph.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Scientific Officer, non PEO NEO</span></div></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a brief biography of each of our current PEO and NEOs:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mark Erlander, Ph.D. - Chief Executive Officer</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Erlander has been our Chief Executive Officer since May 2020 and a director since June 2020. Dr. Erlander was our Chief Scientific Officer from March 2013 to April 2020. Dr. Erlander has more than 18 years of experience directing and leading research and development for gene discovery, with a strong focus on molecular diagnostics. Prior to joining Cardiff Oncology, he was Chief Scientific Officer at bioTheranostics, (a bioM&#233;rieux company,) a molecular diagnostic testing company that is focused on clinical applications in oncology, from 2008 to February 2013. Previously Dr. Erlander was a Group Leader and subsequently Research Fellow at the R. W. Johnson Pharmaceutical Research Institute (Johnson &amp; Johnson). He was also an assistant member and Postdoctoral Fellow at The Scripps Research Institute in the Department of Molecular Biology. Dr. Erlander holds a B.S. degree in Biochemistry from the University of California, Davis; an M.S. degree in Biochemistry from Iowa State University; and a Ph.D. in Neuroscience from the University of California, Los Angeles. Dr. Erlander is an accomplished researcher with 32 issued U.S. patents and 38 U.S. patent applications, and is a lead or contributing author on more than 70 scientific articles. The Board believes that Dr. Erlander&#8217;s research and clinical experience qualifies him to serve as a director of our company.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">James Levine - Chief Financial Officer</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Levine has served as Chief Financial Officer since 2021. Mr. Levine has extensive corporate and investment banking experience with both private and public biotechnology and pharmaceutical companies. Prior to joining Cardiff Oncology, Mr. Levine served as CFO of Cidara Therapeutics, where he led the financial aspects of important pre-clinical and clinical collaborations with Janssen Pharmaceuticals (part of Johnson &amp; Johnson) and Mundipharma with a combined value of over $1.3 billion. Previously, Mr. Levine was the president and chief executive officer of Sapphire Energy Inc., a private industrial biotechnology company that was sold to two private investor groups. He also previously served in the same roles at Verenium Corp., where he negotiated six product commercialization partnerships and asset sales, before selling the company to BASF. He also previously was a managing director in the investment banking division of Goldman Sachs &amp; Co., serving in its healthcare and energy groups. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Levine earned an MBA in finance from the Wharton School of the University of Pennsylvania and a BA in economics from Brandeis University.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tod Smeal, Ph.D. - Chief Scientific Officer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Smeal has served as Chief Scientific Officer since January 2022. Previously he was CSO at Hexagon Bio (2020-2021), CSO of Cancer Biology at Eli Lilly and Company (2015-2020), Director at the Oncology Research Unit of Pfizer (2003-2015), and Senior Group Leader at the SUGEN site of Pharmacia and Upjohn and SUGEN (1998-2003). When Pfizer closed the SUGEN site in 2003, Dr. Smeal continued his oncology research efforts on targeted therapies and their resistance mechanisms with Pfizer at their San Diego oncology research site. Subsequently in 2015, Dr. Smeal joined Eli Lilly where he </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_463">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">led their oncology research efforts at Lilly Research Labs in Indianapolis. During his over 20 years in industry working on targeted therapies, Dr. Smeal has played key leadership roles in delivering about 20 FHD/NMEs and several FDA approved or soon to be approved drugs (e.g., Lorbrena, Xalkori, Vizimpro and Nirogacestat). Dr. Smeal&#8217;s work in developing cancer therapies has been focused on intracellular signaling, kinases, drug pharmacology, and targeted therapies and their resistance mechanisms. He has over 45 publications which includes high impact publications in Cell, Nature, New England Journal of Medicine, Cancer Cell and Cancer Discovery. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From 1994 to 1998, Dr. Smeal was a post-doctoral fellow of the American Cancer Society and a senior post-doctoral fellow of the MIT-Merck fellowship program. Dr. Smeal holds a B.S. in Biology from the Massachusetts Institute of Technology and a Ph.D. in Biology from the University of California, San Diego.</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation Objectives and Philosophy</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a pre-revenue, oncology-focused biotechnology company based in San Diego. We compete with many other biotech companies in seeking to attract and retain a skilled work force. To meet this challenge, we have developed an approach to employee compensation that enables our Board of Directors and management to implement compensation programs, manage these programs to align employee compensation with long-term value creation, and effectively communicate the goals of these programs to our employees and stockholders.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our compensation philosophy is to offer our employees compensation and benefits that are competitive and that meet our goals of attracting, retaining and motivating highly skilled employees so that we can achieve our financial and strategic objectives.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Utilizing this philosophy, our compensation programs are designed to:</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">be &#8220;market-based&#8221; and reflect the competitive environment for personnel;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">stress our &#8220;pay for performance&#8221; approach to setting compensation levels;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">share risks and rewards with employees at all levels;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">be affordable, within the context of our operating expense model;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">evaluate share usage and burn rate when assessing equity opportunities:</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">align the interests of our employees with those of our stockholders;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">reflect our values; and</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">be fairly and equitably administered.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as we administer our compensation programs, we plan to:</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">evolve and modify our programs to reflect the competitive environment and our changing business needs;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">focus on simplicity, flexibility and choice wherever possible;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">openly communicate the details of our programs with our employees and managers to ensure that our programs and their goals are understood;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">provide our managers and employees with the tools they need to administer our compensation programs; and</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">update our stockholders on a regular basis about any changes to our compensation philosophy, approach, and the compensation decisions we make each year.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_463">Table of Contents</a></span></div></div><div style="padding-left:36pt"><span id="i88ddd4b8b6a341349c266961c1a5d35f_112760"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stockholder Engagement and Use of Stockholder Feedback</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly engage with our stockholders through open dialogue and direct individual communication on topics related to our business, strategic vision, financial performance, executive compensation and environmental, social and corporate governance (ESG) matters. Stockholder feedback is important, and the information we glean from these engagements is highly valued. As stewards of good corporate governance, our Compensation Committee evaluates the design of our executive compensation program based on market conditions, stockholder views and other governance considerations.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the negative &#8220;say-on-pay,&#8221; vote at our 2022 Annual Meeting, our Compensation Committee reached out to 19 stockholders on two separate occasions representing just under 20% of our shares outstanding to gather feedback from our stockholders with respect to our compensation program. We received a response from 7 (37%) of these stockholders with 3 (16%) requesting a meeting with representatives from the company, including Compensation Committee members. The table below summarizes the feedback we received from stockholders in these meetings and the actions we&#8217;ve taken as a result:</span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.607%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.609%"></td><td style="width:0.1%"></td></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">What we heard</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">What we did</span></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Compensation related:</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;say-on-pay&#8221; vote frequency:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A yearly vote on &#8220;say-on-pay&#8221; is preferred by shareholders</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are proposing a yearly &#8220;say-on-pay&#8221; advisory vote at the 2023 Annual Meeting (see proposal 3)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Goal setting and Bonus:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We should provide more granularity regarding the goal setting process, the maximum payout potential as well as considerations for how these metrics drive long term Total-Shareholder-Return (&#8220;TSR&#8221;).</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have enhanced our disclosure around goal setting and bonus achievements in this Proxy Statement</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Disclosures:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Compensation disclosures should go beyond SEC requirements for a smaller reporting company to also include our broader philosophy governing the pay determination process</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have enhanced our disclosures in our summary of compensation practices and have listed our peer group</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Compensation table:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We should consider breaking out any compensation in the compensation table where further explanation is warranted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We highlighted new hire and promotion-based grants in the Summary Compensation Table for better clarity</span></div></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Governance related:</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Director election:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Stockholders stated that our plurality voting structure is acceptable and would prefer a resignation policy be in place.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have implemented a formal review process through which the Corporate Governance/Nominating Committee will make a determination whether or not to request the resignation of an incumbent director who failed to receive a majority of the votes cast. We will publicly disclose our Board of Directors&#8217; decision and its reasoning</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Proxy Access:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Stockholders suggested a group of 20 shareholders that collectively own over 3% of a company for consecutive 3 years should be able to propose 20% of board seats.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our current, non-staggered Board allows stockholders to vote for each Board member each year. Shareholders are currently able to provide information for potential candidates to the Corporate Governance/Nominating committee for review and consideration. The Board will continue to review emerging governance practices and if deemed appropriate will open further dialogue with the shareholders on changes to governance practices</span></div></td></tr></table></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Role of the Compensation Committee</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The duties and responsibilities of the Compensation Committee are described in the section &#8220;Committee of our Board of Directors&#8221; on page </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i623122299d3d48bc9cd79b7029019f79_43537">10</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of this Proxy Statement and detailed in the charter of the Compensation Committee. The full text of the Committee Charter is available on our website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">http://cardiffoncology.investorroom.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_463">Table of Contents</a></span></div></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Role of Independent Compensation Consultant</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee has the authority to engage independent advisors to assist it in carrying out its responsibilities. For fiscal 2022, the Compensation Committee engaged the Human Capital Solutions subdivision of Aon plc (&#8220;Aon&#8221;) as its independent executive and Board compensation consultant. Aon reports directly to the Compensation Committee and does not report to management. Aon is independent from Cardiff Oncology and its Board of Directors. Aon has not provided any services to us other than to the Compensation Committee, and receives compensation from us only for services provided to the Compensation Committee. The Compensation Committee assessed the independence of Aon pursuant to SEC and Nasdaq rules and concluded that the work of Aon has not raised any conflict of interest.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aon reviews and advises on all principal aspects of the executive and Board compensation program. Its main responsibilities are to:</span></div><div><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">advise on alignment of pay and performance;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">review and advise on executive total compensation, including base salaries, short- and long-term incentives, associated performance goals and retention;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">advise on trends in executive compensation;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">advise on Board and Board committee compensation;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">provide recommendations regarding the composition of our peer group;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">analyze peer group proxy statements, compensation survey data, and other publicly available data (and apply its experience with other companies to this analysis); and</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">perform any special projects requested by the Compensation Committee.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aon has attended the Compensation Committee's meetings, including executive sessions at which management is not present. Aon communicates regularly with the Compensation Committee's Chair outside of Compensation Committee meetings, and also meets with management to gather information and review proposals. Aon is expected to remain the Compensation Committee's independent consultant until determined otherwise by the Compensation Committee or Aon.</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Roles of Management in Determining Executive Compensation</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee periodically meets with our Chief Executive Officer and/or other executive officers and Aon to obtain recommendations with respect to compensation programs for executives and other employees. On an annual basis, Aon provides the company with compensation data based on our selected peer group. Our Chief Executive Officer then makes recommendations to the Compensation Committee on the base salaries, target cash bonuses and performance measures, and equity compensation for our named executive officers and other members of the executive team. The Compensation Committee considers, but is not bound to accept, management&#8217;s recommendations with respect to executive compensation. Our Chief Executive Officer and certain other executives attend most of the Compensation Committee&#8217;s meetings, but the Compensation Committee also holds private sessions outside the presence of members of management and non-independent directors. The Compensation Committee discusses our Chief Executive Officer&#8217;s compensation package with him but makes decisions with respect to his compensation without him present. The Compensation Committee has delegated to management the authority to make certain decisions regarding compensation for employees other than named executive officers and other executives. The Compensation Committee has not delegated any of its authority with respect to the compensation of the named executive officers and other executives.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_463">Table of Contents</a></span></div></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pay Positioning and Compensation Peers</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In setting compensation, the Compensation Committee compares base salaries, annual incentive opportunities and long-term compensation for each of our executive officers to those of a peer group of similarly sized companies. A key objective of our executive compensation program is to ensure that the overall compensation packages we offer our executives are competitive with the packages offered by companies with which we compete for executive talent. The Compensation Committee consults with Aon to develop a peer group of companies to serve as the basis for comparing our executive compensation program to the market. The Compensation Committee and Chief Executive Officer also solicit information from Aon to evaluate compensation for non-executive employees to ensure compensation levels across the entire company are consistent and competitive.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitive market data is only one of several resources made available to the Compensation Committee to assist in setting executive compensation. When setting fiscal 2022 executive compensation, our Compensation Committee considered the peer group compensation data, along with employee skills and experience, individual performance, scope of responsibilities, and other factors. The Compensation Committee does not use a formula to determine compensation.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In developing our 2022 peer group, the Compensation Committee considered the following key qualitative and quantitative considerations:</span></div><div><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Sector &amp; Stage&#8212; focus on US-based, public oncology companies in Phase I and Phase II of clinical trials;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Market Capitalization&#8212;between approximately $100 and $800 million (as of the date the peer group was determined and based on our market capitalization of $255 million at the time the analysis was conducted);</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Headcount&#8212;generally under 100 employees; and</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Geography &#8211; companies headquartered in San Diego and other biotech hubs such as SF/Bay Area and Boston/Cambridge area;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:17.54pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:17.54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2022 Peer Group</span></div><div style="text-indent:17.54pt"><span><br/></span></div><div style="text-indent:17.54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The companies in our peer group analysis in 2022 included the following:</span></div><div style="text-indent:17.54pt"><span><br/></span></div><div style="text-indent:17.54pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Aldeyra Therapeutics</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Curis</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IDEAYA Biosciences</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Protagonist Therapeutics</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">AnaptysBio</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">CymaBay Therapeutics</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Kezar Life Sciences</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Syndax Pharmaceuticals</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Calithera Biosciences</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Five Prime Therapeutics</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Mustang Bio</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">TCR2 Therapeutics</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Crinetics Pharmaceuticals</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Frequency Therapeutics</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Odonate Therapeutics</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">XOMA</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">CTI BioPharma</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_463">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Elements of Compensation</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s executive compensation program consists of three primary elements: base salaries, annual cash incentives and long-term equity awards.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.774%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.776%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Element of Pay</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Structure</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Highlights</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Base Salary</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">Set to be competitive within our industry and are important in attracting and retaining talented executives.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">Fixed pay set with consideration for responsibilities, market data, individual experience and contribution.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">Reviewed annually and adjusted when appropriate, based on scope of responsibility, performance, experience, and competitive market for executive talent.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">We generally target the 50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> percentile for base salary within our peer group, and allow for adjustments based on factors specific to the individual executive</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">Fiscal year 2022 salaries were selectively increased to strengthen alignment with peer group market practices, to recognize performance and contribution to our overall business success, and to better align salaries with overall leadership responsibilities.</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Annual Cash Incentive Bonuses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">Our annual cash incentive award plan is intended to motivate and reward our executives for the achievement of certain short-term strategic and business goals for the Company.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">Variable compensation paid in cash creates &#8220;pay for performance&#8221; culture.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">Performance metrics evaluated annually for alignment with strategy.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">We generally target the 50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> percentile for annual cash incentive bonus target levels within our peer group, and allow for adjustments based on factors specific to the individual executive</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">In 2022, corporate performance goals were based on demonstrating the value of our lead onvansertib clinical program in mCRC, strengthening the onvansertib pipeline with additional indications and optimizing onvansertib chemistry, manufacturing and controls. </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Long-Term Equity Incentives</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">Long-term equity incentives are awarded to encourage executives and other employees to focus on long-term company performance, to promote retention, and to reward outstanding company and individual performance.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">Stock options align Management's interest with long-term stockholder value creation because value is only created if our stock price increases.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">We generally target the 60</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> percentile for long term equity incentives within our peer group, and allow for adjustments based on factors specific to the individual executive.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">In 2022 our Compensation Committee approved stock option grants to our executive officers. The options vest over a 4 year period. 25% vest at the anniversary of the grant date and the remainder over 36 monthly equal installments. The Committee believes that options represent an efficient method of linking executive and stockholder experiences while promoting long term growth in stockholder value. </span></div></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_463">Table of Contents</a></span></div></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:108%">Base Salary</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Annual base salaries compensate our executive officers for fulfilling the requirements of their respective positions and provide them with a level of cash income predictability and stability with respect to a portion of their total compensation. We believe that the level of an executive officer&#8217;s base salary should reflect the executive&#8217;s performance, experience and breadth of responsibilities, our understanding of salaries for similar positions within our industry and peer group and any other factors relevant to that particular position.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Base salaries are typically negotiated at the outset of an executive&#8217;s employment. Salary levels are considered annually as part of our performance review process, but also in cases including promotion or other changes in the job responsibilities of an executive officer. For named executive officers, initial base salaries generally are established in connection with negotiation of an offer of employment and an employment agreement. Following initial setting of base salaries, they are typically reevaluated in connection with promotion or increased responsibilities, employee&#8217;s merit and Company-wide general increases.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Named Executive Officers Change in Base Salary</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.278%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name and Position</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022 Salary ($)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 Salary ($)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change from 2021 (%)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Mark Erlander, CEO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">570,600</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">532,716</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">7%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">James Levine, CFO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">440,675</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">425,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Tod Smeal, CSO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">402,716</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">N/A</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">N/A</span></div></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Compensation Committee followed the recommendation from Aon for an above market increase for Mr. Erlander to align target cash compensation with market.  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Mr. Levine's employment began in July 2021, therefore the above table for that year reflects his annualized salary for 2021. The Compensation Committee followed the recommendation from Aon and increased Mr. Levine's base salary to reflect market competitiveness. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Mr. Smeal's employment began in January 2022. </span></div><div><span><br/></span></div><div><span id="i88ddd4b8b6a341349c266961c1a5d35f_77072"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Annual Performance Cash Bonuses</span></div><div style="text-align:justify;text-indent:17.4pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We design our annual cash incentive programs to be competitive in relation to the market. We monitor the market and adjust our cash incentive programs as needed. Our cash incentive programs are designed to motivate employees to achieve overall company goals. Our programs are designed to avoid entitlements, to align actual payouts with the actual results achieved and to be easy to understand and administer.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each year, the Compensation Committee recommends, and the Board approves and establishes, the target cash incentive opportunity for each executive officer assuming full achievement of certain significant corporate goals that are also reviewed and approved by the Board. The following table shows the possible cash bonus incentive for each of our current named executive officers for fiscal 2022, (each expressed as a percentage of annual base salary) and the actual dollar awarded, based on the Compensation Committee's assessment that we achieved 85% of our corporate goals:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.502%"></td><td style="width:0.1%"></td></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name and Position</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Bonus Potential</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash incentive % of Annual Salary Actually Earned</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Incentive Bonus Actually Earned ($)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Mark Erlander, CEO</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">55%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">47%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$266,475</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2021</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">50%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">47%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$250,510</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">James Levine, CFO</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">45%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">38%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$168,252</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">45%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">42%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$179,775</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Tod Smeal, CSO</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">45%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">38%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$156,825</span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_463">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 annual performance cash bonus was approved by the Compensation Committee based on our achievement of a set of measurable, detailed goals. In the table below, we present an abbreviated list of the 2022 corporate goals to align with our current public disclosure, as well as the Compensation Committee&#8217;s assessment of our goal attainment:</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:55.042%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Abbreviated Goal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Compensation Committee assessment</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Create Short to Mid-Term Value: Demonstrate the value of lead onvansertib mCRC clinical program</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Clinical operations</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Regulatory activities</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Trial reporting</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Compensation Committee&#8217;s assessment of goal achievement was based on a detailed review of site initiation, patient enrollment, FDA interactions, and clinical data releases.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Create Long-Term Value: Strengthen onvansertib pipeline with additional indications</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Evaluate additional indications</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Initiate new clinical trials</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Compensation Committee&#8217;s assessment of goal achievement was based on a detailed review of initiation and enrollment in clinical trials outside of mCRC, and additional preclinical activity. </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Building the Future: Optimize onvansertib chemistry, manufacturing and controls (CMC)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Compensation Committee&#8217;s assessment of goal achievement was based on progress made in CMC-related programs.</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the above assessment, the Compensation Committee determined that we achieved 85% of our corporate goals for 2022 and this was the percentage applied to calculate the actual bonus payout against the target bonus levels of executives.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Long-term Equity Incentive Awards</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant stock options, pursuant to the 2021 Omnibus Equity Incentive Plan ("2021 Plan") to our employees within a competitive range of the market to complement cash salaries and cash incentives, incentivize all employees to achieve our corporate and strategic goals, and align executive compensation with the long-term interests of our stockholders. We historically provided stock option grants to our named executive officers upon their initial hiring, as negotiated in their employment agreements or offer letters, and on an annual basis thereafter. The Compensation Committee has the discretion to grant stock option awards and restricted stock awards to promote high performance and achievement of our corporate objectives by our executives at any time of the year. The Compensation Committee does not currently have a policy for the automatic awarding of equity awards to the named executive officers or our other employees, nor do we have any formal plan that requires us to award equity or equity-based compensation to any executive on a year-to-year basis. However, it has been our practice to grant awards annually in the first quarter of the fiscal year. The grant date is established when the Compensation Committee approves the grant and all key terms have been determined.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In granting these awards, the Compensation Committee may establish any conditions or restrictions it deems appropriate in accordance with the 2021 Omnibus Equity Incentive Plan, as the case may be. Our Chief Executive Officer typically provides recommendations to the Compensation Committee for equity grants to the executive officers, taking into account each executive&#8217;s performance, achievements, and other criteria deemed relevant. The Compensation Committee, working closely with Aon, reviews the proposed grants, but reserves the right to reject or modify such recommendations. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We size equity grants based on market data that expresses the awards as a percent of common shares outstanding. This sizing approach is helpful to ensure that the dilutive effects of the grants are balanced against the desire to provide employees with appropriate incentives for long-term value creation. The exercise price of the stock options will equal the closing price of our common stock published by Nasdaq on the date of the grant and the term of the options will be 10 years from the date of the grant. The options have a vesting term of four years, with 25% vesting at the first anniversary of the date of grant and the remaining amount vesting in 36 equal monthly installments thereafter.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity awards granted to our named executive officers for fiscal 2022 and certain prior years are reported in the Summary Compensation Table included under the heading &#8220;Summary Compensation Table&#8221; on page </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i792e6564376e43e6b357f567cfb66fb9_8469">33</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of this Proxy Statement.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inducement Grants</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2021, we have utilized inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4) at the time of hire for named executive officers and other executives. The size of the inducement grants is based on competitive market data </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_463">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provided to us by Aon, and is negotiated as part of the executives offer letter or employment agreement. The vesting terms and expiration date of the inducement grants generally are the same as options granted under the 2021 Plan. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Benefit Plans</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to financial compensation, we also provide all employees, including the executive officers, with benefits including group life insurance, and health, vision and dental care insurance. All such benefits terminate at the time each individual is no longer employed with the Company or as otherwise provided in the applicable employment agreement. All of our named executive officers are eligible to participate in all of our employee benefit plans, in each case on the same basis as other employees. We maintain a 401(k) defined contribution plan, which is our primary retirement benefit for employees, including executives. Although permitted under the plan, we have not matched employee contributions to the 401(k) plan. We do not provide our executive officers with any type of defined-benefit retirement plan or the opportunity to defer compensation pursuant to a non-qualified deferred compensation plan. We do not offer our named executive officers any material compensation in the form of perquisites.</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Other Compensation Practices</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Clawback Policy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, the Compensation Committee resolved to adopt a recoupment or &#8220;clawback&#8221; policy for annual cash incentive awards, long-term incentive awards (including stock options and restricted stock) and any other incentive awards paid to executive officers under certain circumstances. Our clawback policy provides that in the event the Company determines it must restate its financial results as reported in a Form 10-K, Form 10-Q or other report filed with the Securities and Exchange Commission to correct an accounting error due to material noncompliance with any financial reporting requirement under the U. S. federal securities laws (a Restatement), the Company will seek to recover, at the direction of the Compensation Committee after it has reviewed the facts and circumstances that led to the requirement for the Restatement and the costs and benefits of seeking recovery, incentive compensation (cash and equity-based) awarded or paid within one year following the filing of the financial report giving rise to the Restatement to a covered officer whose intentional misconduct caused or contributed to the need for the Restatement for a fiscal period if a lower award or payment would have been made to such covered officer based upon the restated financial results. The Committee will determine in its discretion the amount, if any, the Company will seek to recover from such covered officer.</span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i6eaaaa0344f74a9caae5f17960d0edec_497"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Chief Executive Officer&#8217;s Compensation</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, 65% of our Chief Executive Officer&#8217;s compensation was performance based, which is aligned with the Company's pay for performance philosophy:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><img src="crdf-20230427_g1.jpg" alt="1099511628069" style="height:300px;margin-bottom:5pt;vertical-align:text-bottom;width:613px"/></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="i6eaaaa0344f74a9caae5f17960d0edec_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_463">Table of Contents</a></span></div></div><div><span id="i792e6564376e43e6b357f567cfb66fb9_8469"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary Compensation Table</span></div><div style="text-align:center"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides certain summary information concerning compensation awarded to, earned by or paid to our NEO's for fiscal year&#160;2022. </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.065%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.511%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.732%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.511%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.368%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.644%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.511%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.511%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.287%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name and Principal Position</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Salary&#160;($)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Bonus&#160;($)</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option Awards&#160;($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-Equity Incentive Plan Compensation&#160;($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;($)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark Erlander, CEO</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570,600&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">753,272&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,475&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,590,347&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532,716&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,851,972&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,510&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,635,198&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James Levine, CFO</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959,479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,085,227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,775&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,467,695&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tod Smeal, CSO</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402,716&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,487,292&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,825&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,086,833&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.198%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.34pt">The amounts in this column relate to he Annual Performance Cash Bonuses, described above in the summary of compensation practices, earned by the Named Executive Officers in 2022 and 2021.</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Amounts shown in this column do not reflect dollar amounts actually received by our named executive officers. Instead, these amounts represent the aggregate grant date fair value of stock option awards determined in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic&#160;718. The valuation assumptions used in determining&#160;2022 and 2021 amounts are described in Note&#160;6 to our financial statements included in our Annual Reports on Form&#160;10-K for the fiscal years ended December 31, 2022 and 2021. The exercise price and number of stock options granted to NEO's for fiscal 2022 and certain prior years are reported in the Outstanding Equity Awards Table included under the heading &#8220;Outstanding Equity Awards at Fiscal Year-End&#8221; on page </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i50339a1f7e614ed387610618440cce65_2505">34</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of this Proxy Statement.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.34pt">Mr. Levine was hired in July 2021, and, as part of Mr. Levine's employment agreement, he was awarded a new-hire inducement grant of 390,000 non-qualified stock options, with an exercise price of $6.55. These options will vest over four years. The number of options granted was based on the competitive market at time of hire. </span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.34pt">Mr. Smeal was hired in January 2022, and received a $40,000 new-hire signing bonus paid during 2022.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.34pt">As part of Mr. Smeal's offer letter, he was awarded a new-hire inducement grant of 275,088 non-qualified stock options, with an exercise price of $6.58. These options will vest over four years. The number of options granted was based on the competitive market at time of hire.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="i6eaaaa0344f74a9caae5f17960d0edec_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_463">Table of Contents</a></span></div></div><div><span id="i50339a1f7e614ed387610618440cce65_2505"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outstanding Equity Awards at Fiscal Year-End</span></div><div style="text-align:center"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information for the named executive officers regarding the number of shares subject to both exercisable and unexercisable stock options as well as the exercise prices and expiration dates thereof, as of December 31, 2022. Except for the options set forth in the table below, no other equity awards were held by any of our named executive officers as of December 31, 2022.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.859%"><tr><td style="width:1.0%"></td><td style="width:30.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.893%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.893%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.458%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option Awards</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">New Hire or Promotion-based Grant</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Securities<br/>Underlying Unexercised Options (#)<br/>Exercisable</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Securities<br/>Underlying Unexercised Options (#)<br/>Unexercisable</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option<br/>Exercise Price&#160;($)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option<br/>Expiration Date</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark Erlander</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,778&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506.88&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/28/2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,389&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398.16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/11/2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,778&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236.88&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/16/2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316.08&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/11/2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,084&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372.96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/4/2026</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,348&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/22/2027</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,336&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/23/2028</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,203&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.48&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/20/2029</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,494&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,747&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/17/2030</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,152&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,920&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.98&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/10/2031</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370,128&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/9/2032</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James Levine</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/12/2031</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/9/2032</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tod Smeal</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275,088&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.58&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/10/2032</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.198%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">For each executive officer, the shares listed in this table are subject to a single stock option award carrying the varying exercise prices as set forth herein. The option awards remain exercisable until they expire ten years from the date of grant, subject to earlier expiration following termination of employment.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">73,747 will vest on June 17, 2023. </span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">9,064 will vest monthly from January 10, 2023 through June 10, 2025. The employee was promoted to CEO in 2020 and subsequently received a higher stock option grant in 2021. </span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">92,532 Stock Options will vest on March 9, 2023, and 7,711 will vest monthly from April 9, 2023 through March 9, 2026.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">8,125 will vest monthly from January 12, 2023 through July 12, 2025.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">42,504 Stock Options will vest on March 9, 2023, and 3,542 will vest monthly from April 9, 2023 through March 9, 2026.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">68,772 Stock Options will vest on January 10, 2023, and 5,731 will vest monthly from February 10, 2023 through January 10, 2026.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="i6eaaaa0344f74a9caae5f17960d0edec_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_463">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employment Agreements</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mark Erlander Employment Agreement </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;22, 2021, we entered into an amended and restated employment agreement with Dr.&#160;Erlander (the &#8220;Erlander Employment Agreement&#8221;). The term of the Erlander Employment Agreement commenced on February&#160;22, 2021 and will continue until February 21, 2024, following which time the Erlander Employment Agreement will be automatically renewed for successive one year periods at the end of each term, unless either party delivers written notice to the other party of their intent to not renew the agreement. Pursuant to the Erlander Employment Agreement, Dr.&#160;Erlander&#8217;s base compensation is $533,000 per year. Dr.&#160;Erlander is eligible to receive a cash bonus of up to 55% of his base salary per year based on meeting certain performance objectives and bonus criteria.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If Dr.&#160;Erlander&#8217;s employment is terminated by us for cause or as a result of Dr.&#160;Erlander&#8217;s death or permanent disability, or if Dr.&#160;Erlander terminates his employment agreement voluntarily, Dr.&#160;Erlander will be entitled to receive a lump sum equal to (i)&#160;any portion of unpaid base compensation then due for periods prior to termination, (ii)&#160;any bonus earned but not yet paid through the date of his termination, and (iii)&#160;all business expenses reasonably and necessarily incurred by Dr.&#160;Erlander prior to the date of termination. If Dr.&#160;Erlander&#8217;s employment is terminated by us without cause or by Dr.&#160;Erlander for good reason, Dr.&#160;Erlander will be entitled to receive the amounts due upon termination of his employment by us for cause or as a result of his death or permanent disability, or upon termination by Dr.&#160;Erlander of his employment voluntarily, in addition to (provided that Dr.&#160;Erlander executes a written release with respect to certain matters) a severance payment equal to his base compensation for 12&#160;months from the date of termination and the bonus and any benefits that Dr.&#160;Erlander would be eligible for during such 12 month period. In addition, if Dr.&#160;Erlander&#8217;s employment is terminated: (a)&#160;by us without cause within 12&#160;months prior to a change of control (as defined in the Erlander Employment Agreement) that was pending during such 12&#160;month period, (b)&#160;by Dr.&#160;Erlander for good reason within 12&#160;months after a change of control, or (c)&#160;by us without cause at any time upon or within 12&#160;months after a change of control, Dr.&#160;Erlander will be entitled to receive the amounts due upon termination of his employment by us for cause or as a result of his death or permanent disability, or upon termination by Dr.&#160;Erlander of his employment voluntarily, in addition to the severance payments due if Dr.&#160;Erlander&#8217;s employment is terminated by us without cause or by Dr.&#160;Erlander for good reason, and all of Dr.&#160;Erlander&#8217;s unvested stock options and other equity awards would immediately vest and become fully exercisable (x)&#160;in the event a change of control transaction is pending, for a period of six months following the date of termination, and (y)&#160;in the event a change of control transaction is not then pending, for the period of time set forth in the applicable agreement evidencing the award.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">James Levine Employment Agreement </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 12, 2021, we entered into an employment agreement with Mr. Levine (the &#8220;Levine Employment Agreement&#8221;). The term of the Levine Employment Agreement commenced on July&#160;12, 2021 and will continue until July 12, 2024, following which time the Levine Employment Agreement will be automatically renewed for successive one year periods at the end of each term, unless either party delivers written notice to the other party of their intent to not renew the agreement. Pursuant to the Levine Employment Agreement, Mr. Levine&#8217;s base compensation is $425,000 per year. Mr. Levine is eligible to receive a cash bonus of up to 45% of his base salary per year based on meeting certain performance objectives and bonus criteria.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If Mr. Levine&#8217;s employment is terminated by us for cause or as a result of Mr. Levine&#8217;s death or permanent disability, or if Mr. Levine terminates his employment agreement voluntarily, Mr. Levine will be entitled to receive a lump sum equal to (i) any portion of unpaid Base Compensation then due for periods prior to the effective date of termination; (ii) any Bonus and Options earned and not yet paid or granted, as applicable, through the date of termination; and (iii) all business expenses reasonably and necessarily incurred by Mr. Levine prior to the date of termination. If Mr. Levine&#8217;s employment is terminated by us without cause or by Mr. Levine for good reason, Mr. Levine will be entitled to receive the amounts due upon termination of his employment by us for cause or as a result of his death or permanent disability, or upon termination by Mr. Levine of his employment voluntarily, in addition to (provided that Mr. Levine executes a written release with respect to certain matters) a severance payment equal to his base compensation for 12 months from the date of termination and the bonus and any benefits that Mr. Levine would be eligible for during such 12 month period. In addition, if Mr. Levine&#8217;s employment is terminated: (a) by us without cause within 12 months prior to a change of control (as defined in the Levine Employment Agreement) that was pending during such 12 month period, (b) by Mr. Levine for good reason within 12 months after a change of control, or (c) by us without cause at any time upon or within 12 months after a change of control, Mr. Levine will be entitled to receive the amounts due upon termination of his employment by us for cause or as a result of his death or permanent disability, or upon termination by Mr. Levine of his employment voluntarily, in addition to the severance payments due if Mr. Levine&#8217;s employment is terminated by us without cause or by Mr. Levine for good reason, and all of Mr. Levine&#8217;s unvested stock options and other equity awards would immediately vest and become fully exercisable (x) in the event a change of control transaction is </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_463">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pending, for a period of six months following the date of termination, and (y) in the event a change of control transaction is not then pending, for the period of time set forth in the applicable agreement evidencing the award.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tod Smeal Severance Agreement</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 10, 2022 we entered into a severance agreement with Mr. Smeal (the &#8220;Smeal Severance Agreement&#8221;). The term of the Smeal Severance Agreement commenced on January&#160;10, 2022 and will continue until all of obligations of the agreement have been satisfied. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Covered terminations</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If Mr. Smeal experiences a Covered Termination, and if Mr. Smeal delivers to the Company a general release of all claims against the Company and its affiliates (a "Release of Claims"), that becomes effective within 55 days following the Covered Termination and irrevocable within 62 days following the Covered Termination (the "Release Requirements"), then in addition to any accrued but unpaid salary, accrued but unused vacation, incurred but unreimbursed business expenses payable in accordance with applicable law, or vested benefits (other than severance) under any Company benefit plan (the "Accrued Amounts "), Mr. Smeal shall be entitled to receive (i) an amount equal to twelve (12) months of Mr. Smeal's base salary as of the Termination Date, payable in cash in the form of salary continuation, commencing on the first normally-scheduled Company payroll date that is at least 75 days following the Termination Date (with any such amounts that normally would have been payable during the period between the Termination Date and such first payment being included in such first payment), less authorized deductions and applicable withholding taxes and (ii) the potential bonus the Mr. Smeal is or would be eligible for during the twelve (12) month period following the Termination Date. In addition, in the event of Mr. Smeal&#8217;s termination of employment with the Company either (i) by the Company without Cause at any time within twelve (12) months prior to the consummation of a Change of Control if, prior to, or as of such termination, a Change of Control transaction was Pending at any time during such twelve (12)-month period, (ii) by Mr. Smeal for Good Reason at any time within twelve (12) months after the consummation of a Change of Control, or (iii) by the Company without Cause at any time upon or within twelve (12) months after the consummation of a Change of Control, then, notwithstanding any provision of any stock incentive plan, stock option agreement, restricted stock agreement or other agreement relating to capital stock of the Company, all of the shares and equity awards held by Mr. Smeal that are then unvested shall immediately vest and, with respect to all options, warrants and other convertible securities of the Company beneficially held by Mr. Smeal, become fully exercisable for (A) a period of six months following the Termination Date only if at the time of such termination there is a Change of Control transaction Pending or (B) if clause (A) does not apply, then such period of time set forth in the agreement evidencing the security. In order to effectuate the provisions of the preceding sentence, in the event that Mr. Smeal&#8217;s employment is terminated by the Company without Cause or by Mr. Smeal for Good Reason, no equity award held by Mr. Smeal shall expire or terminate prior to the earlier to occur of (a) ten (10) years after the date of the award and (b) twelve (12) months after Mr. Smeal&#8217;s termination of employment with the Company.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Smeal shall be entitled to any rights guaranteed by the Consolidated Omnibus Budget Reconciliation Act of 1985 (&#8220;COBRA&#8221;). In the event Mr. Smeal elects to receive health insurance coverage in accordance with COBRA, the Company shall pay, on behalf of Mr. Smeal, any required premiums for such coverage to the same extent as while Mr. Smeal was employed by the Company, for a period of six (6) months following the Termination Date; provided, Mr. Smeal remains eligible for such COBRA benefit. Premium and other payments required for any further continued health insurance coverage, in accordance with COBRA, shall be the sole responsibility of Mr. Smeal.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other terminations</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">If Mr Smeal's service with the Company is terminated by the Company or by Employee for any or no reason other than a Covered Termination, then Mr. Smeal shall only be entitled to Accrued Amounts.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><div id="i6eaaaa0344f74a9caae5f17960d0edec_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_463">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Potential Payments Upon Termination or Change In Control</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the provisions of the executive severance benefits to which our named executive officers would be entitled to at December 31, 2022 as set forth above, we have no liabilities under termination or change in control conditions. We do not have a formal policy to determine executive severance benefits. Each executive severance arrangement is negotiated on an individual basis.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below estimates the current value of amounts payable to our named executive officer in the event that a termination of employment occurred on December 31, 2022. The closing price of our common stock, as reported on the Nasdaq Capital Market, was $1.40 on December 30, 2022. The following table excludes certain benefits, such as accrued Paid Time Off ("PTO"), that are available to all employees generally. The actual amount of payments and benefits that would be provided can only be determined at the time of a change in control and/or the named executive officer&#8217;s qualifying separation from our Company. The table is merely an illustrative example of the impact of a hypothetical termination of employment or change in control and qualifying termination. The amounts that would actually be paid upon a termination of employment can only be determined at the time of such termination, based on the fact and circumstances then prevailing. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mark Erlander</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.661%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.469%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.838%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Termination</span></td></tr><tr style="height:36pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">By&#160;Cardiff Oncology Without<br/>Cause&#160;Outside&#160;a&#160;Change<br/>In Control</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">By&#160;Cardiff Oncology&#160;Without</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cause&#160;or&#160;by&#160;Dr.&#160;Erlander&#160;for</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Good Reason in Connection</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">with a Change In Control</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value of Equity Securities Accelerated</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820,688&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash Payments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">898,558&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">898,558&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Cash Benefits and Payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">898,558&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,719,246&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.198%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Relates to the termination of the Erlander Employment Agreement: (a)&#160;by us without cause within 12 months prior to a change of control that was pending during such 12 month period, (b)&#160;by Dr.&#160;Erlander for good reason within 12 months after a change of control, or (c)&#160;by us without cause at any time upon or within 12 months after a change of control.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">James Levine</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.661%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.469%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.838%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Termination</span></td></tr><tr style="height:36pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">By&#160;Cardiff Oncology Without<br/>Cause&#160;Outside&#160;a&#160;Change<br/>In Control</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">By&#160;Cardiff Oncology&#160;Without</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cause&#160;or&#160;by&#160;Mr. Levine&#160;for</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Good Reason in Connection</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">with a Change In Control</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value of Equity Securities Accelerated</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478,921&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash Payments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,450&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,450&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Cash Benefits and Payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,450&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142,371&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.198%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Relates to the termination of the Levine Employment Agreement: (a)&#160;by us without cause within 12 months prior to a change of control that was pending during such 12 month period, (b)&#160;by Mr. Levine for good reason within 12 months after a change of control, or (c)&#160;by us without cause at any time upon or within 12 months after a change of control.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_463">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tod Smeal</span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.661%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.469%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.838%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Termination</span></td></tr><tr style="height:36pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">By&#160;Cardiff Oncology Without<br/>Cause&#160;Outside&#160;a&#160;Change<br/>In Control</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">By&#160;Cardiff Oncology&#160;Without</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cause&#160;or&#160;by&#160;Mr. Levine&#160;for</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Good Reason in Connection</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">with a Change In Control</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value of Equity Securities Accelerated</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302,046&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash Payments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602,719&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602,719&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Cash Benefits and Payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602,719&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904,765&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.198%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Relates to the termination of the Smeal Severance Agreement: (a)&#160;by us without cause within 12 months prior to a change of control that was pending during such 12 month period, (b)&#160;by Mr. Smeal for good reason within 12 months after a change of control, or (c)&#160;by us without cause at any time upon or within 12 months after a change of control.</span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i6eaaaa0344f74a9caae5f17960d0edec_37"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Director Compensation</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our non-employee director compensation policy, a new non-employee director receives an initial grant of options to purchase a number of shares of common stock that considers competitive market for comparable companies. These options vest in equal annual installments over 3 years. In addition, each non-employee director receives the following annual compensation for his or her service: </span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Committee membership</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Annual retainer non-employee board member</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Audit</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Compensation</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corporate Governance/Nominating</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chair</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$40,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$16,000</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$10,000</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$8,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$65,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$8,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4,000</span></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, each non-employee director receives an annual equity grant of options to purchase a number of shares of common stock that considers the market for comparable companies. As a result, the 2022 option grant for continuing directors was equal to 26,800 stock options, that vest on the one-year anniversary of the date of the grant, and had an exercise price of $2.50 (subject to adjustment for recapitalizations, stock split, stock dividends and the like). </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth summary information concerning the total compensation paid to our non-employee directors in&#160;2022, paid quarterly in arrears, for services to our company:</span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:49.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fees&#160;Earned&#160;or Paid&#160;in&#160;Cash&#160;($)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option Awards ($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total ($)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. James O. Armitage, M.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,731&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,731&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Brancaccio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Rodney S. Markin, M.D., Ph.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mani Mohindru, Ph.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,964&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gary W. Pace, Ph.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renee P. Tannenbaum, Pharm.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">L&#226;le White</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(8)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:2.2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.198%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Amounts shown in this column do not reflect dollar amounts actually received by our non-employee directors. Instead, these amounts represent the aggregate grant date fair value of stock option awards determined in accordance with FASB ASC Topic&#160;718. The valuation assumptions used in determining&#160;2022 amounts are described in Note&#160;6 to our financial statements included in our Annual Report on Form&#160;10-K for the fiscal year ended December 31, 2022.</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">As of December&#160;31, 2022, 89,574 stock options were outstanding, of which&#160;58,802 were exercisable. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_463">Table of Contents</a></span></div></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Mr. Brancaccio's' term as a director ended on June 10, 2022. As of December&#160;31, 2022, 125,033 stock options were outstanding, all of which were exercisable. The expiration dates of Mr. Brancaccio's' outstanding stock options were modified at the end of his term, resulting in the revaluation of his stock options. </span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">As of December&#160;31, 2022, 124,627 stock options were outstanding, of which&#160;97,827 were exercisable.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">As of December&#160;31, 2022, 70,801 stock options were outstanding, of which 14,667 were exercisable.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">As of December&#160;31, 2022, 89,574 stock options were outstanding, of which 58,802 were exercisable.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">As of December&#160;31, 2022, 70,801 stock options were outstanding, of which 14,667 were exercisable.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">As of December&#160;31, 2022, 60,716 stock options were outstanding, of which 29,944 were exercisable.</span></div><div><span><br/></span></div><div id="i6eaaaa0344f74a9caae5f17960d0edec_444"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pay Versus Performance</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reports the compensation of our Principal Executive Officer ("PEO") and our other highest paid executive officers as reported in the Summary Compensation Table, as well as compensation actually paid ("CAP") for fiscal year&#160;2022 and 2021:</span></div><div style="text-indent:36pt"><span><br/></span></div><div><ix:nonNumeric contextRef="ie01d1de15b9444b183272d5953f012c0_D20220101-20221231" name="ecd:PvpTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90ZXh0cmVnaW9uOmQ0NjAxNzdjYTM0ZDQ5YzQ4MmY2MjhjNTcxYTdkMDAyXzIxOTkwMjMyNTY2NjQ_4a5305d5-a86f-4ff8-b29d-cfdb49df3549" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.902%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.834%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.834%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.834%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.834%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.837%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Summary Compensation Table Total for PEO ($)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Compensation Actually Paid to PEO ($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average Summary Compensation Table Total for Non-PEO NEOs ($)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average Compensation Actually Paid to Non-PEO NEOs ($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value of Initial Fixed $100 Investment Based on Total Shareholder Return ($)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Loss </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">($ in thousands)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie01d1de15b9444b183272d5953f012c0_D20220101-20221231" decimals="0" name="ecd:PeoTotalCompAmt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpmYTliMDI1NjAzOWM0ZGM1YTkwNDU4OWQyMjBiNTFiNS90YWJsZXJhbmdlOmZhOWIwMjU2MDM5YzRkYzVhOTA0NTg5ZDIyMGI1MWI1XzEtMi0xLTEtNDkwMzc_840efb56-53d2-439d-93e8-5d5b90c69ec4">1,590,347</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie01d1de15b9444b183272d5953f012c0_D20220101-20221231" decimals="0" name="ecd:PeoActuallyPaidCompAmt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpmYTliMDI1NjAzOWM0ZGM1YTkwNDU4OWQyMjBiNTFiNS90YWJsZXJhbmdlOmZhOWIwMjU2MDM5YzRkYzVhOTA0NTg5ZDIyMGI1MWI1XzEtNC0xLTEtNDg5Mjk_4ee9715d-6d2d-49ce-b0d1-060ddfd320d1">91,869</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie01d1de15b9444b183272d5953f012c0_D20220101-20221231" decimals="0" name="ecd:NonPeoNeoAvgTotalCompAmt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpmYTliMDI1NjAzOWM0ZGM1YTkwNDU4OWQyMjBiNTFiNS90YWJsZXJhbmdlOmZhOWIwMjU2MDM5YzRkYzVhOTA0NTg5ZDIyMGI1MWI1XzEtOC0xLTEtNDkwMzc_d2b52226-dccd-4110-aafe-5b85f3987c31">1,523,156</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie01d1de15b9444b183272d5953f012c0_D20220101-20221231" decimals="0" name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpmYTliMDI1NjAzOWM0ZGM1YTkwNDU4OWQyMjBiNTFiNS90YWJsZXJhbmdlOmZhOWIwMjU2MDM5YzRkYzVhOTA0NTg5ZDIyMGI1MWI1XzEtMTAtMS0xLTQ4OTM1_edf74a1d-c86b-4533-93b7-67b39e67957c">222,550</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie01d1de15b9444b183272d5953f012c0_D20220101-20221231" decimals="0" name="ecd:TotalShareholderRtnAmt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpmYTliMDI1NjAzOWM0ZGM1YTkwNDU4OWQyMjBiNTFiNS90YWJsZXJhbmdlOmZhOWIwMjU2MDM5YzRkYzVhOTA0NTg5ZDIyMGI1MWI1XzEtMTItMS0xLTQ5MDM3_9cf42c5f-791e-43ff-abd4-042f81337507">8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie01d1de15b9444b183272d5953f012c0_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpmYTliMDI1NjAzOWM0ZGM1YTkwNDU4OWQyMjBiNTFiNS90YWJsZXJhbmdlOmZhOWIwMjU2MDM5YzRkYzVhOTA0NTg5ZDIyMGI1MWI1XzEtMTYtMS0xLTQ5MDM3_b99c6412-7f26-4267-b891-6a0d26cf2374">38,728</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i162e015e217c4d45bddc31b5744d6c17_D20210101-20211231" decimals="0" name="ecd:PeoTotalCompAmt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpmYTliMDI1NjAzOWM0ZGM1YTkwNDU4OWQyMjBiNTFiNS90YWJsZXJhbmdlOmZhOWIwMjU2MDM5YzRkYzVhOTA0NTg5ZDIyMGI1MWI1XzItMi0xLTEtNDkwMzc_a44c395e-3065-4f95-80a8-dc45b41146e2">3,635,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i162e015e217c4d45bddc31b5744d6c17_D20210101-20211231" decimals="0" sign="-" name="ecd:PeoActuallyPaidCompAmt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpmYTliMDI1NjAzOWM0ZGM1YTkwNDU4OWQyMjBiNTFiNS90YWJsZXJhbmdlOmZhOWIwMjU2MDM5YzRkYzVhOTA0NTg5ZDIyMGI1MWI1XzItNC0xLTEtNDg5Njc_206f8634-d533-47d6-b71b-c288a41e8cb2">1,401,408</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i162e015e217c4d45bddc31b5744d6c17_D20210101-20211231" decimals="0" name="ecd:NonPeoNeoAvgTotalCompAmt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpmYTliMDI1NjAzOWM0ZGM1YTkwNDU4OWQyMjBiNTFiNS90YWJsZXJhbmdlOmZhOWIwMjU2MDM5YzRkYzVhOTA0NTg5ZDIyMGI1MWI1XzItOC0xLTEtNDkwMzc_dfb734ba-9e01-4506-be57-d6632ea00d0c">2,148,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i162e015e217c4d45bddc31b5744d6c17_D20210101-20211231" decimals="0" name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpmYTliMDI1NjAzOWM0ZGM1YTkwNDU4OWQyMjBiNTFiNS90YWJsZXJhbmdlOmZhOWIwMjU2MDM5YzRkYzVhOTA0NTg5ZDIyMGI1MWI1XzItMTAtMS0xLTQ4OTcz_114045b3-9f68-4e13-b5c2-5008ac303ef9">539,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i162e015e217c4d45bddc31b5744d6c17_D20210101-20211231" decimals="0" name="ecd:TotalShareholderRtnAmt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpmYTliMDI1NjAzOWM0ZGM1YTkwNDU4OWQyMjBiNTFiNS90YWJsZXJhbmdlOmZhOWIwMjU2MDM5YzRkYzVhOTA0NTg5ZDIyMGI1MWI1XzItMTItMS0xLTQ5MDM3_9978cc38-f207-406f-bf33-f1a5633ed945">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i162e015e217c4d45bddc31b5744d6c17_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpmYTliMDI1NjAzOWM0ZGM1YTkwNDU4OWQyMjBiNTFiNS90YWJsZXJhbmdlOmZhOWIwMjU2MDM5YzRkYzVhOTA0NTg5ZDIyMGI1MWI1XzItMTYtMS0xLTQ5MDM3_268adb32-4a93-4e02-902d-c944bf86db89">28,315</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"><ix:nonNumeric contextRef="ie01d1de15b9444b183272d5953f012c0_D20220101-20221231" name="ecd:NamedExecutiveOfficersFnTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90ZXh0cmVnaW9uOmQ0NjAxNzdjYTM0ZDQ5YzQ4MmY2MjhjNTcxYTdkMDAyXzMyOTg1MzQ4ODg5Nzk_e26ef8da-64be-4e6d-a195-87ea48d88750" continuedAt="i6c4ca9388d4342dcb8fd8850adf8c8d0" escape="true"><ix:nonNumeric contextRef="ie01d1de15b9444b183272d5953f012c0_D20220101-20221231" name="ecd:PeoName" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90ZXh0cmVnaW9uOmQ0NjAxNzdjYTM0ZDQ5YzQ4MmY2MjhjNTcxYTdkMDAyXzMyOTg1MzQ4ODg5Nzg_ac59b8f8-1144-478e-85b8-b0718d4a4343">Mr. Erlander</ix:nonNumeric> served as our PEO during each year shown. The Non-PEO NEO's presented in the table represent the two highest paid NEO's during the respective years as follows:</ix:nonNumeric></span></div><ix:continuation id="i6c4ca9388d4342dcb8fd8850adf8c8d0"><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">2022: James Levine and Tod Smeal</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">2021: Vicki Kelemen and James Levine</span></div></ix:continuation><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"><ix:nonNumeric contextRef="ie01d1de15b9444b183272d5953f012c0_D20220101-20221231" name="ecd:AdjToPeoCompFnTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90ZXh0cmVnaW9uOmQ0NjAxNzdjYTM0ZDQ5YzQ4MmY2MjhjNTcxYTdkMDAyXzMyOTg1MzQ4ODg5ODA_21a8ac97-326c-4155-a41b-f323fa2788c6" continuedAt="i55a1f5bf16374b9ca4b0359a8ece4fdd" escape="true"><ix:nonNumeric contextRef="ie01d1de15b9444b183272d5953f012c0_D20220101-20221231" name="ecd:AdjToNonPeoNeoCompFnTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90ZXh0cmVnaW9uOmQ0NjAxNzdjYTM0ZDQ5YzQ4MmY2MjhjNTcxYTdkMDAyXzMyOTg1MzQ4ODg5ODA_451b0eb2-8a24-4ebd-ae63-b0ec8d41cc7b" continuedAt="ia381b802b2884b2ebe9bf5fb447be109" escape="true">The 2022 Summary Compensation Table totals reported for the PEO and the average of the Other NEOs for each year were subject to the following adjustments per Item 402(v)(2)(iii) of Regulation S-K to calculate &#8220;compensation actually paid&#8221;:</ix:nonNumeric></ix:nonNumeric></span></div><div style="padding-left:36pt"><span><br/></span></div><ix:continuation id="i55a1f5bf16374b9ca4b0359a8ece4fdd" continuedAt="ia9e71d46b4d343779488d9474116822f"><ix:continuation id="ia381b802b2884b2ebe9bf5fb447be109" continuedAt="iec5d37b855cd4d72a6188ab827dd2d0b"><div style="padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"></td><td style="width:50.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.377%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.377%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.377%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.385%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PEO ($)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average for Other NEO's ($)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PEO ($)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average for Other NEO's ($)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Summary Compensation Table</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie01d1de15b9444b183272d5953f012c0_D20220101-20221231" decimals="0" name="ecd:PeoTotalCompAmt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZToxOWNmYzMzYjE1M2M0YmM4OTY5MGQ2MjRjNjZmMzNmMS90YWJsZXJhbmdlOjE5Y2ZjMzNiMTUzYzRiYzg5NjkwZDYyNGM2NmYzM2YxXzItMi0xLTEtNDkwNDA_4c6da71f-c5d7-4bb9-bfa5-4833ec77bd25">1,590,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie01d1de15b9444b183272d5953f012c0_D20220101-20221231" decimals="0" name="ecd:NonPeoNeoAvgTotalCompAmt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZToxOWNmYzMzYjE1M2M0YmM4OTY5MGQ2MjRjNjZmMzNmMS90YWJsZXJhbmdlOjE5Y2ZjMzNiMTUzYzRiYzg5NjkwZDYyNGM2NmYzM2YxXzItNC0xLTEtNDkwNDQ_9eb03ab0-e1e5-4155-b130-67d8d51a51e6">1,523,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i162e015e217c4d45bddc31b5744d6c17_D20210101-20211231" decimals="0" name="ecd:PeoTotalCompAmt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZToxOWNmYzMzYjE1M2M0YmM4OTY5MGQ2MjRjNjZmMzNmMS90YWJsZXJhbmdlOjE5Y2ZjMzNiMTUzYzRiYzg5NjkwZDYyNGM2NmYzM2YxXzItNi0xLTEtNDkwNDI_3bd86130-5f0c-423c-b259-3ebf24657566">3,635,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i162e015e217c4d45bddc31b5744d6c17_D20210101-20211231" decimals="0" name="ecd:NonPeoNeoAvgTotalCompAmt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZToxOWNmYzMzYjE1M2M0YmM4OTY5MGQ2MjRjNjZmMzNmMS90YWJsZXJhbmdlOjE5Y2ZjMzNiMTUzYzRiYzg5NjkwZDYyNGM2NmYzM2YxXzItOC0xLTEtNDkwNDY_72adf02d-975a-42a2-84da-986943d7a21e">2,148,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deduction for amounts reported under the &#8220;Stock Awards&#8221; and &#8220;Option Awards&#8221; columns of the Summary Compensation Table</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6c039ead809495cae54a5ab4e87a488_D20220101-20221231" decimals="0" sign="-" name="ecd:AdjToCompAmt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZToxOWNmYzMzYjE1M2M0YmM4OTY5MGQ2MjRjNjZmMzNmMS90YWJsZXJhbmdlOjE5Y2ZjMzNiMTUzYzRiYzg5NjkwZDYyNGM2NmYzM2YxXzQtMi0xLTEtNDkwNDg_19a7d5fb-0620-4e92-b38e-a2645fa814af">753,272</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f35b7ba98ca4879b389a1204541bc1f_D20220101-20221231" decimals="0" sign="-" name="ecd:AdjToCompAmt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZToxOWNmYzMzYjE1M2M0YmM4OTY5MGQ2MjRjNjZmMzNmMS90YWJsZXJhbmdlOjE5Y2ZjMzNiMTUzYzRiYzg5NjkwZDYyNGM2NmYzM2YxXzQtNC0xLTEtNDkwNDg_f87c8129-fbd8-433f-ac79-c35e124c73d8">919,022</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i808f413dd8bd4a038c815bd31cf674bb_D20210101-20211231" decimals="0" sign="-" name="ecd:AdjToCompAmt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZToxOWNmYzMzYjE1M2M0YmM4OTY5MGQ2MjRjNjZmMzNmMS90YWJsZXJhbmdlOjE5Y2ZjMzNiMTUzYzRiYzg5NjkwZDYyNGM2NmYzM2YxXzQtNi0xLTEtNDkwNDg_d7f746fc-927d-46b6-8e00-99c48131fd28">2,851,972</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67ff1600b4c246b2ab359a056db81b0a_D20210101-20211231" decimals="0" sign="-" name="ecd:AdjToCompAmt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZToxOWNmYzMzYjE1M2M0YmM4OTY5MGQ2MjRjNjZmMzNmMS90YWJsZXJhbmdlOjE5Y2ZjMzNiMTUzYzRiYzg5NjkwZDYyNGM2NmYzM2YxXzQtOC0xLTEtNDkwNDg_91e82de1-77a9-4283-85c4-07258b6b665b">1,701,431</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase/(decrease) for the Inclusion of "Rule 402(v) Equity Values" </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86619fe2a4904a08839c9a77d4598f63_D20220101-20221231" decimals="0" sign="-" name="ecd:AdjToCompAmt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZToxOWNmYzMzYjE1M2M0YmM4OTY5MGQ2MjRjNjZmMzNmMS90YWJsZXJhbmdlOjE5Y2ZjMzNiMTUzYzRiYzg5NjkwZDYyNGM2NmYzM2YxXzUtMi0xLTEtNDkwNDg_2b9f5987-8a89-43ed-b8e6-8fddb0717174">745,206</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icafd16b4fdca433ab80e693f2728fc6c_D20220101-20221231" decimals="0" sign="-" name="ecd:AdjToCompAmt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZToxOWNmYzMzYjE1M2M0YmM4OTY5MGQ2MjRjNjZmMzNmMS90YWJsZXJhbmdlOjE5Y2ZjMzNiMTUzYzRiYzg5NjkwZDYyNGM2NmYzM2YxXzUtNC0xLTEtNDkwNDg_5b7e5886-4b96-4dbe-935c-e557c1595dea">381,584</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i099dab0c3dfb4ba08b9f1e8273c73b43_D20210101-20211231" decimals="0" sign="-" name="ecd:AdjToCompAmt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZToxOWNmYzMzYjE1M2M0YmM4OTY5MGQ2MjRjNjZmMzNmMS90YWJsZXJhbmdlOjE5Y2ZjMzNiMTUzYzRiYzg5NjkwZDYyNGM2NmYzM2YxXzUtNi0xLTEtNDkwNDg_e05730ff-103c-4a35-9953-7cc7faa57611">2,184,634</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48bde130657f4d60a3c8729859ad4a54_D20210101-20211231" decimals="0" name="ecd:AdjToCompAmt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZToxOWNmYzMzYjE1M2M0YmM4OTY5MGQ2MjRjNjZmMzNmMS90YWJsZXJhbmdlOjE5Y2ZjMzNiMTUzYzRiYzg5NjkwZDYyNGM2NmYzM2YxXzUtOC0xLTEtNDkwNDg_84e32d2f-d900-4010-94ce-ace6a0e2ffa2">91,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Compensation&#160;Actually&#160;Paid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie01d1de15b9444b183272d5953f012c0_D20220101-20221231" decimals="0" name="ecd:PeoActuallyPaidCompAmt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZToxOWNmYzMzYjE1M2M0YmM4OTY5MGQ2MjRjNjZmMzNmMS90YWJsZXJhbmdlOjE5Y2ZjMzNiMTUzYzRiYzg5NjkwZDYyNGM2NmYzM2YxXzEwLTItMS0xLTQ4OTI3_4ee9715d-6d2d-49ce-b0d1-060ddfd320d1">91,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie01d1de15b9444b183272d5953f012c0_D20220101-20221231" decimals="0" name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZToxOWNmYzMzYjE1M2M0YmM4OTY5MGQ2MjRjNjZmMzNmMS90YWJsZXJhbmdlOjE5Y2ZjMzNiMTUzYzRiYzg5NjkwZDYyNGM2NmYzM2YxXzEwLTQtMS0xLTQ4OTMz_edf74a1d-c86b-4533-93b7-67b39e67957c">222,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i162e015e217c4d45bddc31b5744d6c17_D20210101-20211231" decimals="0" sign="-" name="ecd:PeoActuallyPaidCompAmt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZToxOWNmYzMzYjE1M2M0YmM4OTY5MGQ2MjRjNjZmMzNmMS90YWJsZXJhbmdlOjE5Y2ZjMzNiMTUzYzRiYzg5NjkwZDYyNGM2NmYzM2YxXzEwLTYtMS0xLTQ4OTY1_206f8634-d533-47d6-b71b-c288a41e8cb2">1,401,408</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i162e015e217c4d45bddc31b5744d6c17_D20210101-20211231" decimals="0" name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZToxOWNmYzMzYjE1M2M0YmM4OTY5MGQ2MjRjNjZmMzNmMS90YWJsZXJhbmdlOjE5Y2ZjMzNiMTUzYzRiYzg5NjkwZDYyNGM2NmYzM2YxXzEwLTgtMS0xLTQ4OTcx_114045b3-9f68-4e13-b5c2-5008ac303ef9">539,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">Compensation Actually Paid excludes the Stock Awards and Option Awards columns from the relevant fiscal year&#8217;s Summary Compensation Table total. The Rule 402(v) Equity Values instead reflect the aggregate of the following components, as applicable: (i) the fair value as of the end of the listed fiscal year of unvested equity awards granted in that year; (ii) the change in fair value during the listed fiscal year of equity awards granted in prior years that remained outstanding and unvested at the end of the listed fiscal year; and (iii) the change in fair value during the listed fiscal year through the vesting date of equity awards granted in prior years that vested during the listed fiscal year, less the fair value at the end of the prior year of awards granted </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_463">Table of Contents</a></span></div></div><ix:continuation id="ia9e71d46b4d343779488d9474116822f"><ix:continuation id="iec5d37b855cd4d72a6188ab827dd2d0b"><div style="padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prior to the listed fiscal year that failed to meet applicable vesting conditions during the listed fiscal year. Equity values are calculated in accordance with FASB ASC Topic 718, calculated as follows:</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.964%"><tr><td style="width:1.0%"></td><td style="width:46.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.480%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.314%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.480%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.314%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.480%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.314%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.480%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.319%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8220;Inclusion of Rule 402(v) Equity Values&#8221;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PEO ($)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average for Other NEO's ($)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PEO ($)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average for Other NEO's ($)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Year-End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia69205d3273d42cfa5b47e45431f4273_D20220101-20221231" decimals="0" name="crdf:AdjustmentToCompensationAmountEquityAwards" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpiNzc0N2Q1NWZjZTM0ZTEyYjIzMzI1MzgzZjllZDgxNi90YWJsZXJhbmdlOmI3NzQ3ZDU1ZmNlMzRlMTJiMjMzMjUzODNmOWVkODE2XzItMi0xLTEtNTE4MjE_2866d432-d01d-4eb0-b46f-921121ff423b">446,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i222ba39e2bff496a82ec7ce575a3569c_D20220101-20221231" decimals="0" name="crdf:AdjustmentToCompensationAmountEquityAwards" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpiNzc0N2Q1NWZjZTM0ZTEyYjIzMzI1MzgzZjllZDgxNi90YWJsZXJhbmdlOmI3NzQ3ZDU1ZmNlMzRlMTJiMjMzMjUzODNmOWVkODE2XzItNC0xLTEtNTE4MjE_6226318f-f746-4565-9201-ad232d4759e0">253,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa076cb47d104183826cd32c0caf6c74_D20210101-20211231" decimals="0" name="crdf:AdjustmentToCompensationAmountEquityAwards" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpiNzc0N2Q1NWZjZTM0ZTEyYjIzMzI1MzgzZjllZDgxNi90YWJsZXJhbmdlOmI3NzQ3ZDU1ZmNlMzRlMTJiMjMzMjUzODNmOWVkODE2XzItNi0xLTEtNTE4MjE_cc726ffa-3e6d-4e7e-b9c8-15650f27596f">1,992,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1374971d2a224cd48aec91e78ac8bd8b_D20210101-20211231" decimals="0" name="crdf:AdjustmentToCompensationAmountEquityAwards" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpiNzc0N2Q1NWZjZTM0ZTEyYjIzMzI1MzgzZjllZDgxNi90YWJsZXJhbmdlOmI3NzQ3ZDU1ZmNlMzRlMTJiMjMzMjUzODNmOWVkODE2XzItOC0xLTEtNTE4MjE_3d17e7b6-d6f0-4386-a75b-2108420d32be">1,380,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bcd6aa3ae8a4718aaa3527feb1a9750_D20220101-20221231" decimals="0" sign="-" name="crdf:AdjustmentToCompensationAmountEquityAwards" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpiNzc0N2Q1NWZjZTM0ZTEyYjIzMzI1MzgzZjllZDgxNi90YWJsZXJhbmdlOmI3NzQ3ZDU1ZmNlMzRlMTJiMjMzMjUzODNmOWVkODE2XzMtMi0xLTEtNTE4MjM_00289cfd-1274-481f-8725-21560045b0d6">288,112</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iacbe2ef0043b41eca3c977825b71bcc7_D20220101-20221231" decimals="0" sign="-" name="crdf:AdjustmentToCompensationAmountEquityAwards" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpiNzc0N2Q1NWZjZTM0ZTEyYjIzMzI1MzgzZjllZDgxNi90YWJsZXJhbmdlOmI3NzQ3ZDU1ZmNlMzRlMTJiMjMzMjUzODNmOWVkODE2XzMtNC0xLTEtNTE4MjM_474e1808-5317-4772-8820-bd16b372e00a">457,723</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6423de9d56142b9894e5e2217b5c134_D20210101-20211231" decimals="0" sign="-" name="crdf:AdjustmentToCompensationAmountEquityAwards" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpiNzc0N2Q1NWZjZTM0ZTEyYjIzMzI1MzgzZjllZDgxNi90YWJsZXJhbmdlOmI3NzQ3ZDU1ZmNlMzRlMTJiMjMzMjUzODNmOWVkODE2XzMtNi0xLTEtNTE4MjM_6c59d22e-49fc-4107-b478-4b4d5b859557">2,270,502</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia51f311be92445049c84ed71423fc1ac_D20210101-20211231" decimals="0" sign="-" name="crdf:AdjustmentToCompensationAmountEquityAwards" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpiNzc0N2Q1NWZjZTM0ZTEyYjIzMzI1MzgzZjllZDgxNi90YWJsZXJhbmdlOmI3NzQ3ZDU1ZmNlMzRlMTJiMjMzMjUzODNmOWVkODE2XzMtOC0xLTEtNTE4MjM_b40f9572-7ff1-4f82-9a2f-b74c36cd9a8f">701,257</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Awards that are granted and vest in the same year, the fair value as of the vesting date </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4757a2404ced49b79c5f7734d44d691d_D20220101-20221231" decimals="0" name="crdf:AdjustmentToCompensationAmountEquityAwards" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpiNzc0N2Q1NWZjZTM0ZTEyYjIzMzI1MzgzZjllZDgxNi90YWJsZXJhbmdlOmI3NzQ3ZDU1ZmNlMzRlMTJiMjMzMjUzODNmOWVkODE2XzQtMi0xLTEtNTIxODA_c4756ae9-35eb-4f0b-a453-8c587c6596a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i424d110c9c7447cf8d86db48ddc56f09_D20220101-20221231" decimals="0" name="crdf:AdjustmentToCompensationAmountEquityAwards" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpiNzc0N2Q1NWZjZTM0ZTEyYjIzMzI1MzgzZjllZDgxNi90YWJsZXJhbmdlOmI3NzQ3ZDU1ZmNlMzRlMTJiMjMzMjUzODNmOWVkODE2XzQtNC0xLTEtNTIxODA_4e20a3f2-2a1c-4fae-ab45-29fe6bf6163d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac46fe9783ba4350948ac1b50c0f82e8_D20210101-20211231" decimals="0" name="crdf:AdjustmentToCompensationAmountEquityAwards" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpiNzc0N2Q1NWZjZTM0ZTEyYjIzMzI1MzgzZjllZDgxNi90YWJsZXJhbmdlOmI3NzQ3ZDU1ZmNlMzRlMTJiMjMzMjUzODNmOWVkODE2XzQtNi0xLTEtNTIxODA_3f43a577-93e1-490c-9c6f-e484e5facc97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b2e7c637d8641d0ab07136fac2ce541_D20210101-20211231" decimals="0" name="crdf:AdjustmentToCompensationAmountEquityAwards" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpiNzc0N2Q1NWZjZTM0ZTEyYjIzMzI1MzgzZjllZDgxNi90YWJsZXJhbmdlOmI3NzQ3ZDU1ZmNlMzRlMTJiMjMzMjUzODNmOWVkODE2XzQtOC0xLTEtNTIxODA_8c419557-10c1-470c-a6dc-dfadcae0061d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in Fair Value of Prior Years&#8217; Equity Awards that Vested During the Year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6097bc48663442fa8090165e5ebaafcf_D20220101-20221231" decimals="0" sign="-" name="crdf:AdjustmentToCompensationAmountEquityAwards" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpiNzc0N2Q1NWZjZTM0ZTEyYjIzMzI1MzgzZjllZDgxNi90YWJsZXJhbmdlOmI3NzQ3ZDU1ZmNlMzRlMTJiMjMzMjUzODNmOWVkODE2XzUtMi0xLTEtNTE4MjU_89160cdf-dedb-4a1d-be2c-43c03e70a7ba">903,882</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56212971324f4fd1bdfe65dd27e611ab_D20220101-20221231" decimals="0" sign="-" name="crdf:AdjustmentToCompensationAmountEquityAwards" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpiNzc0N2Q1NWZjZTM0ZTEyYjIzMzI1MzgzZjllZDgxNi90YWJsZXJhbmdlOmI3NzQ3ZDU1ZmNlMzRlMTJiMjMzMjUzODNmOWVkODE2XzUtNC0xLTEtNTE4MjU_58e41519-bf45-4e07-b23e-9c6f2b2f92ad">177,498</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i388d394b3cb749cca54ab1a0e0ad8209_D20210101-20211231" decimals="0" sign="-" name="crdf:AdjustmentToCompensationAmountEquityAwards" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpiNzc0N2Q1NWZjZTM0ZTEyYjIzMzI1MzgzZjllZDgxNi90YWJsZXJhbmdlOmI3NzQ3ZDU1ZmNlMzRlMTJiMjMzMjUzODNmOWVkODE2XzUtNi0xLTEtNTE4MjU_f268bc11-3328-4cdc-80b8-f75022141191">1,906,142</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35341a6be28048239380a00aa3e164a4_D20210101-20211231" decimals="0" sign="-" name="crdf:AdjustmentToCompensationAmountEquityAwards" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpiNzc0N2Q1NWZjZTM0ZTEyYjIzMzI1MzgzZjllZDgxNi90YWJsZXJhbmdlOmI3NzQ3ZDU1ZmNlMzRlMTJiMjMzMjUzODNmOWVkODE2XzUtOC0xLTEtNTE4MjU_673f96e4-ad1d-4b53-8e02-e1065f0fcbb2">587,466</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtract: Awards Granted in any prior fiscal year that failed to vest Change in Value of Prior Years&#8217; Equity Awards that Forfeited During the Year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c34c7e022294fe4aeb274e2e44b75ef_D20220101-20221231" decimals="0" name="crdf:AdjustmentToCompensationAmountEquityAwards" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpiNzc0N2Q1NWZjZTM0ZTEyYjIzMzI1MzgzZjllZDgxNi90YWJsZXJhbmdlOmI3NzQ3ZDU1ZmNlMzRlMTJiMjMzMjUzODNmOWVkODE2XzYtMi0xLTEtNTE4Mjc_a7a3c341-04f7-436e-87f4-74f0af3665e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d89663085a84502b34c2da05d99e96e_D20220101-20221231" decimals="0" name="crdf:AdjustmentToCompensationAmountEquityAwards" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpiNzc0N2Q1NWZjZTM0ZTEyYjIzMzI1MzgzZjllZDgxNi90YWJsZXJhbmdlOmI3NzQ3ZDU1ZmNlMzRlMTJiMjMzMjUzODNmOWVkODE2XzYtNC0xLTEtNTE4Mjc_a3883bdb-b4b7-4538-9ddc-ab1d7b2d0b98">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101ba4e616204ee3a06df10ad6050ef9_D20210101-20211231" decimals="0" name="crdf:AdjustmentToCompensationAmountEquityAwards" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpiNzc0N2Q1NWZjZTM0ZTEyYjIzMzI1MzgzZjllZDgxNi90YWJsZXJhbmdlOmI3NzQ3ZDU1ZmNlMzRlMTJiMjMzMjUzODNmOWVkODE2XzYtNi0xLTEtNTE4Mjc_24257b4f-644e-4721-88dc-1db228c1f15c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bc58d898e84d1cae4dc8e8325704b9_D20210101-20211231" decimals="0" name="crdf:AdjustmentToCompensationAmountEquityAwards" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpiNzc0N2Q1NWZjZTM0ZTEyYjIzMzI1MzgzZjllZDgxNi90YWJsZXJhbmdlOmI3NzQ3ZDU1ZmNlMzRlMTJiMjMzMjUzODNmOWVkODE2XzYtOC0xLTEtNTE4Mjc_231b95f0-7970-40dc-8a9e-46544e982986">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase/(decrease) for the &#8220;Inclusion of Rule 402(v) Equity Values&#8221; (i)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86619fe2a4904a08839c9a77d4598f63_D20220101-20221231" decimals="0" sign="-" name="ecd:AdjToCompAmt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpiNzc0N2Q1NWZjZTM0ZTEyYjIzMzI1MzgzZjllZDgxNi90YWJsZXJhbmdlOmI3NzQ3ZDU1ZmNlMzRlMTJiMjMzMjUzODNmOWVkODE2XzYtMi0xLTEtNTE4MDg_dd639887-5f4d-44ee-8f4a-529906cf9f90">745,206</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icafd16b4fdca433ab80e693f2728fc6c_D20220101-20221231" decimals="0" sign="-" name="ecd:AdjToCompAmt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpiNzc0N2Q1NWZjZTM0ZTEyYjIzMzI1MzgzZjllZDgxNi90YWJsZXJhbmdlOmI3NzQ3ZDU1ZmNlMzRlMTJiMjMzMjUzODNmOWVkODE2XzYtNC0xLTEtNTE4MDg_da534402-c39c-4c31-bfd5-78c8dad1ee28">381,584</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i099dab0c3dfb4ba08b9f1e8273c73b43_D20210101-20211231" decimals="0" sign="-" name="ecd:AdjToCompAmt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpiNzc0N2Q1NWZjZTM0ZTEyYjIzMzI1MzgzZjllZDgxNi90YWJsZXJhbmdlOmI3NzQ3ZDU1ZmNlMzRlMTJiMjMzMjUzODNmOWVkODE2XzYtNi0xLTEtNTE4MDg_09721f53-f51f-4fca-aa17-65b86d731fbe">2,184,634</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48bde130657f4d60a3c8729859ad4a54_D20210101-20211231" decimals="0" name="ecd:AdjToCompAmt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpiNzc0N2Q1NWZjZTM0ZTEyYjIzMzI1MzgzZjllZDgxNi90YWJsZXJhbmdlOmI3NzQ3ZDU1ZmNlMzRlMTJiMjMzMjUzODNmOWVkODE2XzYtOC0xLTEtNTE4MDg_825e04e8-faf5-4e52-9ce4-4a59cf1abe57">91,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="padding-left:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_463">Table of Contents</a></span></div></div><div><span><br/></span></div><div id="i6eaaaa0344f74a9caae5f17960d0edec_451"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes information about our equity compensation plans as of December 31, 2022.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Number of Shares of Common Stock to be Issued upon Exercise of Outstanding Options, Warrants and Rights</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted- Average Exercise Price of Outstanding Options, Warrants and Rights</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Number of Options Remaining Available for Future Issuance Under Equity Compensation Plans (excluding securities reflected in column (a))</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(c)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:10.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Equity Compensation Plans Approved by Stockholders</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4,149,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.87</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,087,075&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:10.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Equity Compensation Plans Not Approved by Stockholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">920,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.13</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10.1pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,069,458&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,087,075&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.198%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">These options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).</span></div><div><span><br/></span></div><div id="i6eaaaa0344f74a9caae5f17960d0edec_67"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">TRANSACTIONS WITH RELATED PERSONS</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a description of transactions or series of transactions since January&#160;1, 2021, or any currently proposed transaction, to which we were or are to be a participant and in which the amount involved in the transaction or series of transactions exceeds $120,000, and in which any of our directors, executive officers or persons who we know hold more than five percent of any class of our capital stock, including their immediate family members, had or will have a direct or indirect material interest, other than compensation arrangements with our directors and executive officers.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any related party transactions during the covered period. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into indemnification agreements with our directors and executive officers under which we agreed to indemnify those individuals under the circumstances and to the extent provided for in the agreements, for expenses, damages, judgments, fines, settlements and any other amounts they may be required to pay in actions, suits or proceedings which they are or may be made a party or threatened to be made a party by reason of their position as a director, officer or other agent of ours, and otherwise to the fullest extent permitted under Delaware law and our By-Laws. We also have an insurance policy covering our directors and executive officers with respect to certain liabilities, including liabilities arising under the Securities Act of 1933, as amended, or otherwise.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board has adopted a written related party transaction policy to set forth the policies and procedures for the review, approval and ratification of related party transactions. This policy covers any financial transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships (including any indebtedness or guarantee of indebtedness) in which we are or are to be a participant, since the beginning of our last completed fiscal year, and a related party has or will have a direct or indirect material interest. A related party is any individual who is, or who has been since the beginning of our last fiscal year, an executive officer, director or nominee for election as a director, or any person known to be the record or beneficial owner of more than 5% of any class of our voting securities, any immediate family member of any of the foregoing persons or any entity which is owned or controlled by any of the foregoing persons, or any entity in which one of the foregoing persons has a substantial ownership interest in or control over such entity. Transactions involving the employment or compensation of our executive officers or compensation to our directors, transactions with another company at which a related party&#8217;s only relationship is as a director and/or beneficial owner of less than 10% of such company&#8217;s equity interests, transactions in which all of our stockholders receive proportional benefits, certain regulated transactions and certain banking-related services are not considered related-person transactions under this policy. Under our Audit Committee Charter and our related party transaction policy, our Audit Committee is responsible for reviewing and approving in advance any related party transaction. In connection with its review of a related party transaction, the Audit Committee will take into account, among other factors it deems appropriate, whether the related party transaction is on terms no less favorable than terms generally available to an unaffiliated third-party under the same or similar circumstances and the extent of the related party&#8217;s interest in the related party transaction.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_463">Table of Contents</a></span></div></div><div style="text-indent:24.75pt"><span><br/></span></div><div id="i6eaaaa0344f74a9caae5f17960d0edec_70"></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">OTHER MATTERS</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cardiff Oncology has no knowledge of any other matters that may come before the Annual Meeting and does not intend to present any other matters. However, if any other matters shall properly come before the Annual Meeting or any adjournment or postponement thereof, the persons soliciting proxies will have the discretion to vote as they see fit unless directed otherwise.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We will bear the cost of soliciting proxies in the accompanying form. In addition to the use of the mailings, proxies may also be solicited by our directors, officers or other employees, personally or by telephone, facsimile or</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">email, none of whom will be compensated separately for these solicitation activities. We have engaged Kingsdale Advisors to assist in the solicitation of proxies. We will pay a fee of $12,500 plus reasonable out-of-pocket charges. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> If you do not plan to attend the Annual Meeting, in order that your shares may be represented and in order to assure the required quorum, please sign, date and return your proxy promptly. In the event you are able to attend the Annual Meeting, at your request, Cardiff Oncology will cancel your previously submitted proxy.</span></div><div><span><br/></span></div><div id="i6eaaaa0344f74a9caae5f17960d0edec_73"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">ADDITIONAL INFORMATION</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Householding</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The SEC has adopted rules that permit companies and intermediaries (e.g., brokers) to satisfy the delivery requirements for Proxy Availability Notice or other Annual Meeting materials with respect to two or more stockholders sharing the same address by delivering a single Notice or other Annual Meeting materials addressed to those stockholders. This process, which is commonly referred to as householding, potentially provides extra convenience for stockholders and cost savings for companies. Stockholders who participate in householding will continue to be able to access and receive separate proxy cards.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This year, a number of brokers with account holders who are our stockholders will be &#8220;householding&#8221; our proxy materials. A Notice or proxy materials will be delivered in one single envelope to multiple stockholders sharing an address unless contrary instructions have been received from one or more of the affected stockholders. Once you have received notice from your broker that they will be householding communications to your address, householding will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish to participate in householding and would prefer to receive a separate Notice or proxy materials, please notify your broker or call our Secretary at (858) 952-7570, or submit a request in writing to our Secretary, c/o Cardiff Oncology, Inc., 11055 Flintkote Avenue, San Diego, CA 92121. Stockholders who currently receive multiple copies of the Notice or proxy materials at their address and would like to request householding of their communications should contact their broker. In addition, we will promptly deliver, upon written or oral request to the address or telephone number above, a separate copy of the Notice or proxy materials to a stockholder at a shared address to which a single copy of the documents was delivered.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Annual Reports and Form 10-K</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additional copies of Cardiff Oncology&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 may be obtained without charge by writing to the Secretary, Cardiff Oncology, Inc., 11055 Flintkote Avenue, San Diego, CA 92121.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.859%"><tr><td style="width:1.0%"></td><td style="width:29.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:67.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By Order of the Board of Directors</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ Dr. Rodney S. Markin MD, Ph.D.</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dr. Rodney S. Markin MD, Ph.D.</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Chairman of the Board of Directors</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">April 27, 2023</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_463">Table of Contents</a></span></div></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Directions to the Annual Meeting of Stockholders of Cardiff Oncology, Inc.</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cardiff Oncology, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11055 Flintkote Avenue</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">San Diego, CA 92121</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">North</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (Los Angeles/Orange County/Carlsbad)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Take 5 Fwy South. Take CARMEL MOUNTAIN ROAD exit.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Turn Left on CARMEL MOUNTAIN ROAD&#8212;go 0.3 miles</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Turn Right on VISTA SORRENTO PARKWAY&#8212;go 1.4 miles</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Turn Right on SORRENTO VALLEY BOULEVARD &#8212;go 0.2 miles</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Turn Right on ROSELLE STREET &#8212;go 0.3 miles</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Turn Left on DUNHILL STREET &#8212; go 0.2 miles</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Arrive at 11055 FLINTKOTE AVENUE, on the RIGHT</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">South</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (La Jolla/San Diego International Airport Airport/Chula Vista)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Take 5 Fwy North. Take SORRENTO VALLEY ROAD exit.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Turn Left on ROSELLE STREET &#8212;go 0.3 miles</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Turn Left on DUNHILL STREET &#8212; go 0.2 miles</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Arrive at 11055 FLINTKOTE AVENUE, on the RIGHT</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i6eaaaa0344f74a9caae5f17960d0edec_79"></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_463">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROXY CARD</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARDIFF ONCOLOGY, INC.</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROXY FOR ANNUAL MEETING TO BE HELD ON JUNE 15, 2023</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The undersigned hereby appoints, Mark Erlander and Brigitte Lindsay, and each of them, as proxies, each with full power of substitution, to represent and to vote all the shares of common stock of Cardiff Oncology, Inc. (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), which the undersigned would be entitled to vote, at the Company&#8217;s Annual Meeting of Stockholders to be held on June 15, 2023 and at any adjournments thereof, subject to the directions indicated on this Proxy Card.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In their discretion, the proxy is authorized to vote upon any other matter that may properly come before the meeting or any adjournments thereof.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">THIS PROXY WILL BE VOTED IN ACCORDANCE WITH THE SPECIFICATIONS MADE, BUT IF NO CHOICES ARE INDICATED, THIS PROXY WILL BE VOTED FOR THE ELECTION OF ALL NOMINEES AND FOR THE PROPOSALS LISTED ON THE REVERSE SIDE.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This proxy is governed by the laws of the State of Delaware.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IMPORTANT&#8212;This Proxy must be signed and dated on the reverse side.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Stockholders to Be Held on June 15, 2023 at 9:00 am local time at the Company&#8217;s offices located at 11055 Flintkote Avenue, San Diego, CA 92121. The proxy statement and the 2022 Annual Report on Form 10-K are available at www.annualgeneralmeetings.com/crdf2023.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THIS IS YOUR PROXY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">YOUR VOTE IS IMPORTANT!</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dear Stockholder:</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cordially invite you to attend the Annual Meeting of Stockholders of Cardiff Oncology, Inc. to be held at Cardiff Oncology's offices located at 11055 Flintkote Avenue, San Diego, CA 92121, on June 15, 2023, beginning at 9:00 a.m. local time.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please read the proxy statement which describes the proposals and presents other important information, and complete, sign and return your proxy promptly in the enclosed envelope.</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">THE BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">FOR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8221; PROPOSALS 1,2 AND 4. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">THE BOARD OF DIRECTORS RECOMMENDS A VOTE "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">1 YEAR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">" ON PROPOSAL 3. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1. Election of Directors Nominees</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">FOR</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">WITHHOLD</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">01-Dr. James O. Armitage</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%">o</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%">o</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">02-Mark Erlander, Ph.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%">o</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%">o</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;03-Dr. Rodney Markin</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%">o</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%">o</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">04-Mani Mohindru, Ph.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%">o</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%">o</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">05-Gary W. Pace, Ph.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%">o</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%">o</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">06-Renee P. Tannenbaum, Pharm.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%">o</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%">o</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">07-L&#226;le White</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%">o</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%">o</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6eaaaa0344f74a9caae5f17960d0edec_463">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2. Proposal to ratify BDO USA, LLP as the Company&#8217;s independent registered public accountants for fiscal year ending December 31, 2023.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">FOR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%">o</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">AGAINST</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%">o</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">ABSTAIN</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%">o</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3. Proposal to indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's, named executive officers. </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1 YEAR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%">o</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2 YEARS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%">o</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">3 YEARS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%">o</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">ABSTAIN</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%">o</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4. Proposal to approve, on an advisory basis, the compensation of the Company&#8217;s named executive officers.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">FOR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%">o</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">AGAINST</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%">o</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">ABSTAIN</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%">o</span></div></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Important: Please sign exactly as name appears on this proxy. When signing as attorney, executor, trustee, guardian, corporate officer, etc., please indicate full title.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.198%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dated:                             </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Signature</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Name (printed)</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Title</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">VOTING INSTRUCTIONS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You may vote your proxy in the following ways:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:115%">                                                                                                  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">VIA INTERNET:</span></div><div><span><br/></span></div><div style="text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Login to www.annualgeneralmeetings.com/crdf2023</span></div><div style="text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Enter your control number (12 digit number located below)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:115%">                                                                                                  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">VIA MAIL:</span></div><div><span><br/></span></div><div style="text-indent:48pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pacific Stock Transfer Company</span></div><div style="text-indent:48pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c/o Proxy Department</span></div><div style="text-indent:48pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6725 Via Austi Pkwy, Suite 300</span></div><div style="text-indent:48pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Las Vegas, Nevada 89119</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CONTROL NUMBER:</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You may vote by Internet 24 hours a day, 7 days a week. Internet voting is available through 11:59 p.m. (EDT),</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prevailing time, on June 14, 2023.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>2
<FILENAME>crdf-20230427.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:d60d8c77-ec40-464e-a25d-a3547cb6d562,g:838ee74e-ea21-4773-8d7d-e22a95cb2f30-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:crdf="http://www.cardiffoncology.com/20230427" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cardiffoncology.com/20230427">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei-sub/2022q4" schemaLocation="https://xbrl.sec.gov/dei/2022q4/dei-sub-2022q4.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd-sub/2022q4" schemaLocation="https://xbrl.sec.gov/ecd/2022q4/ecd-sub-2022q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crdf-20230427_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crdf-20230427_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crdf-20230427_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="crdf_DeductionForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember" abstract="true" name="DeductionForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="crdf_AdjustmentToCompensationAmountEquityAwards" abstract="false" name="AdjustmentToCompensationAmountEquityAwards" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_EquityAwardsChangeInFairValueFromLastDayOfPriorYearToLastDayOfYearOfUnvestedEquityAwardsMember" abstract="true" name="EquityAwardsChangeInFairValueFromLastDayOfPriorYearToLastDayOfYearOfUnvestedEquityAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="crdf_EquityAwardsChangeInFairValueOfPriorYearsEquityAwardsThatVestedDuringTheYearMember" abstract="true" name="EquityAwardsChangeInFairValueOfPriorYearsEquityAwardsThatVestedDuringTheYearMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="crdf_EquityAwardsYearEndFairValueOfEquityAwardsGrantedDuringYearThatRemainedUnvestedAsOfLastDayOfYearMember" abstract="true" name="EquityAwardsYearEndFairValueOfEquityAwardsGrantedDuringYearThatRemainedUnvestedAsOfLastDayOfYearMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="crdf_EquityAwardsAddAwardsThatAreGrantedAndVestInTheSameYearTheFairValueAsOfTheVestingDateMember" abstract="true" name="EquityAwardsAddAwardsThatAreGrantedAndVestInTheSameYearTheFairValueAsOfTheVestingDateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="crdf_IncreasedecreaseForTheInclusionOfRule402vEquityValuesMember" abstract="true" name="IncreasedecreaseForTheInclusionOfRule402vEquityValuesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="crdf_EquityAwardsChangeInValueOfPriorYearsEquityAwardsThatForfeitedDuringTheYearMember" abstract="true" name="EquityAwardsChangeInValueOfPriorYearsEquityAwardsThatForfeitedDuringTheYearMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>3
<FILENAME>crdf-20230427_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:d60d8c77-ec40-464e-a25d-a3547cb6d562,g:838ee74e-ea21-4773-8d7d-e22a95cb2f30-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2022q4/ecd-2022q4.xsd#PvpAdjustmentsOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2022q4/ecd-2022q4.xsd#ecd_AllAdjToCompMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DeductionForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember_c2dd3daa-af66-4a45-9d51-c2f021da91a8" xlink:href="crdf-20230427.xsd#crdf_DeductionForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_crdf_DeductionForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember_c2dd3daa-af66-4a45-9d51-c2f021da91a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_IncreasedecreaseForTheInclusionOfRule402vEquityValuesMember_6192c24e-a996-4e7d-aa16-2fb3d65bbd97" xlink:href="crdf-20230427.xsd#crdf_IncreasedecreaseForTheInclusionOfRule402vEquityValuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_crdf_IncreasedecreaseForTheInclusionOfRule402vEquityValuesMember_6192c24e-a996-4e7d-aa16-2fb3d65bbd97" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_EquityAwardsYearEndFairValueOfEquityAwardsGrantedDuringYearThatRemainedUnvestedAsOfLastDayOfYearMember_e0d218dd-67f3-4533-99b7-a852b1aad385" xlink:href="crdf-20230427.xsd#crdf_EquityAwardsYearEndFairValueOfEquityAwardsGrantedDuringYearThatRemainedUnvestedAsOfLastDayOfYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_crdf_EquityAwardsYearEndFairValueOfEquityAwardsGrantedDuringYearThatRemainedUnvestedAsOfLastDayOfYearMember_e0d218dd-67f3-4533-99b7-a852b1aad385" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_EquityAwardsChangeInFairValueFromLastDayOfPriorYearToLastDayOfYearOfUnvestedEquityAwardsMember_86613b9e-fa34-45f7-89e2-ddb2a9264f92" xlink:href="crdf-20230427.xsd#crdf_EquityAwardsChangeInFairValueFromLastDayOfPriorYearToLastDayOfYearOfUnvestedEquityAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_crdf_EquityAwardsChangeInFairValueFromLastDayOfPriorYearToLastDayOfYearOfUnvestedEquityAwardsMember_86613b9e-fa34-45f7-89e2-ddb2a9264f92" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_EquityAwardsAddAwardsThatAreGrantedAndVestInTheSameYearTheFairValueAsOfTheVestingDateMember_ae604dad-2cda-4118-bbfe-0134a4372410" xlink:href="crdf-20230427.xsd#crdf_EquityAwardsAddAwardsThatAreGrantedAndVestInTheSameYearTheFairValueAsOfTheVestingDateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_crdf_EquityAwardsAddAwardsThatAreGrantedAndVestInTheSameYearTheFairValueAsOfTheVestingDateMember_ae604dad-2cda-4118-bbfe-0134a4372410" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_EquityAwardsChangeInFairValueOfPriorYearsEquityAwardsThatVestedDuringTheYearMember_3bb4269e-22a1-4a46-bb39-4f9ad631ac94" xlink:href="crdf-20230427.xsd#crdf_EquityAwardsChangeInFairValueOfPriorYearsEquityAwardsThatVestedDuringTheYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_crdf_EquityAwardsChangeInFairValueOfPriorYearsEquityAwardsThatVestedDuringTheYearMember_3bb4269e-22a1-4a46-bb39-4f9ad631ac94" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_EquityAwardsChangeInValueOfPriorYearsEquityAwardsThatForfeitedDuringTheYearMember_ac32071a-4535-4520-a35b-dd57c8fad5be" xlink:href="crdf-20230427.xsd#crdf_EquityAwardsChangeInValueOfPriorYearsEquityAwardsThatForfeitedDuringTheYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_crdf_EquityAwardsChangeInValueOfPriorYearsEquityAwardsThatForfeitedDuringTheYearMember_ac32071a-4535-4520-a35b-dd57c8fad5be" xlink:type="arc" order="7"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>crdf-20230427_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:d60d8c77-ec40-464e-a25d-a3547cb6d562,g:838ee74e-ea21-4773-8d7d-e22a95cb2f30-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_crdf_DeductionForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember_label_en-US" xlink:label="lab_crdf_DeductionForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deduction for amounts reported under the &#8220;Stock Awards&#8221; and &#8220;Option Awards&#8221; columns of the Summary Compensation Table( [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DeductionForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember" xlink:href="crdf-20230427.xsd#crdf_DeductionForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_DeductionForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember" xlink:to="lab_crdf_DeductionForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_IncreasedecreaseForTheInclusionOfRule402vEquityValuesMember_label_en-US" xlink:label="lab_crdf_IncreasedecreaseForTheInclusionOfRule402vEquityValuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase/(decrease) for the Inclusion of Rule 402(v) Equity Values [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_IncreasedecreaseForTheInclusionOfRule402vEquityValuesMember" xlink:href="crdf-20230427.xsd#crdf_IncreasedecreaseForTheInclusionOfRule402vEquityValuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_IncreasedecreaseForTheInclusionOfRule402vEquityValuesMember" xlink:to="lab_crdf_IncreasedecreaseForTheInclusionOfRule402vEquityValuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_EquityAwardsYearEndFairValueOfEquityAwardsGrantedDuringYearThatRemainedUnvestedAsOfLastDayOfYearMember_label_en-US" xlink:label="lab_crdf_EquityAwardsYearEndFairValueOfEquityAwardsGrantedDuringYearThatRemainedUnvestedAsOfLastDayOfYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Awards, Year-End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_EquityAwardsYearEndFairValueOfEquityAwardsGrantedDuringYearThatRemainedUnvestedAsOfLastDayOfYearMember" xlink:href="crdf-20230427.xsd#crdf_EquityAwardsYearEndFairValueOfEquityAwardsGrantedDuringYearThatRemainedUnvestedAsOfLastDayOfYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_EquityAwardsYearEndFairValueOfEquityAwardsGrantedDuringYearThatRemainedUnvestedAsOfLastDayOfYearMember" xlink:to="lab_crdf_EquityAwardsYearEndFairValueOfEquityAwardsGrantedDuringYearThatRemainedUnvestedAsOfLastDayOfYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_EquityAwardsAddAwardsThatAreGrantedAndVestInTheSameYearTheFairValueAsOfTheVestingDateMember_label_en-US" xlink:label="lab_crdf_EquityAwardsAddAwardsThatAreGrantedAndVestInTheSameYearTheFairValueAsOfTheVestingDateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Awards, Add: Awards that are granted and vest in the same year, the fair value as of the vesting date [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_EquityAwardsAddAwardsThatAreGrantedAndVestInTheSameYearTheFairValueAsOfTheVestingDateMember" xlink:href="crdf-20230427.xsd#crdf_EquityAwardsAddAwardsThatAreGrantedAndVestInTheSameYearTheFairValueAsOfTheVestingDateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_EquityAwardsAddAwardsThatAreGrantedAndVestInTheSameYearTheFairValueAsOfTheVestingDateMember" xlink:to="lab_crdf_EquityAwardsAddAwardsThatAreGrantedAndVestInTheSameYearTheFairValueAsOfTheVestingDateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_EquityAwardsChangeInValueOfPriorYearsEquityAwardsThatForfeitedDuringTheYearMember_label_en-US" xlink:label="lab_crdf_EquityAwardsChangeInValueOfPriorYearsEquityAwardsThatForfeitedDuringTheYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Awards, Change in Value of Prior Years&#8217; Equity Awards that Forfeited During the Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_EquityAwardsChangeInValueOfPriorYearsEquityAwardsThatForfeitedDuringTheYearMember" xlink:href="crdf-20230427.xsd#crdf_EquityAwardsChangeInValueOfPriorYearsEquityAwardsThatForfeitedDuringTheYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_EquityAwardsChangeInValueOfPriorYearsEquityAwardsThatForfeitedDuringTheYearMember" xlink:to="lab_crdf_EquityAwardsChangeInValueOfPriorYearsEquityAwardsThatForfeitedDuringTheYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_EquityAwardsChangeInFairValueOfPriorYearsEquityAwardsThatVestedDuringTheYearMember_label_en-US" xlink:label="lab_crdf_EquityAwardsChangeInFairValueOfPriorYearsEquityAwardsThatVestedDuringTheYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Awards, Change in Fair Value of Prior Years&#8217; Equity Awards that Vested During the Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_EquityAwardsChangeInFairValueOfPriorYearsEquityAwardsThatVestedDuringTheYearMember" xlink:href="crdf-20230427.xsd#crdf_EquityAwardsChangeInFairValueOfPriorYearsEquityAwardsThatVestedDuringTheYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_EquityAwardsChangeInFairValueOfPriorYearsEquityAwardsThatVestedDuringTheYearMember" xlink:to="lab_crdf_EquityAwardsChangeInFairValueOfPriorYearsEquityAwardsThatVestedDuringTheYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_EquityAwardsChangeInFairValueFromLastDayOfPriorYearToLastDayOfYearOfUnvestedEquityAwardsMember_label_en-US" xlink:label="lab_crdf_EquityAwardsChangeInFairValueFromLastDayOfPriorYearToLastDayOfYearOfUnvestedEquityAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Awards, Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_EquityAwardsChangeInFairValueFromLastDayOfPriorYearToLastDayOfYearOfUnvestedEquityAwardsMember" xlink:href="crdf-20230427.xsd#crdf_EquityAwardsChangeInFairValueFromLastDayOfPriorYearToLastDayOfYearOfUnvestedEquityAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_EquityAwardsChangeInFairValueFromLastDayOfPriorYearToLastDayOfYearOfUnvestedEquityAwardsMember" xlink:to="lab_crdf_EquityAwardsChangeInFairValueFromLastDayOfPriorYearToLastDayOfYearOfUnvestedEquityAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_AdjustmentToCompensationAmountEquityAwards_label_en-US" xlink:label="lab_crdf_AdjustmentToCompensationAmountEquityAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To Compensation Amount, Equity Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AdjustmentToCompensationAmountEquityAwards" xlink:href="crdf-20230427.xsd#crdf_AdjustmentToCompensationAmountEquityAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_AdjustmentToCompensationAmountEquityAwards" xlink:to="lab_crdf_AdjustmentToCompensationAmountEquityAwards" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>crdf-20230427_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:d60d8c77-ec40-464e-a25d-a3547cb6d562,g:838ee74e-ea21-4773-8d7d-e22a95cb2f30-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2022q4/ecd-2022q4.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2022q4/ecd-2022q4.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AdjustmentToCompensationAmountEquityAwards" xlink:href="crdf-20230427.xsd#crdf_AdjustmentToCompensationAmountEquityAwards"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_crdf_AdjustmentToCompensationAmountEquityAwards" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2022q4/ecd-2022q4.xsd#ecd_AllAdjToCompMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DeductionForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember" xlink:href="crdf-20230427.xsd#crdf_DeductionForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_crdf_DeductionForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_IncreasedecreaseForTheInclusionOfRule402vEquityValuesMember" xlink:href="crdf-20230427.xsd#crdf_IncreasedecreaseForTheInclusionOfRule402vEquityValuesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_crdf_IncreasedecreaseForTheInclusionOfRule402vEquityValuesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_EquityAwardsYearEndFairValueOfEquityAwardsGrantedDuringYearThatRemainedUnvestedAsOfLastDayOfYearMember" xlink:href="crdf-20230427.xsd#crdf_EquityAwardsYearEndFairValueOfEquityAwardsGrantedDuringYearThatRemainedUnvestedAsOfLastDayOfYearMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_crdf_EquityAwardsYearEndFairValueOfEquityAwardsGrantedDuringYearThatRemainedUnvestedAsOfLastDayOfYearMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_EquityAwardsChangeInFairValueFromLastDayOfPriorYearToLastDayOfYearOfUnvestedEquityAwardsMember" xlink:href="crdf-20230427.xsd#crdf_EquityAwardsChangeInFairValueFromLastDayOfPriorYearToLastDayOfYearOfUnvestedEquityAwardsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_crdf_EquityAwardsChangeInFairValueFromLastDayOfPriorYearToLastDayOfYearOfUnvestedEquityAwardsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_EquityAwardsAddAwardsThatAreGrantedAndVestInTheSameYearTheFairValueAsOfTheVestingDateMember" xlink:href="crdf-20230427.xsd#crdf_EquityAwardsAddAwardsThatAreGrantedAndVestInTheSameYearTheFairValueAsOfTheVestingDateMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_crdf_EquityAwardsAddAwardsThatAreGrantedAndVestInTheSameYearTheFairValueAsOfTheVestingDateMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_EquityAwardsChangeInFairValueOfPriorYearsEquityAwardsThatVestedDuringTheYearMember" xlink:href="crdf-20230427.xsd#crdf_EquityAwardsChangeInFairValueOfPriorYearsEquityAwardsThatVestedDuringTheYearMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_crdf_EquityAwardsChangeInFairValueOfPriorYearsEquityAwardsThatVestedDuringTheYearMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_EquityAwardsChangeInValueOfPriorYearsEquityAwardsThatForfeitedDuringTheYearMember" xlink:href="crdf-20230427.xsd#crdf_EquityAwardsChangeInValueOfPriorYearsEquityAwardsThatForfeitedDuringTheYearMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_crdf_EquityAwardsChangeInValueOfPriorYearsEquityAwardsThatForfeitedDuringTheYearMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>crdf-20230427_g1.jpg
<TEXT>
begin 644 crdf-20230427_g1.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH "0!D]J\W7]KG]GEV"CXA#)]=*NQ_.*O1Y/]6W^Z:_-R@#[IM/VF_@/>
MD"'XDV*Y_P">J21_^A**V=-^+OPKU@A-,^)&AS,>B)JL6[_OG=FOS]HH _2"
MVNK6\A%Q9W,<L9Z/&X8'\14E?G'IVK:KH\WVG2=3N+63_GI;S,C?FI%=AX>_
M:2^./ADJ+#XC:A*J_P %^PN01Z?O0Q_*@#[LHKY4\+?M[>.[ K%XN\(Z=J,8
MX,EJ[6\A]SG>I_ "O3_!W[:?P:\2E8-8NKS19VXQ?V^Z,GV>/<,>[!: /7**
MIZ)XAT'Q+8KJ?AW6K6_MV^[/9W"R(?Q4D5<H **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ$8[(YI3G+=MFY\.R3XL@)/\#_\ H)KTBO-_AU_R-<'^X_\ Z":](KYW-_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MA!'2OL/]FK]I*P^+FG#PWXEDBM_$5M'ET&%6]0=9$'9O[R]NHXX !ZS1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 445B>,O%L7AVU\BW(:[E7]VG78/[Q_IZUI2I3K34(+5F5:M3P]-SF[)#
M/&7C.'P_$;.S*O>..!U$8]3[^@_R?/+BXGNYVN;F5GD<Y=V.231//-<S-<7$
MC.[L2[L<DFF5]3A,)3PL++?JSXK'8ZKC:EWHELOZZA11176<(4444 %%%% !
M1110 4444 %%%% !1110!M_#S_D;+?\ W9/_ $ UZ37FWP\_Y&RV_P!V3_T
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV45]$T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3']W9+&P/?<!C/%58?\ @J-^QO-IFHWG_">:DEWIEP(IM%E\.7:W\@*L_F)
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M:ZL;+XGV[WJVMD7B@A66TY?:,*@"XYP,#VI?A-X.OE_X*W_%?Q5?>&9Q9S^
M+"*VU"6S812,8[$.JN1M8X3! .?EKZPHK5X=.ISWZI_<K&$<7*-'V=NC7WNY
M\X?\$,M U[PU^S%IVE^(M%N["X'B74V^SWMLT3A2JX.U@#@U]YUYK\/?^1MM
M?I)_Z U>E5\_F-/V56$+[17YL^GRBJZ]&I4M:\F_P0-T/TK\VZ_21NA^E?FW
M7GGK!1110 5\Q_M5^,M1L?VG/#O@W5OCAK7@SP[=>&#->W>F:B\*K*)+G:Q4
M<$L51<XZ8KZ<KYU_:-\*>/+?]J+PY\4=%^"UUXQTG3_#+6US:1K&8VE9[@ '
M>",KO5NE %7]FWQSXGN/VA;OP-X*^-.J>/O"$>@_:-1U+5]SFSN2Y"HDC#+$
MX'3@ACQE,UUGB/\ ;4\->&I[S4[KX5>+G\/:?J/V*[\2C356W63<%W ,P8KD
MC!P"<CC) /)?#OX>?$GQK^TQHOQ:L_@3'\.M'T;3IHK]!-$&U%W1P%*1!<\L
MO)7HF=V=H'G_ (X^%W[0?Q#\ :]H?C_X9^,M:\8KJ7F1ZG/K.-*AMQ(IQ;0B
M0([$9 4*<!BV01@ 'T3X[_:8T;PQXT3X>>$? FN>*M7_ +,74+BWT2%"(+=L
M;68NPR3D' !X(^E2ZE^T_P" -%^$-O\ &#6-*UFTM[NX%K:Z1<Z<4OI;DD@0
MK&3@DX)!!VX'7M7E/QT^%EQXD\1Z-K'B;X >(;VWC\.VT=KXA\&7P34[>=47
M]U-$YV@*2PW8. 1SP0,O6O@+^T9XL_9MT0^+4U'4M<T#Q:=2LM(NM4 OFT[:
M%$1F!XF!#,.<J&P.0%H ]P^%7[0NB?$GQ1=^ =4\(:UX:\06=HMVVD:[;"-Y
M;<D#S8R"0P!(!Z$$]\''/?MM>-_B%X#^$]MJG@6^O;"";6(8=<U738=\]E9D
M-N=.FTY"C=D<D#(W9K$_9\\ :EJ'QAF^(VH?";Q1HT%CI)M;35/&'B2:YO)6
M8_-$L3LW[L98@Y SR,ECCN?VB_\ A>=GX=T_7_@:8KN>PU!9-8T*6*$_VG:<
M;HPTBG:>,?*02&.#D $ \K^ 6J7&H_%'2;OX.?M77'BS198'_P"$A\/^--2F
M-[C'W[='CR2"=QQ@#;RS!N.Z\>?M=Z/X*UG6+2W^%'BS5--\/3B+6M;L]/46
M\#=]I=@7 ]>!WS@@GS:U^'_C/XO_ !X\'^-?#7[-<GP\M] U(7FNZK.$A:\"
MLK>4$15WYVLN[!)$AS@#G,^)GP_^//CFY\=^'_'7P\\7Z]J4]W.WA:>VUGR=
M&MK09*$1B15>3:.%(8L2 P!!) /1_'7Q/U36/VCOA$_A#Q3?)H'B33+N[EM(
MIWCBNXS;EXS)'G!(R#@C@U>\7?ME^'_"=YJ=T_PH\776A:-?_8]3\10Z:JVT
M<FX*2N]@67++SQG<,=1GE] ^&'Q#7Q[\"]6F\'7L5OX;\-26NN22( +.46WE
M[7Y[L.*X'Q]\-?V@?B!X7\5^'_'_ ,-O&&N>*6U)Y-,U#^V=FCV]J'1AY$(D
M57<@,H3:?O@G!!H ]X^)7[6/@OX=^*=-\&6_A/7M=U#6=$CU+2(=$LA,;I'9
M@J*NX-NPC,?EP%'KQ6G\-OVB/#?Q"\6:IX&NO#6K:#JNDZ7;ZA=6FMQQQGR)
M45]PVNV-H= V<8+8Z@XX'PY\-_'!_:3^'7C:Y\(W<6FZ7\-8K*^NI8P!:W6R
M8&)N>&&\#\:YW]O+2O$?@SQAH?Q*^'\BKJ7B/3;KPO>VZMA[A)E/EE0.207;
MGL1'[4 >Y_!CXOZ'\</!Q\<^&M'O[2P:]EM[9M0C16G"$ R*%9OESD<X.5/%
M=;7/_"GP'9?##X;Z+X L-I32]/CA=U&!))C,C_\  G+-^-=!0 4444 =E\ /
M&_\ PK[XNZ+XAEFV6YNQ;WA)X\F3Y&)]ANW?517WE7YMU]^?!7Q>?'?PJT+Q
M1))OEN-/1;EL]94_=R'_ +[5J .HHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** ,#XD:C]B\.-;JV&N9 @^G4_P L?C7G5=5\5+[S=4M]/4\0PEC]
M6/\ @!^=<K7U.64_9X1/OJ?%YQ5]KCI+I'3^OF?+G_!837M<\-_L6:CJ?AW6
M;NPN5U_3U%Q97+12 &0Y&Y2#@UI^._VX?%'P^^-^F?LP>!/V?-3\9^(KSP1;
MZOIK6>NPVRSR$D&.5IEVPH%1V,I8\[5"$L*T/^"E_P "_B;^T5^RU>_#3X1^
M'TU/69M8LYX[5[R* &.-R6.^5E7@=LYK.T/]GOXKV?\ P40TWX^7/AM%\+6W
MPICT674?MT)9;T2;C'Y>_>>/XMNWWIU%66(;C>SY5?[[DT7AWA4IV;7,[7ZV
MC;S$^'W_  4D\":U\ ?'7QI^*/P]U+PI??#O6'TKQ)X:-VEW,+S>(XXHI $#
MEI"4Y"[2K$_*-QN?!G]M+XN^-OB+X?\ !7Q<_8Y\2^"[#Q;8/=^'M>CU1-3@
M:-5#C[4(8E-GD%1B3D%E! !R/)+S_@G[\9OB'\-?VC? GB"RM=&N?'GQ*EU_
MP3=SWT<D5U&EW+-&9!$S-$'5@OS ,N_.TX(KT?X/:G_P46\=^-O"WAKXJ_"S
M0O 'A#0]+>W\67":U:ZE-XB<1A%,"Q%FM1E<X)& [99B%43"IB;QYK_=OJ]^
MVENWZ%U*6#Y9.%OG+9635M==;KK\MS%O/^"H]X^F:K\7?#7[,.NZI\)-$UP:
M9J/Q$@UN!7W>8L9FCL2OF21;G7#;Q]X9VG*CK?BS^WAJ/@S]H#2_V>OA?\"K
M_P <ZIX@\&Q:]H$^FZW#;1W/F/( CF9 L,8CB9S,6/4*$)(KY@\._P#!./XW
M?#73;[X-V_['?@WQM(^O%])^)NN>-)8;-+!G4[;FPAGCF9PH(RF,%N-^T%OI
M#2_V9?B+X>_X*!^%/B]I'A:VC\%:#\)(_#WVZWNT58KF-Y=L20O(TVT*RX)W
M<<%B034TYXR2]ZZU73;OTV^_U+JT\O@_=L]';7?:U[.]_N]#A?B?_P %$?B;
MXW_8_P#B5XN^'OPCU+PIXX\$ZU_8GB2R;58+@Z$265KM9&C"S!61H]H4$,=P
M) !.+<_&_7?$?P<_9CUGXY> O%^GZKJ7C/1K'2[JR\:HAU0>5:>7J5U^YD,\
M4Q8N8"5?[P+Y.:VH/V,_CQJ'@?\ :E\-7/ANVM9_B7XCEO?!K2ZE"RWL8FFE
M7=M8^46R@_>;<%N<8.*E[^SW^UG\2_A=^SKHGBSX'PZ%?_"OQQI2ZU;#Q+9W
M&=,LH[1/MNY)-N7\N0^4I9AM[Y%9OZR]97V[?WO3MJ7'ZG'2-DK]]=8^NU[H
M]E\%_MR^'-4E^+^G?$/P6_AN_P#A!+*^J6CZD)_MUF(Y'BN(B8T($@CX7!(W
MISE@*Y>?_@HOK$OPW^'.HZ!^SKJ&I^._BBD]QX8\!V^OQJ?L<98_:9KIXE6)
M&C D'R$;<DD!21QW[>_["/QC^-OQ]TWQC\$I5MM%\;Z7;:%\4I4O(HBEG!>0
M3)<;78&1MD:KA 3B +C#G.K^W1^Q'XA\?>.OAU\5OA5\)M-\9Z?X*TY](U'X
M?7>M?V:MY8;2(O)N"RB-H]S=6'1.& *G:4\8E)+IY;W>^W1?CT,84\ W!M_%
MK:^UEL]5O+S6G5'H_P (OVS-2^*G@?X@!_@AJVF?$'X<12#6_AX]^D\TT_E/
M)!'!/&A6592A57"=><$%2WJ/PE\8^(?B#\-]'\:>+/ EWX8U+4K-9KS0+]RT
MUBY)S&Y*KDC']T=>E?/G[)GP'^+GP/\  ?Q%^(VC_LQ^#_!OB?5;5_\ A$?"
M=AKL]Y-,8DD:"*^NGN6A?,C*H:/R\#<6(R OT'\)=4^(^M?#?1]5^+WAJTT?
MQ-/9JVLZ983B6&VFR<HC!W##&.=Q^M;T)56ES[V[>?HM?+\#EQ,:,6_9VM==
M?+7J]+]=?4^0K[PYXI_X*%_MK?$;X6^-_B;XAT3X=_"[R+&/P_X<U$VK:A>2
M%U,LS '<-T4W49"A N,L6M_"ZU\9_L/_ +?'AO\ 9=T;XF:[XB^'OQ$T*>YT
MRP\1WQN9M(NXDF<B-R!A28<<  B7D$H&.[\1?@!^U5^SG^U5XC_:<_9(\':1
MXRTGQU;Q#Q7X,U#5$LI4N4 Q-%+(RIR=S9))!ED&PY4BU\"_V=OVE_BS^UG;
M?ME?M<Z!I/AF?P[I$FG>#O!NE:@EV;4.LBM+-*A9&.V:7D$EF8<($ /(H3]H
MM'S\V^MK7[[6MI8[G4A[-^\O9\NBTOS6[;WOK?\ $QM%_P""J/Q \6_#?6?B
MYX)_8MUW5?#OA74)X/%NK0^*($CL4C():,-$'N&"$.ZJH$:E2S8.1S_[37[<
M7QIU'X\_!&[_ &>O!FK:OX2\463ZO8Z7:ZO#:-XGD,8S:R$J3";?/S*Q*,S=
M"4!KR_\ 8_\ ^&Q?$/[('Q"^$/P+^"^C>)=$\9>)M7TQ]<N?$D5G+HKS0Q0W
M#20R@>>AB92A1MRMNR&&!7KOQ,_8X_:&^#UG^SOKOP*\#V?CJ^^$UI>0ZWIQ
MUJ'3Q<2SK&S.DDY \O?YOJP&WY3DXSC4Q-6DG=]&]/-;::Z:]?T-72P="NU:
M/VDKO^[UUTUT6WZG:> ?C/\ #?P;^V?\=]9\2KXATX^%O"^G:AXAN[_Q +G3
MTA6SAD(MK185,+A>#^\?>V< ;L#,L_\ @J-X@L=#TCXP?$#]DCQ+H'PKUS4%
MMK#QY-K,$TBJ[%4FELD3?'&2,[MY!'W=Y(!2[_8T^*7Q)_:!_:"UCQCI":-X
M?^)W@VPT[0M66]AF*W*6D*,6C1]X"2H<Y"[@IP>0:X76_P!GO_@H#\6OV<_#
M_P"P?XV^#_AS0O#FER6=GJ?Q'B\30W$=Q86KJT0BM%Q,),(G+ ;BN"$W$C5S
MQ4;V3^U;3=WTOV5NNGJ8QA@YM<S3TC>[M9<JNUKJT^FOH>U?$K]NOQ1X<_:/
MU']F3X5_LZ:AXVUZ#PY#JVFR6'B&"UAN4?:S>:\R;((U5O\ 6;GW,44+\V1B
M:9_P5#\%O^RSKO[0_B/X4ZIINI^'O%'_  CNH>$GOT9EU$[2%^T%541X8Y=E
M!!1AM/&=7X<?LW?$3P7_ ,%$]9^-2>'@G@I_A7;Z#IFIO?1,[W$<MGB,QAO,
M'R0O\Q4+QUY%><>"/V3/VFO"OP&^,?A&'X5>#]3U#Q9\3[K6--T'QC(EU::I
MIKD$;6AF'D39"LC.1M*\A20RVY8M-M7^UTVMMT_X<B,,"TD[?9Z[WW6]O\CZ
M%_8U_:A^+/Q<^+\'A3XC?LQ7WA:UETM[W3?$FE>)K?7-*N1M8>4;JV5427J0
MF6X&3C*[OK6OS6_X)\?L;_&'X<?MNZ3\7]"^!4_P=\&6VC7<.N>%G\?KK2ZU
M</!*J;1&S;$1F1QO.08AC[Q _2FO$QTJDJJY][=?5^2_(^BRV%&%!JG:U^GH
MO-_FP;H?I7YMU^DC=#]*_-NN(]$**** "L[Q1XO\+^"=+.M>+=>M=.M1(J>?
M=2A%+,0 !GJ<D5HU\J?MY>#O$D?CRR^(VN^#;K7O"L6BPV8-NY(TNY^V([RL
M@Z^9'^[!. 2X&057(!]3"]LVM!?B[B,#('$PD&PJ>ASTQ[U'#K.CW+%;?5;:
M0JI9@DZG '4\'I7S7XDA\+>(?V(M3\+_ ++]OKVNVM]J:6R6$D;S75B3,DLL
M)4#*J%'N/WF<G.:B_9[\'_"#PQ\5)OA5XL_9^U'P=XEU3PW,ENUSXD>]CU&T
M=2LH!5ML;D*QPN<;6&01@@'TM_PD.@?]!RS_ / E/\:DO]7TK2O+_M34[>V\
MY]D7VB94WMZ#)Y/L*^4O%/[*GP,\1?M&:5\%?AWX0>SM=)LQJOC&^_M*XE;R
MC@16J[W(4OE22!G:X(/!SH>(/ WAWX_?M'_%*Q^(=L]W;^%_#<5MH,#3NJV;
M-#N,J@$?-O#-SD?-R#Q0!]2U7U#5])TD1G5=4M[82OLB-Q.J;V]!D\GVKS#]
MB7Q9K'C']FOP]J&NW<EQ<VZSVAGE8EG2*9T3)/7"!5_X#7@OCJ^LOBC\=OB=
M<>.?A/K?C.+04-E8QZ=?B!-&M(]ZR3+N.#(2H=5"MD[R10!]FWEY9Z?;/>W]
MU'!#&,R2S2!54>I)X%%K=VM];I>65S'-%(N8Y8G#*P]01P:^4O$]QX-^*>H_
M _X2Z/K>J:IX,U*.XN9X]6N/W]T( 0L4YC"@F,H\?'OR>#61-XHU7X,>!OCU
M\._!-[/;:=HE]9_V)$DS'[$MW/Y,JHQ.1\K#!SG*YZG- 'V!8ZOI.IR2Q:;J
M=O<- ^R=8)U<QMZ-@\'V-6*^3]!\#^'_ (!_%[X*:G\/;:2T?Q7H[VOB%5G=
MEO2886+N"2,[Y=W& -B\<5]84 %<1??L[_"K5?BJGQEU;0Y;K7(I$DMWN+R1
MH89%145TBSL# *#TZC=UYKMZ* "BBB@ HHHH *^L?V#?$[:E\.-3\+RR;GTO
M4]\8S]V.5<@?]])(?QKY.KW/]@S7_L/Q+U/P^\F$O])+J,_>DCD4C_QUWH ^
ML:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,!8H?EM=JN-FT<]2O.&(5.RL^KZ^AU4L-3J8256[;3V5M%W9]@?\-5_LO?\
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M%^(O@#XH:&/$_P -O&^DZ_IQD,?V[1M0CN8MXQE=T;$!AD9'49KYB^ '@?\
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MXZ\5R7Q0_9\^,47Q0U_XC? SQ/H5M_PF&CK8:]:ZXLH\DA!&)X3&I^;:!PW
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(/UP:ZBUNK:]MH[VRN(YH9D#Q2Q.&5U(R&!'!!'.:?7Y\TT[,_24TU='PO\
M&;]GSQS\&KXR:I;_ &S2G?%MJUNA\MO17'_+-O8\'L3BN#K]'M0TZPU:QETS
M5+**YMYT*303QAT=3U!!X(KYK^.W[%MQ9^=XJ^#T331<O/H;MET]3"Q^\/\
M8//H3P*0SYUHI]Q;SVD[VMU \4L;%9(Y%*LK#@@@]#3* "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *?;Q&>XC@49+N% ^IIE:?@NR.I>,=)TY
M1DW&IP1@?[TBC^M 'Z(T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9?C
M:,R^%KU1VB!_(@_TK4JGX@A-QH5Y !RUK(!]=IQ6M%\M:+\U^9CB(\^'G'NG
M^1Y/1117V9^>A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/N+DG'3*^4#^<M 'V71110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4DB+(
MC1N,A@0:6BC8-SQZ>%[>=[=_O(Y4_4'%,K3\96ALO$]Y%C :8N/^!?-_6LRO
MM:<_:4U+NC\[JP=*K*#Z-H****LS"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *YGXR^,?^$ ^%6O\ B]+E89;+2Y6M9&&0)V&R(?C(R#\:Z:O"
M/^"@/C'^Q/A+9>$H+D+-K>J+YD9'WX(1O;\I##7K9#@O[1SFAA[74I*_HM7^
M"9Y6>XW^SLGKXA.SC%V]7HOQ:/C:BBBOZ>/YD"BBB@ !(.0:^HOV5?\ @HUX
MK^&GV;P-\:9+G6]!7$<&IYWWEBO09)_UT8]#\P'0G 6OEVBO(SK(LLS_  ;P
MV-IJ4>CZQ?>+W3_/9W1[&29]FO#V,6)P-1QEU722[26S7Y;JS/V0\&^-?"?Q
M"\.6WBWP3K]MJ>FW:;H+NUDW*WJ#W5AT*G!!X(!K4K\E_@-^T?\ %#]G?Q'_
M &WX!UD_9I7!O])N26M;L#^^F>&QT=<,/7&0?T0_9J_;!^%W[26F+;:/=#3-
M?BBW7F@7DH\U<=6B;@3)[CD?Q*N1G^;.+O#W,^&I.O2O5P_\R6L?\:Z?XEH_
M)NQ_3?!WB+E?$ZCAZUJ6(_E;TE_@?7_"]5YI7/6*\3^.W['WA[QUYWB;X>+#
MI6KG+RVN-MM='OP/]6Y]1P>XY+5[917YZ?HI^=7B;PMXA\&ZS-X>\4:1-97D
M!Q)!.N#[$=B#V(R#VJA7W[\4/A#X(^+FC?V3XMTP-(BG[+?0X6>W)[JWIZJ<
M@]Q7R'\:OV<_&_P;NVN[N(W^CN^(-5MXSM&>BR+SY;?7@]B>< 'GU%%% !11
M10 4444 %%%% !1110 4444 %?2'_!/_ ,.$R^(O%TL? 6&S@;'7.YW'Z1U\
MWU]J_L?^%#X7^!VG3RQ[9M5FEOI01V8[4/XHB'\: /3Z*** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MAW6V@VQER1P9Y 4C'Y;V^J"OL"@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?$2&UOK<MI.G%;C57QPR@_+%]7(Q_NACVK[@1$B01QH%51A548 'I0 M%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^O%+6MJ^T/* "25&.<8/Y5W_ (2UV]\2:!#K.H>'[K2YI2P:QO!B2/#$#/U
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %1W5K!>VSVEU&'CD4JZGN#4E%--IW0FDU9GEGB;P_<>'=3:
MSDRT;?-!(?XE_P 1WK.KU3Q+X?MO$6FM9S860<PR8^XW^'K7F-_876F7<EC>
MQ%)(VPRG^?TKZC 8M8FG9_$M_P#,^+S/ /!U;Q^![>7D0T445WGF!1110 44
M44 %%%% !1110 4444 %?$_[=_BW_A(?CI)HD1;R]$TV"UQNRK.P,S,!V.)5
M4_[GM7VO))'$C2RR!%4$LS'  [DU^:_Q \4R>./'.L>,9493JFISW*QNV2BN
MY95_ $#\*_2/#3!>VS2KB6M*<;?.3_R3/SGQ)QOL<KI89;U)7^45_FT9%%%%
M?MA^*F9J'@[PWJGB.R\6W^F"34=.1EL[DR,#&&!!& <'@GJ#57QC\,_ _CZ6
MWN/%F@I=2VN?(E$SQNH/4;D8$CV/%<W\+?C(=?\ "6J^*/'][86$5CKDEDDR
M HFT*A7.XGYB6-=-I/Q(\!Z[KLGAG1_%EE<W\>[=;13 L<=0.S8[XSC%?.T,
M9PWFN$5U3<:[4N6:C>;V3<7N_=TW?NZ;'TF(P7$N4XMI.HI4$X\T'*T%NTI+
M9>]KLO>UW*D'P<^&MKI6H:':^%8HK/5?*^WVT4TBI+Y9RG ;Y<'GY<9[YI/B
M/X6UC5/A^_AGP=8:;*R)&B66J1EX98E&-F<Y!X!#9ZJ.1UJ?7/BI\.O#6K#0
MM>\8V-K=\;H99N4STW=E_'%6O$OCKP?X.LXK_P 3>(K6SBG/[AI9.9/]T#EA
MR.1ZU52CP[]4KT82ITXJ+A-Q<(N*;;LVOAU;=GI=O35D4ZW$GUNA6G&I4DY*
M<%)3DIM)*Z3^+W8Q5UK9+71'FG@/X.^(X_'VC>(K[P'I?ANPT5)7,%G?&>2[
MF==N2W)P.#R>,8YSQVVL? [X4Z]KK^)-6\&V\MW))YDK^9(J2-ZLBL%8^N0<
M]ZU9/'7@Z+PX/%[^);/^S&( OA,#'DG&,COGC'K46E_$GP%K>O/X8TGQ98W%
M^F<VT4P+$CJ!V8CG(&<8/I7#@LFX6P-!86;IU/:24TI^S=VTHQ<8I**TC:/+
M%7L]]3T,=G7%F/KO%P52G[.+@W#VBLE)RDI2;<G[TKRYI.UUMH1^+?A?X$\<
MSV=SXH\/I<R6'_'JZRO&4'!Q\C#(R!P>*O>*?">@>--(?0?$UA]JM)'5GA\U
MT#%3D9*D'KSBN0\+_'?1O&6L>(M%TFZLH'TR)CI<LUQN6[VJY:4XZ(,+T['K
MZ:_@;X@V>IZ'I$7B?Q'I#ZMJB2F!-.E/E7&QV'[O=R< <^X-=.%S#AK'SG[%
M0DJR:D[1M/DDJ?+*^LG=I133NGIHU?EQ>7<3Y?"'MG.+HM.,;RO#GBZG-&VD
M5:+<FFK-:ZIVZ&32]/ETMM%>T0VC6Y@,&/E,>W;M^F.*Q+#X3?#[3$TN.R\/
M!%T6>2;2P;F4_9W<@L1EN<D X.1^9K4'BCP\=;E\.#6(/MT%OY\]KYGSQQ<?
M.WH.1U]:H^'_ (G?#_Q5JCZ)X>\76-W=("?(AF!+ =2O]X#VS7H5WD=6M"-;
MV;G?EC?E;NFGRJ^MU)1=ELTGND>=06>T:,Y4?:*%N:5N9*S37-*VEG%R5WNF
MULV3OX&\*R:]>>)GTE3?:A9_9+R?S7S)#@#;C.!T'( /%5I/AAX%E\&I\/I-
M 4Z/&VY++SY, [R_WMV[[Q)ZUOT5T2RW+I<UZ,'S*2?NK52=Y)Z:J32<K[M:
MG-',\RCRVK37*XM>\]'%6BUKHXIM1MLG9'/>+/A1\/O',MK/XI\-QW4EFFRW
MD\UT94_NDHP+#V.1R?6D@^$OPYM=)U#0;?PK;I9ZHX>^M@S;'8="!GY,=MN,
M=JZ*BHEE&53K2K2P\'.6C?)&[5N75VN]-->FFQI'.,WA1C1CB)J$=4N>5DT^
M9-*]E[VNG77<Y;0_@K\,?#=_::KHOA9(+JQ=FMK@7,K.I*[3EBQ+#' #9 R<
M 9-:_AKPAX<\(17,/AS31;+>737-R!(S;Y6QEOF)QG X'%:5%5A\KRS!M.A0
MA"U[<L8JUTD[675))^22Z$XG-<TQB:Q%><[VOS2D[V;:O=]&VUYMOJ%%%%=Q
MP!7Z>_L)^&?C'X<^ U@_QB\1W5W->8FTBPO1F:PLRHV1NY^8D_>"L3L4JO&"
M!\T?\$]/V/6^)6M0_&SXD:43X>TZ?.D6<Z?+J-PI^^0>L2$?1F&.0K _?U?@
M'BQQ3A,5)9/ATI.#O.5D[/\ EB^C_F:_P]T?T+X1\*8O"1><XAN*FK0C=KF7
M\TEU7\J?^+^5A1117XD?N84444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<%%%%??'P9\R-_R;?XI_['0_RBKOO'.AZ/H/Q@^&\>BZ;!:C;/&?(B"Y543
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !39(HY
MHS%-&KHPPRL,@CZ4ZBC8-SD/$GPS24M=^'F"MU-LYX/^Z>WT/YUQUU:7-C.U
MM>0/%(I^9'7!%>P54U;1-+UN#R-2M%D ^ZW1E^AZBO6PN:5*7NU=5^/_  3P
M\9DM*M[U'W7VZ?\  /)J*ZG7/ACJ%INGT:;[1&.?*? <?T/Z?2N9GMY[64P7
M,+QNOWD=2"/P->Y1Q%&NKP=SYO$87$8:5JD;?E]XRBBBMCG"O//VK/%P\&_
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MEI'V?P7I'GZG+&%O=<O0'N9_4 XQ&F?X%P.!G)YKT:...&-888U1$4!548
MZ "G5_/G%''N=<3-TI/V='^2+W_Q/>7X+RN?T3PKX?Y)PNE5BO:5_P">2V_P
MK:/XOSL%%%%?#GW84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP;3XJZAX!\&_$+QJVG^.O&VF7/V>6RLT6,B 3GB 2AY"7/ $)W93>#D>+?\
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M^79'Q'+"X*')348NUV]6M=9-O\3^@/#K.<RSWAJ.*QU3GJ.4E>R6B>FD4E^
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M,LBQ6\Q5I9+N9P2D4,<8+2NP!("@\ L< $@ [BBOG[X-?\%+/V;OC'\2M/\
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M^'^C_!;]GW1?%VN7'_";^ [27X>ZAKEFY?5;.WL8W5IY@JH+DPA'92%):08
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M8^#KFPT_4I7QL6.=@5&[(P7VCU(XKZ5H **** "BBB@ HHHH **** "BBB@
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MY"%#@]-Y/<U[Y^Q]^R]X9_8Z^ ^E_ 3PAXDO]6L-+N+F:*^U)$69S-,\K A
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M%?\ !1?XT?LPCPUK'[&_A+PO:> )(-?T/5O#OCM+BZTO[!$Q'D1;07/D[U"
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MT:>%2E))W>[1\IF^&Q%7&N4(-JRV39C5=\.?\C#8?]?L7_H8JY_PK_Q=_P!
MC_R8C_\ BJLZ+X'\46FLVEW<:7MCBN8W=O/0X 8$GAJ[*F)PSIM*:V[H\^E@
M\6JL6Z<MUT9Z%1117R)]V?%OB_\ Y3Q>%?\ L@LG_I;>5J?M%_&R"P_;QL_
M?[+_ .RKI_C[XU:9X&W:GXGUO7C8V>@:1)+E8V)W!V9I 2$56 F #-N<#V;5
M/V2O"FJ?MEZ;^VA+XIU%=9TWP6WAR/2%2/[,\)FEE\TG&_?F4CKC@5R?Q_\
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M1^+NG:S!IMKJ5H[E9+!IY25?:S2'8X7^(!OGVMY7\#/A?\*?%G_!5[X>Z_\
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MW@#]AS1;#X%^*OV?_CU\9O&/Q8T;Q9+F[F\<ZF9Y[9 J[4A<',>UT612.5<
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MR BGL#7T-^V!^R_X9_;$^ VJ? /Q?XDO])L-5N+:66^TU$:9##.DR@!P5Y*
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M  1:\)^'-&\&_&[6=*T:WM[F3X\ZU8-+%$%)MH([=H8N/X4,TI Z#>?6K_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH YZU^$GPJLOB!<?%FR^&7AZ'Q5>0B&[\31:+ NH3QA0@1
M[@)YC*%55P6QA0.@KH:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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..1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139930156986512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">DEF 14A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Cardiff Oncology, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001213037<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139930158590528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTableTextBlock', window );">Pay vs Performance [Table Text Block]</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:4.902%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.834%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.834%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.980%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.834%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.834%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.837%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Summary Compensation Table Total for PEO ($)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Compensation Actually Paid to PEO ($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average Summary Compensation Table Total for Non-PEO NEOs ($)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average Compensation Actually Paid to Non-PEO NEOs ($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value of Initial Fixed $100 Investment Based on Total Shareholder Return ($)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Loss </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">($ in thousands)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,590,347&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,869&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,523,156&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,550&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,728)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,635,198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,401,408)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,148,786&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539,237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,315)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NamedExecutiveOfficersFnTextBlock', window );">Named Executive Officers, Footnote [Text Block]</a></td>
<td class="text">Mr. Erlander served as our PEO during each year shown. The Non-PEO NEO's presented in the table represent the two highest paid NEO's during the respective years as follows:<div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">2022: James Levine and Tod Smeal</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">2021: Vicki Kelemen and James Levine</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoTotalCompAmt', window );">PEO Total Compensation Amount</a></td>
<td class="nump">$ 1,590,347<span></span>
</td>
<td class="nump">$ 3,635,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoActuallyPaidCompAmt', window );">PEO Actually Paid Compensation Amount</a></td>
<td class="nump">$ 91,869<span></span>
</td>
<td class="num">(1,401,408)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToPeoCompFnTextBlock', window );">Adjustment To PEO Compensation, Footnote [Text Block]</a></td>
<td class="text">The 2022 Summary Compensation Table totals reported for the PEO and the average of the Other NEOs for each year were subject to the following adjustments per Item 402(v)(2)(iii) of Regulation S-K to calculate &#8220;compensation actually paid&#8221;:<div style="padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"/><td style="width:50.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.385%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PEO ($)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average for Other NEO's ($)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PEO ($)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average for Other NEO's ($)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Summary Compensation Table</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,590,347&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,523,156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,635,198&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,148,786&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deduction for amounts reported under the &#8220;Stock Awards&#8221; and &#8220;Option Awards&#8221; columns of the Summary Compensation Table</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(753,272)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(919,022)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,851,972)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,701,431)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase/(decrease) for the Inclusion of "Rule 402(v) Equity Values" </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(745,206)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(381,584)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,184,634)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Compensation&#160;Actually&#160;Paid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,869&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,550&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,401,408)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539,237&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">Compensation Actually Paid excludes the Stock Awards and Option Awards columns from the relevant fiscal year&#8217;s Summary Compensation Table total. The Rule 402(v) Equity Values instead reflect the aggregate of the following components, as applicable: (i) the fair value as of the end of the listed fiscal year of unvested equity awards granted in that year; (ii) the change in fair value during the listed fiscal year of equity awards granted in prior years that remained outstanding and unvested at the end of the listed fiscal year; and (iii) the change in fair value during the listed fiscal year through the vesting date of equity awards granted in prior years that vested during the listed fiscal year, less the fair value at the end of the prior year of awards granted </span></div><div style="padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prior to the listed fiscal year that failed to meet applicable vesting conditions during the listed fiscal year. Equity values are calculated in accordance with FASB ASC Topic 718, calculated as follows:</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.964%"><tr><td style="width:1.0%"/><td style="width:46.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.480%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.314%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.480%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.314%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.480%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.314%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.480%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.319%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8220;Inclusion of Rule 402(v) Equity Values&#8221;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PEO ($)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average for Other NEO's ($)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PEO ($)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average for Other NEO's ($)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Year-End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446,788&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,637&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,992,010&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,380,605&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(288,112)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(457,723)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,270,502)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(701,257)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Awards that are granted and vest in the same year, the fair value as of the vesting date </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in Fair Value of Prior Years&#8217; Equity Awards that Vested During the Year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(903,882)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(177,498)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,906,142)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(587,466)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtract: Awards Granted in any prior fiscal year that failed to vest Change in Value of Prior Years&#8217; Equity Awards that Forfeited During the Year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase/(decrease) for the &#8220;Inclusion of Rule 402(v) Equity Values&#8221; (i)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(745,206)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(381,584)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,184,634)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,882&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonPeoNeoAvgTotalCompAmt', window );">Non-PEO NEO Average Total Compensation Amount</a></td>
<td class="nump">$ 1,523,156<span></span>
</td>
<td class="nump">2,148,786<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonPeoNeoAvgCompActuallyPaidAmt', window );">Non-PEO NEO Average Compensation Actually Paid Amount</a></td>
<td class="nump">$ 222,550<span></span>
</td>
<td class="nump">539,237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToNonPeoNeoCompFnTextBlock', window );">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</a></td>
<td class="text">The 2022 Summary Compensation Table totals reported for the PEO and the average of the Other NEOs for each year were subject to the following adjustments per Item 402(v)(2)(iii) of Regulation S-K to calculate &#8220;compensation actually paid&#8221;:<div style="padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"/><td style="width:50.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.385%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PEO ($)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average for Other NEO's ($)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PEO ($)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average for Other NEO's ($)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Summary Compensation Table</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,590,347&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,523,156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,635,198&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,148,786&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deduction for amounts reported under the &#8220;Stock Awards&#8221; and &#8220;Option Awards&#8221; columns of the Summary Compensation Table</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(753,272)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(919,022)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,851,972)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,701,431)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase/(decrease) for the Inclusion of "Rule 402(v) Equity Values" </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(745,206)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(381,584)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,184,634)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Compensation&#160;Actually&#160;Paid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,869&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,550&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,401,408)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539,237&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">Compensation Actually Paid excludes the Stock Awards and Option Awards columns from the relevant fiscal year&#8217;s Summary Compensation Table total. The Rule 402(v) Equity Values instead reflect the aggregate of the following components, as applicable: (i) the fair value as of the end of the listed fiscal year of unvested equity awards granted in that year; (ii) the change in fair value during the listed fiscal year of equity awards granted in prior years that remained outstanding and unvested at the end of the listed fiscal year; and (iii) the change in fair value during the listed fiscal year through the vesting date of equity awards granted in prior years that vested during the listed fiscal year, less the fair value at the end of the prior year of awards granted </span></div><div style="padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prior to the listed fiscal year that failed to meet applicable vesting conditions during the listed fiscal year. Equity values are calculated in accordance with FASB ASC Topic 718, calculated as follows:</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.964%"><tr><td style="width:1.0%"/><td style="width:46.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.480%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.314%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.480%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.314%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.480%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.314%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.480%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.319%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8220;Inclusion of Rule 402(v) Equity Values&#8221;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PEO ($)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average for Other NEO's ($)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PEO ($)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average for Other NEO's ($)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Year-End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446,788&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,637&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,992,010&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,380,605&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(288,112)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(457,723)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,270,502)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(701,257)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Awards that are granted and vest in the same year, the fair value as of the vesting date </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in Fair Value of Prior Years&#8217; Equity Awards that Vested During the Year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(903,882)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(177,498)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,906,142)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(587,466)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtract: Awards Granted in any prior fiscal year that failed to vest Change in Value of Prior Years&#8217; Equity Awards that Forfeited During the Year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase/(decrease) for the &#8220;Inclusion of Rule 402(v) Equity Values&#8221; (i)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(745,206)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(381,584)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,184,634)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,882&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TotalShareholderRtnAmt', window );">Total Shareholder Return Amount</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (38,728,000)<span></span>
</td>
<td class="num">(28,315,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoName', window );">PEO Name</a></td>
<td class="text">Mr. Erlander<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember', window );">PEO [Member] | Deduction for amounts reported under the &#8220;Stock Awards&#8221; and &#8220;Option Awards&#8221; columns of the Summary Compensation Table( [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="num">$ (753,272)<span></span>
</td>
<td class="num">(2,851,972)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember', window );">PEO [Member] | Increase/(decrease) for the Inclusion of Rule 402(v) Equity Values [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="num">(745,206)<span></span>
</td>
<td class="num">(2,184,634)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember', window );">PEO [Member] | Equity Awards, Year-End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_AdjustmentToCompensationAmountEquityAwards', window );">Adjustment To Compensation Amount, Equity Awards</a></td>
<td class="nump">446,788<span></span>
</td>
<td class="nump">1,992,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember', window );">PEO [Member] | Equity Awards, Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_AdjustmentToCompensationAmountEquityAwards', window );">Adjustment To Compensation Amount, Equity Awards</a></td>
<td class="num">(288,112)<span></span>
</td>
<td class="num">(2,270,502)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember', window );">PEO [Member] | Equity Awards, Add: Awards that are granted and vest in the same year, the fair value as of the vesting date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_AdjustmentToCompensationAmountEquityAwards', window );">Adjustment To Compensation Amount, Equity Awards</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember', window );">PEO [Member] | Equity Awards, Change in Fair Value of Prior Years&#8217; Equity Awards that Vested During the Year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_AdjustmentToCompensationAmountEquityAwards', window );">Adjustment To Compensation Amount, Equity Awards</a></td>
<td class="num">(903,882)<span></span>
</td>
<td class="num">(1,906,142)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember', window );">PEO [Member] | Equity Awards, Change in Value of Prior Years&#8217; Equity Awards that Forfeited During the Year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_AdjustmentToCompensationAmountEquityAwards', window );">Adjustment To Compensation Amount, Equity Awards</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember', window );">Non-PEO NEO [Member] | Deduction for amounts reported under the &#8220;Stock Awards&#8221; and &#8220;Option Awards&#8221; columns of the Summary Compensation Table( [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="num">(919,022)<span></span>
</td>
<td class="num">(1,701,431)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember', window );">Non-PEO NEO [Member] | Increase/(decrease) for the Inclusion of Rule 402(v) Equity Values [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="num">(381,584)<span></span>
</td>
<td class="nump">91,882<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember', window );">Non-PEO NEO [Member] | Equity Awards, Year-End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_AdjustmentToCompensationAmountEquityAwards', window );">Adjustment To Compensation Amount, Equity Awards</a></td>
<td class="nump">253,637<span></span>
</td>
<td class="nump">1,380,605<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember', window );">Non-PEO NEO [Member] | Equity Awards, Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_AdjustmentToCompensationAmountEquityAwards', window );">Adjustment To Compensation Amount, Equity Awards</a></td>
<td class="num">(457,723)<span></span>
</td>
<td class="num">(701,257)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember', window );">Non-PEO NEO [Member] | Equity Awards, Add: Awards that are granted and vest in the same year, the fair value as of the vesting date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_AdjustmentToCompensationAmountEquityAwards', window );">Adjustment To Compensation Amount, Equity Awards</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember', window );">Non-PEO NEO [Member] | Equity Awards, Change in Fair Value of Prior Years&#8217; Equity Awards that Vested During the Year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_AdjustmentToCompensationAmountEquityAwards', window );">Adjustment To Compensation Amount, Equity Awards</a></td>
<td class="num">(177,498)<span></span>
</td>
<td class="num">(587,466)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember', window );">Non-PEO NEO [Member] | Equity Awards, Change in Value of Prior Years&#8217; Equity Awards that Forfeited During the Year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_AdjustmentToCompensationAmountEquityAwards', window );">Adjustment To Compensation Amount, Equity Awards</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_AdjustmentToCompensationAmountEquityAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_AdjustmentToCompensationAmountEquityAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToNonPeoNeoCompFnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToNonPeoNeoCompFnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToPeoCompFnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToPeoCompFnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NamedExecutiveOfficersFnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NamedExecutiveOfficersFnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonPeoNeoAvgCompActuallyPaidAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonPeoNeoAvgCompActuallyPaidAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonPeoNeoAvgTotalCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonPeoNeoAvgTotalCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PeoActuallyPaidCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PeoActuallyPaidCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PeoName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PeoName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PeoTotalCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PeoTotalCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TotalShareholderRtnAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iv<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TotalShareholderRtnAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_ExecutiveCategoryAxis=ecd_PeoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=crdf_DeductionForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=crdf_DeductionForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=crdf_IncreasedecreaseForTheInclusionOfRule402vEquityValuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=crdf_IncreasedecreaseForTheInclusionOfRule402vEquityValuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=crdf_EquityAwardsYearEndFairValueOfEquityAwardsGrantedDuringYearThatRemainedUnvestedAsOfLastDayOfYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=crdf_EquityAwardsYearEndFairValueOfEquityAwardsGrantedDuringYearThatRemainedUnvestedAsOfLastDayOfYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=crdf_EquityAwardsChangeInFairValueFromLastDayOfPriorYearToLastDayOfYearOfUnvestedEquityAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=crdf_EquityAwardsChangeInFairValueFromLastDayOfPriorYearToLastDayOfYearOfUnvestedEquityAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=crdf_EquityAwardsAddAwardsThatAreGrantedAndVestInTheSameYearTheFairValueAsOfTheVestingDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=crdf_EquityAwardsAddAwardsThatAreGrantedAndVestInTheSameYearTheFairValueAsOfTheVestingDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=crdf_EquityAwardsChangeInFairValueOfPriorYearsEquityAwardsThatVestedDuringTheYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=crdf_EquityAwardsChangeInFairValueOfPriorYearsEquityAwardsThatVestedDuringTheYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=crdf_EquityAwardsChangeInValueOfPriorYearsEquityAwardsThatForfeitedDuringTheYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=crdf_EquityAwardsChangeInValueOfPriorYearsEquityAwardsThatForfeitedDuringTheYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>crdf-20230427_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:crdf="http://www.cardiffoncology.com/20230427"
  xmlns:dei="http://xbrl.sec.gov/dei/2022q4"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2022q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="crdf-20230427.xsd" xlink:type="simple"/>
    <context id="ie01d1de15b9444b183272d5953f012c0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i162e015e217c4d45bddc31b5744d6c17_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if6c039ead809495cae54a5ab4e87a488_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:DeductionForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2f35b7ba98ca4879b389a1204541bc1f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:DeductionForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i808f413dd8bd4a038c815bd31cf674bb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:DeductionForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i67ff1600b4c246b2ab359a056db81b0a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:DeductionForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i86619fe2a4904a08839c9a77d4598f63_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:IncreasedecreaseForTheInclusionOfRule402vEquityValuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icafd16b4fdca433ab80e693f2728fc6c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:IncreasedecreaseForTheInclusionOfRule402vEquityValuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i099dab0c3dfb4ba08b9f1e8273c73b43_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:IncreasedecreaseForTheInclusionOfRule402vEquityValuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i48bde130657f4d60a3c8729859ad4a54_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:IncreasedecreaseForTheInclusionOfRule402vEquityValuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia69205d3273d42cfa5b47e45431f4273_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:EquityAwardsYearEndFairValueOfEquityAwardsGrantedDuringYearThatRemainedUnvestedAsOfLastDayOfYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i222ba39e2bff496a82ec7ce575a3569c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:EquityAwardsYearEndFairValueOfEquityAwardsGrantedDuringYearThatRemainedUnvestedAsOfLastDayOfYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifa076cb47d104183826cd32c0caf6c74_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:EquityAwardsYearEndFairValueOfEquityAwardsGrantedDuringYearThatRemainedUnvestedAsOfLastDayOfYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1374971d2a224cd48aec91e78ac8bd8b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:EquityAwardsYearEndFairValueOfEquityAwardsGrantedDuringYearThatRemainedUnvestedAsOfLastDayOfYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6bcd6aa3ae8a4718aaa3527feb1a9750_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:EquityAwardsChangeInFairValueFromLastDayOfPriorYearToLastDayOfYearOfUnvestedEquityAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iacbe2ef0043b41eca3c977825b71bcc7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:EquityAwardsChangeInFairValueFromLastDayOfPriorYearToLastDayOfYearOfUnvestedEquityAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib6423de9d56142b9894e5e2217b5c134_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:EquityAwardsChangeInFairValueFromLastDayOfPriorYearToLastDayOfYearOfUnvestedEquityAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia51f311be92445049c84ed71423fc1ac_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:EquityAwardsChangeInFairValueFromLastDayOfPriorYearToLastDayOfYearOfUnvestedEquityAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4757a2404ced49b79c5f7734d44d691d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:EquityAwardsAddAwardsThatAreGrantedAndVestInTheSameYearTheFairValueAsOfTheVestingDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i424d110c9c7447cf8d86db48ddc56f09_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:EquityAwardsAddAwardsThatAreGrantedAndVestInTheSameYearTheFairValueAsOfTheVestingDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iac46fe9783ba4350948ac1b50c0f82e8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:EquityAwardsAddAwardsThatAreGrantedAndVestInTheSameYearTheFairValueAsOfTheVestingDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3b2e7c637d8641d0ab07136fac2ce541_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:EquityAwardsAddAwardsThatAreGrantedAndVestInTheSameYearTheFairValueAsOfTheVestingDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6097bc48663442fa8090165e5ebaafcf_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:EquityAwardsChangeInFairValueOfPriorYearsEquityAwardsThatVestedDuringTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i56212971324f4fd1bdfe65dd27e611ab_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:EquityAwardsChangeInFairValueOfPriorYearsEquityAwardsThatVestedDuringTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i388d394b3cb749cca54ab1a0e0ad8209_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:EquityAwardsChangeInFairValueOfPriorYearsEquityAwardsThatVestedDuringTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i35341a6be28048239380a00aa3e164a4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:EquityAwardsChangeInFairValueOfPriorYearsEquityAwardsThatVestedDuringTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8c34c7e022294fe4aeb274e2e44b75ef_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:EquityAwardsChangeInValueOfPriorYearsEquityAwardsThatForfeitedDuringTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5d89663085a84502b34c2da05d99e96e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:EquityAwardsChangeInValueOfPriorYearsEquityAwardsThatForfeitedDuringTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i101ba4e616204ee3a06df10ad6050ef9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:EquityAwardsChangeInValueOfPriorYearsEquityAwardsThatForfeitedDuringTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i18bc58d898e84d1cae4dc8e8325704b9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">crdf:EquityAwardsChangeInValueOfPriorYearsEquityAwardsThatForfeitedDuringTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ie01d1de15b9444b183272d5953f012c0_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NTYvZnJhZzpmNWMwYTdiY2YxNTM0NjNmOTZkZDY5YzYyOWZkZjIxZC90YWJsZTphNDNhNmExNWZhN2Q0OGVlYjBlNWI3OTMwZTg3MDliNC90YWJsZXJhbmdlOmE0M2E2YTE1ZmE3ZDQ4ZWViMGU1Yjc5MzBlODcwOWI0XzItMS0xLTEtNDc3NTc_ce97fa7d-e0be-4805-b3cf-f1f9012d1ce4">0001213037</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="ie01d1de15b9444b183272d5953f012c0_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NTYvZnJhZzpmNWMwYTdiY2YxNTM0NjNmOTZkZDY5YzYyOWZkZjIxZC90YWJsZTphNDNhNmExNWZhN2Q0OGVlYjBlNWI3OTMwZTg3MDliNC90YWJsZXJhbmdlOmE0M2E2YTE1ZmE3ZDQ4ZWViMGU1Yjc5MzBlODcwOWI0XzMtMS0xLTEtNDc3NTc_8a1cc244-3da2-40b4-89c9-02063ad0b5ee">DEF 14A</dei:DocumentType>
    <dei:AmendmentFlag
      contextRef="ie01d1de15b9444b183272d5953f012c0_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NTYvZnJhZzpmNWMwYTdiY2YxNTM0NjNmOTZkZDY5YzYyOWZkZjIxZC90YWJsZTphNDNhNmExNWZhN2Q0OGVlYjBlNWI3OTMwZTg3MDliNC90YWJsZXJhbmdlOmE0M2E2YTE1ZmE3ZDQ4ZWViMGU1Yjc5MzBlODcwOWI0XzQtMS0xLTEtNDc3NTc_0b590f9d-8e90-436a-a5c3-b7b8da117087">false</dei:AmendmentFlag>
    <dei:EntityRegistrantName
      contextRef="ie01d1de15b9444b183272d5953f012c0_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY18xL2ZyYWc6ZmFlMDAwMGQ3YzNiNGYxY2EwNjg0NmMwMjIxOTBhN2QvdGFibGU6NjllOWYyZWZiYTExNDhiZGE0MTIxNWYwMDQ4YTAwYjEvdGFibGVyYW5nZTo2OWU5ZjJlZmJhMTE0OGJkYTQxMjE1ZjAwNDhhMDBiMV8xMS0wLTEtMS00Nzc1OQ_90969a3e-be7a-408c-98fa-d8f25972d094">Cardiff Oncology, Inc.</dei:EntityRegistrantName>
    <ecd:PvpTableTextBlock
      contextRef="ie01d1de15b9444b183272d5953f012c0_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90ZXh0cmVnaW9uOmQ0NjAxNzdjYTM0ZDQ5YzQ4MmY2MjhjNTcxYTdkMDAyXzIxOTkwMjMyNTY2NjQ_4a5305d5-a86f-4ff8-b29d-cfdb49df3549">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.834%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.834%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.834%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.834%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.837%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Summary Compensation Table Total for PEO ($)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Compensation Actually Paid to PEO ($)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average Summary Compensation Table Total for Non-PEO NEOs ($)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average Compensation Actually Paid to Non-PEO NEOs ($)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value of Initial Fixed $100 Investment Based on Total Shareholder Return ($)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Loss &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;($ in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,590,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,523,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38,728)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,635,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,401,408)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,148,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,315)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</ecd:PvpTableTextBlock>
    <ecd:PeoTotalCompAmt
      contextRef="ie01d1de15b9444b183272d5953f012c0_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpmYTliMDI1NjAzOWM0ZGM1YTkwNDU4OWQyMjBiNTFiNS90YWJsZXJhbmdlOmZhOWIwMjU2MDM5YzRkYzVhOTA0NTg5ZDIyMGI1MWI1XzEtMi0xLTEtNDkwMzc_840efb56-53d2-439d-93e8-5d5b90c69ec4"
      unitRef="usd">1590347</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="ie01d1de15b9444b183272d5953f012c0_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpmYTliMDI1NjAzOWM0ZGM1YTkwNDU4OWQyMjBiNTFiNS90YWJsZXJhbmdlOmZhOWIwMjU2MDM5YzRkYzVhOTA0NTg5ZDIyMGI1MWI1XzEtNC0xLTEtNDg5Mjk_4ee9715d-6d2d-49ce-b0d1-060ddfd320d1"
      unitRef="usd">91869</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="ie01d1de15b9444b183272d5953f012c0_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpmYTliMDI1NjAzOWM0ZGM1YTkwNDU4OWQyMjBiNTFiNS90YWJsZXJhbmdlOmZhOWIwMjU2MDM5YzRkYzVhOTA0NTg5ZDIyMGI1MWI1XzEtOC0xLTEtNDkwMzc_d2b52226-dccd-4110-aafe-5b85f3987c31"
      unitRef="usd">1523156</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="ie01d1de15b9444b183272d5953f012c0_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpmYTliMDI1NjAzOWM0ZGM1YTkwNDU4OWQyMjBiNTFiNS90YWJsZXJhbmdlOmZhOWIwMjU2MDM5YzRkYzVhOTA0NTg5ZDIyMGI1MWI1XzEtMTAtMS0xLTQ4OTM1_edf74a1d-c86b-4533-93b7-67b39e67957c"
      unitRef="usd">222550</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:TotalShareholderRtnAmt
      contextRef="ie01d1de15b9444b183272d5953f012c0_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpmYTliMDI1NjAzOWM0ZGM1YTkwNDU4OWQyMjBiNTFiNS90YWJsZXJhbmdlOmZhOWIwMjU2MDM5YzRkYzVhOTA0NTg5ZDIyMGI1MWI1XzEtMTItMS0xLTQ5MDM3_9cf42c5f-791e-43ff-abd4-042f81337507"
      unitRef="usd">8</ecd:TotalShareholderRtnAmt>
    <us-gaap:NetIncomeLoss
      contextRef="ie01d1de15b9444b183272d5953f012c0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpmYTliMDI1NjAzOWM0ZGM1YTkwNDU4OWQyMjBiNTFiNS90YWJsZXJhbmdlOmZhOWIwMjU2MDM5YzRkYzVhOTA0NTg5ZDIyMGI1MWI1XzEtMTYtMS0xLTQ5MDM3_b99c6412-7f26-4267-b891-6a0d26cf2374"
      unitRef="usd">-38728000</us-gaap:NetIncomeLoss>
    <ecd:PeoTotalCompAmt
      contextRef="i162e015e217c4d45bddc31b5744d6c17_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpmYTliMDI1NjAzOWM0ZGM1YTkwNDU4OWQyMjBiNTFiNS90YWJsZXJhbmdlOmZhOWIwMjU2MDM5YzRkYzVhOTA0NTg5ZDIyMGI1MWI1XzItMi0xLTEtNDkwMzc_a44c395e-3065-4f95-80a8-dc45b41146e2"
      unitRef="usd">3635198</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="i162e015e217c4d45bddc31b5744d6c17_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpmYTliMDI1NjAzOWM0ZGM1YTkwNDU4OWQyMjBiNTFiNS90YWJsZXJhbmdlOmZhOWIwMjU2MDM5YzRkYzVhOTA0NTg5ZDIyMGI1MWI1XzItNC0xLTEtNDg5Njc_206f8634-d533-47d6-b71b-c288a41e8cb2"
      unitRef="usd">-1401408</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="i162e015e217c4d45bddc31b5744d6c17_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpmYTliMDI1NjAzOWM0ZGM1YTkwNDU4OWQyMjBiNTFiNS90YWJsZXJhbmdlOmZhOWIwMjU2MDM5YzRkYzVhOTA0NTg5ZDIyMGI1MWI1XzItOC0xLTEtNDkwMzc_dfb734ba-9e01-4506-be57-d6632ea00d0c"
      unitRef="usd">2148786</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="i162e015e217c4d45bddc31b5744d6c17_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpmYTliMDI1NjAzOWM0ZGM1YTkwNDU4OWQyMjBiNTFiNS90YWJsZXJhbmdlOmZhOWIwMjU2MDM5YzRkYzVhOTA0NTg5ZDIyMGI1MWI1XzItMTAtMS0xLTQ4OTcz_114045b3-9f68-4e13-b5c2-5008ac303ef9"
      unitRef="usd">539237</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:TotalShareholderRtnAmt
      contextRef="i162e015e217c4d45bddc31b5744d6c17_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpmYTliMDI1NjAzOWM0ZGM1YTkwNDU4OWQyMjBiNTFiNS90YWJsZXJhbmdlOmZhOWIwMjU2MDM5YzRkYzVhOTA0NTg5ZDIyMGI1MWI1XzItMTItMS0xLTQ5MDM3_9978cc38-f207-406f-bf33-f1a5633ed945"
      unitRef="usd">33</ecd:TotalShareholderRtnAmt>
    <us-gaap:NetIncomeLoss
      contextRef="i162e015e217c4d45bddc31b5744d6c17_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpmYTliMDI1NjAzOWM0ZGM1YTkwNDU4OWQyMjBiNTFiNS90YWJsZXJhbmdlOmZhOWIwMjU2MDM5YzRkYzVhOTA0NTg5ZDIyMGI1MWI1XzItMTYtMS0xLTQ5MDM3_268adb32-4a93-4e02-902d-c944bf86db89"
      unitRef="usd">-28315000</us-gaap:NetIncomeLoss>
    <ecd:NamedExecutiveOfficersFnTextBlock
      contextRef="ie01d1de15b9444b183272d5953f012c0_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90ZXh0cmVnaW9uOmQ0NjAxNzdjYTM0ZDQ5YzQ4MmY2MjhjNTcxYTdkMDAyXzMyOTg1MzQ4ODg5Nzk_e26ef8da-64be-4e6d-a195-87ea48d88750">Mr. Erlander served as our PEO during each year shown. The Non-PEO NEO's presented in the table represent the two highest paid NEO's during the respective years as follows:&lt;div style="padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;2022: James Levine and Tod Smeal&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;2021: Vicki Kelemen and James Levine&lt;/span&gt;&lt;/div&gt;</ecd:NamedExecutiveOfficersFnTextBlock>
    <ecd:PeoName
      contextRef="ie01d1de15b9444b183272d5953f012c0_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90ZXh0cmVnaW9uOmQ0NjAxNzdjYTM0ZDQ5YzQ4MmY2MjhjNTcxYTdkMDAyXzMyOTg1MzQ4ODg5Nzg_ac59b8f8-1144-478e-85b8-b0718d4a4343">Mr. Erlander</ecd:PeoName>
    <ecd:AdjToPeoCompFnTextBlock
      contextRef="ie01d1de15b9444b183272d5953f012c0_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90ZXh0cmVnaW9uOmQ0NjAxNzdjYTM0ZDQ5YzQ4MmY2MjhjNTcxYTdkMDAyXzMyOTg1MzQ4ODg5ODA_21a8ac97-326c-4155-a41b-f323fa2788c6">The 2022 Summary Compensation Table totals reported for the PEO and the average of the Other NEOs for each year were subject to the following adjustments per Item 402(v)(2)(iii) of Regulation S-K to calculate &#x201c;compensation actually paid&#x201d;:&lt;div style="padding-left:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;PEO ($)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average for Other NEO's ($)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;PEO ($)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average for Other NEO's ($)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Summary Compensation Table&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,590,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,523,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,635,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,148,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deduction for amounts reported under the &#x201c;Stock Awards&#x201d; and &#x201c;Option Awards&#x201d; columns of the Summary Compensation Table&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(i)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(753,272)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(919,022)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,851,972)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,701,431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase/(decrease) for the Inclusion of "Rule 402(v) Equity Values" &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(i)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(745,206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(381,584)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,184,634)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Compensation&#160;Actually&#160;Paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,401,408)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(i)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt"&gt;Compensation Actually Paid excludes the Stock Awards and Option Awards columns from the relevant fiscal year&#x2019;s Summary Compensation Table total. The Rule 402(v) Equity Values instead reflect the aggregate of the following components, as applicable: (i) the fair value as of the end of the listed fiscal year of unvested equity awards granted in that year; (ii) the change in fair value during the listed fiscal year of equity awards granted in prior years that remained outstanding and unvested at the end of the listed fiscal year; and (iii) the change in fair value during the listed fiscal year through the vesting date of equity awards granted in prior years that vested during the listed fiscal year, less the fair value at the end of the prior year of awards granted &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;prior to the listed fiscal year that failed to meet applicable vesting conditions during the listed fiscal year. Equity values are calculated in accordance with FASB ASC Topic 718, calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.964%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.480%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.314%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.480%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.314%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.480%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.314%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.480%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x201c;Inclusion of Rule 402(v) Equity Values&#x201d;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;PEO ($)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average for Other NEO's ($)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;PEO ($)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average for Other NEO's ($)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Add: Year-End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,992,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,380,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Add: Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(288,112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(457,723)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,270,502)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(701,257)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Add: Awards that are granted and vest in the same year, the fair value as of the vesting date &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in Fair Value of Prior Years&#x2019; Equity Awards that Vested During the Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(903,882)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(177,498)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,906,142)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(587,466)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtract: Awards Granted in any prior fiscal year that failed to vest Change in Value of Prior Years&#x2019; Equity Awards that Forfeited During the Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Increase/(decrease) for the &#x201c;Inclusion of Rule 402(v) Equity Values&#x201d; (i)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(745,206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(381,584)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,184,634)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ecd:AdjToPeoCompFnTextBlock>
    <ecd:AdjToNonPeoNeoCompFnTextBlock
      contextRef="ie01d1de15b9444b183272d5953f012c0_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90ZXh0cmVnaW9uOmQ0NjAxNzdjYTM0ZDQ5YzQ4MmY2MjhjNTcxYTdkMDAyXzMyOTg1MzQ4ODg5ODA_451b0eb2-8a24-4ebd-ae63-b0ec8d41cc7b">The 2022 Summary Compensation Table totals reported for the PEO and the average of the Other NEOs for each year were subject to the following adjustments per Item 402(v)(2)(iii) of Regulation S-K to calculate &#x201c;compensation actually paid&#x201d;:&lt;div style="padding-left:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;PEO ($)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average for Other NEO's ($)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;PEO ($)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average for Other NEO's ($)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Summary Compensation Table&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,590,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,523,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,635,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,148,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deduction for amounts reported under the &#x201c;Stock Awards&#x201d; and &#x201c;Option Awards&#x201d; columns of the Summary Compensation Table&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(i)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(753,272)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(919,022)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,851,972)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,701,431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase/(decrease) for the Inclusion of "Rule 402(v) Equity Values" &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(i)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(745,206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(381,584)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,184,634)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Compensation&#160;Actually&#160;Paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,401,408)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(i)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt"&gt;Compensation Actually Paid excludes the Stock Awards and Option Awards columns from the relevant fiscal year&#x2019;s Summary Compensation Table total. The Rule 402(v) Equity Values instead reflect the aggregate of the following components, as applicable: (i) the fair value as of the end of the listed fiscal year of unvested equity awards granted in that year; (ii) the change in fair value during the listed fiscal year of equity awards granted in prior years that remained outstanding and unvested at the end of the listed fiscal year; and (iii) the change in fair value during the listed fiscal year through the vesting date of equity awards granted in prior years that vested during the listed fiscal year, less the fair value at the end of the prior year of awards granted &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;prior to the listed fiscal year that failed to meet applicable vesting conditions during the listed fiscal year. Equity values are calculated in accordance with FASB ASC Topic 718, calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.964%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.480%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.314%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.480%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.314%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.480%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.314%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.480%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x201c;Inclusion of Rule 402(v) Equity Values&#x201d;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;PEO ($)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average for Other NEO's ($)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;PEO ($)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average for Other NEO's ($)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Add: Year-End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,992,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,380,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Add: Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(288,112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(457,723)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,270,502)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(701,257)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Add: Awards that are granted and vest in the same year, the fair value as of the vesting date &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in Fair Value of Prior Years&#x2019; Equity Awards that Vested During the Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(903,882)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(177,498)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,906,142)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(587,466)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtract: Awards Granted in any prior fiscal year that failed to vest Change in Value of Prior Years&#x2019; Equity Awards that Forfeited During the Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Increase/(decrease) for the &#x201c;Inclusion of Rule 402(v) Equity Values&#x201d; (i)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(745,206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(381,584)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,184,634)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ecd:AdjToNonPeoNeoCompFnTextBlock>
    <ecd:PeoTotalCompAmt
      contextRef="ie01d1de15b9444b183272d5953f012c0_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZToxOWNmYzMzYjE1M2M0YmM4OTY5MGQ2MjRjNjZmMzNmMS90YWJsZXJhbmdlOjE5Y2ZjMzNiMTUzYzRiYzg5NjkwZDYyNGM2NmYzM2YxXzItMi0xLTEtNDkwNDA_4c6da71f-c5d7-4bb9-bfa5-4833ec77bd25"
      unitRef="usd">1590347</ecd:PeoTotalCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="ie01d1de15b9444b183272d5953f012c0_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZToxOWNmYzMzYjE1M2M0YmM4OTY5MGQ2MjRjNjZmMzNmMS90YWJsZXJhbmdlOjE5Y2ZjMzNiMTUzYzRiYzg5NjkwZDYyNGM2NmYzM2YxXzItNC0xLTEtNDkwNDQ_9eb03ab0-e1e5-4155-b130-67d8d51a51e6"
      unitRef="usd">1523156</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:PeoTotalCompAmt
      contextRef="i162e015e217c4d45bddc31b5744d6c17_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZToxOWNmYzMzYjE1M2M0YmM4OTY5MGQ2MjRjNjZmMzNmMS90YWJsZXJhbmdlOjE5Y2ZjMzNiMTUzYzRiYzg5NjkwZDYyNGM2NmYzM2YxXzItNi0xLTEtNDkwNDI_3bd86130-5f0c-423c-b259-3ebf24657566"
      unitRef="usd">3635198</ecd:PeoTotalCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="i162e015e217c4d45bddc31b5744d6c17_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZToxOWNmYzMzYjE1M2M0YmM4OTY5MGQ2MjRjNjZmMzNmMS90YWJsZXJhbmdlOjE5Y2ZjMzNiMTUzYzRiYzg5NjkwZDYyNGM2NmYzM2YxXzItOC0xLTEtNDkwNDY_72adf02d-975a-42a2-84da-986943d7a21e"
      unitRef="usd">2148786</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:AdjToCompAmt
      contextRef="if6c039ead809495cae54a5ab4e87a488_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZToxOWNmYzMzYjE1M2M0YmM4OTY5MGQ2MjRjNjZmMzNmMS90YWJsZXJhbmdlOjE5Y2ZjMzNiMTUzYzRiYzg5NjkwZDYyNGM2NmYzM2YxXzQtMi0xLTEtNDkwNDg_19a7d5fb-0620-4e92-b38e-a2645fa814af"
      unitRef="usd">-753272</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="i2f35b7ba98ca4879b389a1204541bc1f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZToxOWNmYzMzYjE1M2M0YmM4OTY5MGQ2MjRjNjZmMzNmMS90YWJsZXJhbmdlOjE5Y2ZjMzNiMTUzYzRiYzg5NjkwZDYyNGM2NmYzM2YxXzQtNC0xLTEtNDkwNDg_f87c8129-fbd8-433f-ac79-c35e124c73d8"
      unitRef="usd">-919022</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="i808f413dd8bd4a038c815bd31cf674bb_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZToxOWNmYzMzYjE1M2M0YmM4OTY5MGQ2MjRjNjZmMzNmMS90YWJsZXJhbmdlOjE5Y2ZjMzNiMTUzYzRiYzg5NjkwZDYyNGM2NmYzM2YxXzQtNi0xLTEtNDkwNDg_d7f746fc-927d-46b6-8e00-99c48131fd28"
      unitRef="usd">-2851972</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="i67ff1600b4c246b2ab359a056db81b0a_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZToxOWNmYzMzYjE1M2M0YmM4OTY5MGQ2MjRjNjZmMzNmMS90YWJsZXJhbmdlOjE5Y2ZjMzNiMTUzYzRiYzg5NjkwZDYyNGM2NmYzM2YxXzQtOC0xLTEtNDkwNDg_91e82de1-77a9-4283-85c4-07258b6b665b"
      unitRef="usd">-1701431</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="i86619fe2a4904a08839c9a77d4598f63_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZToxOWNmYzMzYjE1M2M0YmM4OTY5MGQ2MjRjNjZmMzNmMS90YWJsZXJhbmdlOjE5Y2ZjMzNiMTUzYzRiYzg5NjkwZDYyNGM2NmYzM2YxXzUtMi0xLTEtNDkwNDg_2b9f5987-8a89-43ed-b8e6-8fddb0717174"
      unitRef="usd">-745206</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="icafd16b4fdca433ab80e693f2728fc6c_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZToxOWNmYzMzYjE1M2M0YmM4OTY5MGQ2MjRjNjZmMzNmMS90YWJsZXJhbmdlOjE5Y2ZjMzNiMTUzYzRiYzg5NjkwZDYyNGM2NmYzM2YxXzUtNC0xLTEtNDkwNDg_5b7e5886-4b96-4dbe-935c-e557c1595dea"
      unitRef="usd">-381584</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="i099dab0c3dfb4ba08b9f1e8273c73b43_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZToxOWNmYzMzYjE1M2M0YmM4OTY5MGQ2MjRjNjZmMzNmMS90YWJsZXJhbmdlOjE5Y2ZjMzNiMTUzYzRiYzg5NjkwZDYyNGM2NmYzM2YxXzUtNi0xLTEtNDkwNDg_e05730ff-103c-4a35-9953-7cc7faa57611"
      unitRef="usd">-2184634</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="i48bde130657f4d60a3c8729859ad4a54_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZToxOWNmYzMzYjE1M2M0YmM4OTY5MGQ2MjRjNjZmMzNmMS90YWJsZXJhbmdlOjE5Y2ZjMzNiMTUzYzRiYzg5NjkwZDYyNGM2NmYzM2YxXzUtOC0xLTEtNDkwNDg_84e32d2f-d900-4010-94ce-ace6a0e2ffa2"
      unitRef="usd">91882</ecd:AdjToCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="ie01d1de15b9444b183272d5953f012c0_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZToxOWNmYzMzYjE1M2M0YmM4OTY5MGQ2MjRjNjZmMzNmMS90YWJsZXJhbmdlOjE5Y2ZjMzNiMTUzYzRiYzg5NjkwZDYyNGM2NmYzM2YxXzEwLTItMS0xLTQ4OTI3_4ee9715d-6d2d-49ce-b0d1-060ddfd320d1"
      unitRef="usd">91869</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="ie01d1de15b9444b183272d5953f012c0_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZToxOWNmYzMzYjE1M2M0YmM4OTY5MGQ2MjRjNjZmMzNmMS90YWJsZXJhbmdlOjE5Y2ZjMzNiMTUzYzRiYzg5NjkwZDYyNGM2NmYzM2YxXzEwLTQtMS0xLTQ4OTMz_edf74a1d-c86b-4533-93b7-67b39e67957c"
      unitRef="usd">222550</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="i162e015e217c4d45bddc31b5744d6c17_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZToxOWNmYzMzYjE1M2M0YmM4OTY5MGQ2MjRjNjZmMzNmMS90YWJsZXJhbmdlOjE5Y2ZjMzNiMTUzYzRiYzg5NjkwZDYyNGM2NmYzM2YxXzEwLTYtMS0xLTQ4OTY1_206f8634-d533-47d6-b71b-c288a41e8cb2"
      unitRef="usd">-1401408</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="i162e015e217c4d45bddc31b5744d6c17_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZToxOWNmYzMzYjE1M2M0YmM4OTY5MGQ2MjRjNjZmMzNmMS90YWJsZXJhbmdlOjE5Y2ZjMzNiMTUzYzRiYzg5NjkwZDYyNGM2NmYzM2YxXzEwLTgtMS0xLTQ4OTcx_114045b3-9f68-4e13-b5c2-5008ac303ef9"
      unitRef="usd">539237</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <crdf:AdjustmentToCompensationAmountEquityAwards
      contextRef="ia69205d3273d42cfa5b47e45431f4273_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpiNzc0N2Q1NWZjZTM0ZTEyYjIzMzI1MzgzZjllZDgxNi90YWJsZXJhbmdlOmI3NzQ3ZDU1ZmNlMzRlMTJiMjMzMjUzODNmOWVkODE2XzItMi0xLTEtNTE4MjE_2866d432-d01d-4eb0-b46f-921121ff423b"
      unitRef="usd">446788</crdf:AdjustmentToCompensationAmountEquityAwards>
    <crdf:AdjustmentToCompensationAmountEquityAwards
      contextRef="i222ba39e2bff496a82ec7ce575a3569c_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpiNzc0N2Q1NWZjZTM0ZTEyYjIzMzI1MzgzZjllZDgxNi90YWJsZXJhbmdlOmI3NzQ3ZDU1ZmNlMzRlMTJiMjMzMjUzODNmOWVkODE2XzItNC0xLTEtNTE4MjE_6226318f-f746-4565-9201-ad232d4759e0"
      unitRef="usd">253637</crdf:AdjustmentToCompensationAmountEquityAwards>
    <crdf:AdjustmentToCompensationAmountEquityAwards
      contextRef="ifa076cb47d104183826cd32c0caf6c74_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpiNzc0N2Q1NWZjZTM0ZTEyYjIzMzI1MzgzZjllZDgxNi90YWJsZXJhbmdlOmI3NzQ3ZDU1ZmNlMzRlMTJiMjMzMjUzODNmOWVkODE2XzItNi0xLTEtNTE4MjE_cc726ffa-3e6d-4e7e-b9c8-15650f27596f"
      unitRef="usd">1992010</crdf:AdjustmentToCompensationAmountEquityAwards>
    <crdf:AdjustmentToCompensationAmountEquityAwards
      contextRef="i1374971d2a224cd48aec91e78ac8bd8b_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpiNzc0N2Q1NWZjZTM0ZTEyYjIzMzI1MzgzZjllZDgxNi90YWJsZXJhbmdlOmI3NzQ3ZDU1ZmNlMzRlMTJiMjMzMjUzODNmOWVkODE2XzItOC0xLTEtNTE4MjE_3d17e7b6-d6f0-4386-a75b-2108420d32be"
      unitRef="usd">1380605</crdf:AdjustmentToCompensationAmountEquityAwards>
    <crdf:AdjustmentToCompensationAmountEquityAwards
      contextRef="i6bcd6aa3ae8a4718aaa3527feb1a9750_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpiNzc0N2Q1NWZjZTM0ZTEyYjIzMzI1MzgzZjllZDgxNi90YWJsZXJhbmdlOmI3NzQ3ZDU1ZmNlMzRlMTJiMjMzMjUzODNmOWVkODE2XzMtMi0xLTEtNTE4MjM_00289cfd-1274-481f-8725-21560045b0d6"
      unitRef="usd">-288112</crdf:AdjustmentToCompensationAmountEquityAwards>
    <crdf:AdjustmentToCompensationAmountEquityAwards
      contextRef="iacbe2ef0043b41eca3c977825b71bcc7_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpiNzc0N2Q1NWZjZTM0ZTEyYjIzMzI1MzgzZjllZDgxNi90YWJsZXJhbmdlOmI3NzQ3ZDU1ZmNlMzRlMTJiMjMzMjUzODNmOWVkODE2XzMtNC0xLTEtNTE4MjM_474e1808-5317-4772-8820-bd16b372e00a"
      unitRef="usd">-457723</crdf:AdjustmentToCompensationAmountEquityAwards>
    <crdf:AdjustmentToCompensationAmountEquityAwards
      contextRef="ib6423de9d56142b9894e5e2217b5c134_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpiNzc0N2Q1NWZjZTM0ZTEyYjIzMzI1MzgzZjllZDgxNi90YWJsZXJhbmdlOmI3NzQ3ZDU1ZmNlMzRlMTJiMjMzMjUzODNmOWVkODE2XzMtNi0xLTEtNTE4MjM_6c59d22e-49fc-4107-b478-4b4d5b859557"
      unitRef="usd">-2270502</crdf:AdjustmentToCompensationAmountEquityAwards>
    <crdf:AdjustmentToCompensationAmountEquityAwards
      contextRef="ia51f311be92445049c84ed71423fc1ac_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpiNzc0N2Q1NWZjZTM0ZTEyYjIzMzI1MzgzZjllZDgxNi90YWJsZXJhbmdlOmI3NzQ3ZDU1ZmNlMzRlMTJiMjMzMjUzODNmOWVkODE2XzMtOC0xLTEtNTE4MjM_b40f9572-7ff1-4f82-9a2f-b74c36cd9a8f"
      unitRef="usd">-701257</crdf:AdjustmentToCompensationAmountEquityAwards>
    <crdf:AdjustmentToCompensationAmountEquityAwards
      contextRef="i4757a2404ced49b79c5f7734d44d691d_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpiNzc0N2Q1NWZjZTM0ZTEyYjIzMzI1MzgzZjllZDgxNi90YWJsZXJhbmdlOmI3NzQ3ZDU1ZmNlMzRlMTJiMjMzMjUzODNmOWVkODE2XzQtMi0xLTEtNTIxODA_c4756ae9-35eb-4f0b-a453-8c587c6596a7"
      unitRef="usd">0</crdf:AdjustmentToCompensationAmountEquityAwards>
    <crdf:AdjustmentToCompensationAmountEquityAwards
      contextRef="i424d110c9c7447cf8d86db48ddc56f09_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpiNzc0N2Q1NWZjZTM0ZTEyYjIzMzI1MzgzZjllZDgxNi90YWJsZXJhbmdlOmI3NzQ3ZDU1ZmNlMzRlMTJiMjMzMjUzODNmOWVkODE2XzQtNC0xLTEtNTIxODA_4e20a3f2-2a1c-4fae-ab45-29fe6bf6163d"
      unitRef="usd">0</crdf:AdjustmentToCompensationAmountEquityAwards>
    <crdf:AdjustmentToCompensationAmountEquityAwards
      contextRef="iac46fe9783ba4350948ac1b50c0f82e8_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpiNzc0N2Q1NWZjZTM0ZTEyYjIzMzI1MzgzZjllZDgxNi90YWJsZXJhbmdlOmI3NzQ3ZDU1ZmNlMzRlMTJiMjMzMjUzODNmOWVkODE2XzQtNi0xLTEtNTIxODA_3f43a577-93e1-490c-9c6f-e484e5facc97"
      unitRef="usd">0</crdf:AdjustmentToCompensationAmountEquityAwards>
    <crdf:AdjustmentToCompensationAmountEquityAwards
      contextRef="i3b2e7c637d8641d0ab07136fac2ce541_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpiNzc0N2Q1NWZjZTM0ZTEyYjIzMzI1MzgzZjllZDgxNi90YWJsZXJhbmdlOmI3NzQ3ZDU1ZmNlMzRlMTJiMjMzMjUzODNmOWVkODE2XzQtOC0xLTEtNTIxODA_8c419557-10c1-470c-a6dc-dfadcae0061d"
      unitRef="usd">0</crdf:AdjustmentToCompensationAmountEquityAwards>
    <crdf:AdjustmentToCompensationAmountEquityAwards
      contextRef="i6097bc48663442fa8090165e5ebaafcf_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpiNzc0N2Q1NWZjZTM0ZTEyYjIzMzI1MzgzZjllZDgxNi90YWJsZXJhbmdlOmI3NzQ3ZDU1ZmNlMzRlMTJiMjMzMjUzODNmOWVkODE2XzUtMi0xLTEtNTE4MjU_89160cdf-dedb-4a1d-be2c-43c03e70a7ba"
      unitRef="usd">-903882</crdf:AdjustmentToCompensationAmountEquityAwards>
    <crdf:AdjustmentToCompensationAmountEquityAwards
      contextRef="i56212971324f4fd1bdfe65dd27e611ab_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpiNzc0N2Q1NWZjZTM0ZTEyYjIzMzI1MzgzZjllZDgxNi90YWJsZXJhbmdlOmI3NzQ3ZDU1ZmNlMzRlMTJiMjMzMjUzODNmOWVkODE2XzUtNC0xLTEtNTE4MjU_58e41519-bf45-4e07-b23e-9c6f2b2f92ad"
      unitRef="usd">-177498</crdf:AdjustmentToCompensationAmountEquityAwards>
    <crdf:AdjustmentToCompensationAmountEquityAwards
      contextRef="i388d394b3cb749cca54ab1a0e0ad8209_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpiNzc0N2Q1NWZjZTM0ZTEyYjIzMzI1MzgzZjllZDgxNi90YWJsZXJhbmdlOmI3NzQ3ZDU1ZmNlMzRlMTJiMjMzMjUzODNmOWVkODE2XzUtNi0xLTEtNTE4MjU_f268bc11-3328-4cdc-80b8-f75022141191"
      unitRef="usd">-1906142</crdf:AdjustmentToCompensationAmountEquityAwards>
    <crdf:AdjustmentToCompensationAmountEquityAwards
      contextRef="i35341a6be28048239380a00aa3e164a4_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpiNzc0N2Q1NWZjZTM0ZTEyYjIzMzI1MzgzZjllZDgxNi90YWJsZXJhbmdlOmI3NzQ3ZDU1ZmNlMzRlMTJiMjMzMjUzODNmOWVkODE2XzUtOC0xLTEtNTE4MjU_673f96e4-ad1d-4b53-8e02-e1065f0fcbb2"
      unitRef="usd">-587466</crdf:AdjustmentToCompensationAmountEquityAwards>
    <crdf:AdjustmentToCompensationAmountEquityAwards
      contextRef="i8c34c7e022294fe4aeb274e2e44b75ef_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpiNzc0N2Q1NWZjZTM0ZTEyYjIzMzI1MzgzZjllZDgxNi90YWJsZXJhbmdlOmI3NzQ3ZDU1ZmNlMzRlMTJiMjMzMjUzODNmOWVkODE2XzYtMi0xLTEtNTE4Mjc_a7a3c341-04f7-436e-87f4-74f0af3665e9"
      unitRef="usd">0</crdf:AdjustmentToCompensationAmountEquityAwards>
    <crdf:AdjustmentToCompensationAmountEquityAwards
      contextRef="i5d89663085a84502b34c2da05d99e96e_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpiNzc0N2Q1NWZjZTM0ZTEyYjIzMzI1MzgzZjllZDgxNi90YWJsZXJhbmdlOmI3NzQ3ZDU1ZmNlMzRlMTJiMjMzMjUzODNmOWVkODE2XzYtNC0xLTEtNTE4Mjc_a3883bdb-b4b7-4538-9ddc-ab1d7b2d0b98"
      unitRef="usd">0</crdf:AdjustmentToCompensationAmountEquityAwards>
    <crdf:AdjustmentToCompensationAmountEquityAwards
      contextRef="i101ba4e616204ee3a06df10ad6050ef9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpiNzc0N2Q1NWZjZTM0ZTEyYjIzMzI1MzgzZjllZDgxNi90YWJsZXJhbmdlOmI3NzQ3ZDU1ZmNlMzRlMTJiMjMzMjUzODNmOWVkODE2XzYtNi0xLTEtNTE4Mjc_24257b4f-644e-4721-88dc-1db228c1f15c"
      unitRef="usd">0</crdf:AdjustmentToCompensationAmountEquityAwards>
    <crdf:AdjustmentToCompensationAmountEquityAwards
      contextRef="i18bc58d898e84d1cae4dc8e8325704b9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpiNzc0N2Q1NWZjZTM0ZTEyYjIzMzI1MzgzZjllZDgxNi90YWJsZXJhbmdlOmI3NzQ3ZDU1ZmNlMzRlMTJiMjMzMjUzODNmOWVkODE2XzYtOC0xLTEtNTE4Mjc_231b95f0-7970-40dc-8a9e-46544e982986"
      unitRef="usd">0</crdf:AdjustmentToCompensationAmountEquityAwards>
    <ecd:AdjToCompAmt
      contextRef="i86619fe2a4904a08839c9a77d4598f63_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpiNzc0N2Q1NWZjZTM0ZTEyYjIzMzI1MzgzZjllZDgxNi90YWJsZXJhbmdlOmI3NzQ3ZDU1ZmNlMzRlMTJiMjMzMjUzODNmOWVkODE2XzYtMi0xLTEtNTE4MDg_dd639887-5f4d-44ee-8f4a-529906cf9f90"
      unitRef="usd">-745206</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="icafd16b4fdca433ab80e693f2728fc6c_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpiNzc0N2Q1NWZjZTM0ZTEyYjIzMzI1MzgzZjllZDgxNi90YWJsZXJhbmdlOmI3NzQ3ZDU1ZmNlMzRlMTJiMjMzMjUzODNmOWVkODE2XzYtNC0xLTEtNTE4MDg_da534402-c39c-4c31-bfd5-78c8dad1ee28"
      unitRef="usd">-381584</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="i099dab0c3dfb4ba08b9f1e8273c73b43_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpiNzc0N2Q1NWZjZTM0ZTEyYjIzMzI1MzgzZjllZDgxNi90YWJsZXJhbmdlOmI3NzQ3ZDU1ZmNlMzRlMTJiMjMzMjUzODNmOWVkODE2XzYtNi0xLTEtNTE4MDg_09721f53-f51f-4fca-aa17-65b86d731fbe"
      unitRef="usd">-2184634</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="i48bde130657f4d60a3c8729859ad4a54_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlYWFhYTAzNDRmNzRhOWNhYWU1ZjE3OTYwZDBlZGVjL3NlYzo2ZWFhYWEwMzQ0Zjc0YTljYWFlNWYxNzk2MGQwZWRlY180NDQvZnJhZzpkNDYwMTc3Y2EzNGQ0OWM0ODJmNjI4YzU3MWE3ZDAwMi90YWJsZTpiNzc0N2Q1NWZjZTM0ZTEyYjIzMzI1MzgzZjllZDgxNi90YWJsZXJhbmdlOmI3NzQ3ZDU1ZmNlMzRlMTJiMjMzMjUzODNmOWVkODE2XzYtOC0xLTEtNTE4MDg_825e04e8-faf5-4e52-9ce4-4a59cf1abe57"
      unitRef="usd">91882</ecd:AdjToCompAmt>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M+W-H965T,BYX;6SM7.MSHT82_U>FE%1B5V&+&4 @OZK\S.UE'RY[=Z^N4OF
M86R11:#PD.VJ^^.O>T ,2&@L.9#DKOQAUPAZ>KJ;?OQZ!CAZC)-OZ83SC#Q-
MPR@]'DRR;'8P'*;>A$_==#^>\0BNW,?)U,W@9_(P3&<)=WTQ:!H.F:Z/AE,W
MB 8G1^+<=7)R%.=9&$3\.B%I/IVZR?,9#^/'XP$=+$[<! ^3#$\,3XYF[@._
MY=F7V74"OX85%S^8\B@-XH@D_/YX<$H/SJT1#A 47P/^F-:.":IR%\??\,<[
M_WB@HT0\Y%Z&+%SX,^?G/ R1$\CQ>\ET4,V) ^O'"^Y70GE0YLY-^7D<_BOP
ML\GQP!D0G]^[>9C=Q(__X*5"%O+SXC 5_Y/'DE8?$"]/LWA:#@8)ID%4_'6?
M2D-L,H"5 ]C2 &JN&6"4 PRA:"&94.O"S=R3HR1^) E2 S<\$+81HT&;(,+;
M>)LE<#6 <=G)M?M,YBFYYHEPB<CCY")(O3!.\X23/?+E]H+L?+][-,Q@,APR
M]$K&9P5CMH8Q9>1#'&63E%Q&/O>;#(8@924J6XAZQI0<+[BW3PRJ$:8SUB+0
M^>;#J4(<H[*<(?@9K[+<+Y_=NY#_VF:W@JW9SA;#]B"=N1X_'D!<ICR9\\')
M#]_1D7[8IG-'S!H6,"L+F"KN;18HU":?^5-&SL+8^]9J 37;?W,W(3MTE]P6
MJ86<QU/(6JDKXKZ<(,[<D,"TY/KR$SIHD^C4RW(W#)_)M1OX)(LKJAVV2T[G
M/($,M1G[CW&TAX,_7GY*!8?%:/5\*\-PXJ]NF',2WY-W49 %,,%5\,1]\CW5
M=3@UYVD&^1'L!EG))RB+D.)VXB9\$H<^3\@-S_(D$@P_0HI_'Z?(G001R29Q
MGKJ1G^Z*\"!4L\:Z9I@V&5/-&8WQ!#,T:HT(8TRS+)TX9,=P-)LY8@@EAC8R
M+(V.X3S53!W_X26-FD#EC(AEC#5FV,0P0!M',ZC5EA;.E3?WE1YI51YI*5WG
MHSL%TUT^<2_'ZD ^W=\''D]2C5S%<1;%&7JHVC?5$WQ(]LEE$H*AX6X(Z7WB
MIB3."T?T\R2('@AWO0EY1C=.)_%CM$\^3WC=)7Y,B5 ^RF"XN'F<9,+Q$EY>
M*,X]QF0"=0@\@\S0LXJQY2Q( <0S+BJAF"]%8>[C$(IS>D!^^,YA;'0H'.*
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M(03LQ:PU+SF8$C2::M"X6>C\=8O':O&W]ID^EDU-"73-GK;SS4ZQ:E?<FE\
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M3>_CJ%IC'B+VYEY(E>,4QA^T_ )02P,$%     @ $8";5HWW+%JT    B0(
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M7PWOR>834$L! A0#%     @ $8";5@=!36*!    L0   !
M ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  1@)M6+^."^NT
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M=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ $8";5K+WPF_N @
MB0X   T              ( !.!<  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M"  1@)M6EXJ[',     3 @  "P              @ %1&@  7W)E;',O+G)E
M;'-02P$"% ,4    "  1@)M6LDS[;U0!  #% @  #P              @ $Z
M&P  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ $8";5HWW+%JT    B0(
M !H              ( !NQP  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ $8";5FZG)+P> 0  5P0  !,              ( !IQT
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      H "@"$ @  ]AX

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>30</ContextCount>
  <ElementCount>17</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>9</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>1</UnitCount>
  <MyReports>
    <Report instance="crdf-20230427.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995100 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="crdf-20230427.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="DEF 14A" original="crdf-20230427.htm">crdf-20230427.htm</File>
    <File>crdf-20230427.xsd</File>
    <File>crdf-20230427_def.xml</File>
    <File>crdf-20230427_lab.xml</File>
    <File>crdf-20230427_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>crdf-20230427_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="2">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/dei/2022q4</BaseTaxonomy>
    <BaseTaxonomy items="35">http://xbrl.sec.gov/ecd/2022q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "crdf-20230427.htm": {
   "axisCustom": 0,
   "axisStandard": 2,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 2,
    "http://xbrl.sec.gov/dei/2022q4": 4,
    "http://xbrl.sec.gov/ecd/2022q4": 35
   },
   "contextCount": 30,
   "dts": {
    "definitionLink": {
     "local": [
      "crdf-20230427_def.xml"
     ]
    },
    "inline": {
     "local": [
      "crdf-20230427.htm"
     ]
    },
    "labelLink": {
     "local": [
      "crdf-20230427_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "crdf-20230427_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "crdf-20230427.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd",
      "https://xbrl.sec.gov/dei/2022q4/dei-2022q4_def.xsd",
      "https://xbrl.sec.gov/dei/2022q4/dei-2022q4_lab.xsd",
      "https://xbrl.sec.gov/dei/2022q4/dei-2022q4_pre.xsd",
      "https://xbrl.sec.gov/dei/2022q4/dei-sub-2022q4.xsd",
      "https://xbrl.sec.gov/ecd/2022q4/ecd-2022q4.xsd",
      "https://xbrl.sec.gov/ecd/2022q4/ecd-sub-2022q4.xsd"
     ]
    }
   },
   "elementCount": 221,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022q4": 3,
    "total": 3
   },
   "keyCustom": 1,
   "keyStandard": 16,
   "memberCustom": 7,
   "memberStandard": 2,
   "nsprefix": "crdf",
   "nsuri": "http://www.cardiffoncology.com/20230427",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230427.htm",
      "contextRef": "ie01d1de15b9444b183272d5953f012c0_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "995100 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://xbrl.sec.gov/dei/role/document/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230427.htm",
      "contextRef": "ie01d1de15b9444b183272d5953f012c0_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230427.htm",
      "contextRef": "ie01d1de15b9444b183272d5953f012c0_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ecd:PvpTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "menuCat": "Notes",
     "order": "2",
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "shortName": "Pay vs Performance Disclosure",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230427.htm",
      "contextRef": "ie01d1de15b9444b183272d5953f012c0_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ecd:PvpTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 9,
   "tag": {
    "crdf_AdjustmentToCompensationAmountEquityAwards": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To Compensation Amount, Equity Awards"
       }
      }
     },
     "localname": "AdjustmentToCompensationAmountEquityAwards",
     "nsuri": "http://www.cardiffoncology.com/20230427",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_DeductionForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deduction for amounts reported under the \u201cStock Awards\u201d and \u201cOption Awards\u201d columns of the Summary Compensation Table( [Member]"
       }
      }
     },
     "localname": "DeductionForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember",
     "nsuri": "http://www.cardiffoncology.com/20230427",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_EquityAwardsAddAwardsThatAreGrantedAndVestInTheSameYearTheFairValueAsOfTheVestingDateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards, Add: Awards that are granted and vest in the same year, the fair value as of the vesting date [Member]"
       }
      }
     },
     "localname": "EquityAwardsAddAwardsThatAreGrantedAndVestInTheSameYearTheFairValueAsOfTheVestingDateMember",
     "nsuri": "http://www.cardiffoncology.com/20230427",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_EquityAwardsChangeInFairValueFromLastDayOfPriorYearToLastDayOfYearOfUnvestedEquityAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards, Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards [Member]"
       }
      }
     },
     "localname": "EquityAwardsChangeInFairValueFromLastDayOfPriorYearToLastDayOfYearOfUnvestedEquityAwardsMember",
     "nsuri": "http://www.cardiffoncology.com/20230427",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_EquityAwardsChangeInFairValueOfPriorYearsEquityAwardsThatVestedDuringTheYearMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards, Change in Fair Value of Prior Years\u2019 Equity Awards that Vested During the Year [Member]"
       }
      }
     },
     "localname": "EquityAwardsChangeInFairValueOfPriorYearsEquityAwardsThatVestedDuringTheYearMember",
     "nsuri": "http://www.cardiffoncology.com/20230427",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_EquityAwardsChangeInValueOfPriorYearsEquityAwardsThatForfeitedDuringTheYearMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards, Change in Value of Prior Years\u2019 Equity Awards that Forfeited During the Year [Member]"
       }
      }
     },
     "localname": "EquityAwardsChangeInValueOfPriorYearsEquityAwardsThatForfeitedDuringTheYearMember",
     "nsuri": "http://www.cardiffoncology.com/20230427",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_EquityAwardsYearEndFairValueOfEquityAwardsGrantedDuringYearThatRemainedUnvestedAsOfLastDayOfYearMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards, Year-End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year [Member]"
       }
      }
     },
     "localname": "EquityAwardsYearEndFairValueOfEquityAwardsGrantedDuringYearThatRemainedUnvestedAsOfLastDayOfYearMember",
     "nsuri": "http://www.cardiffoncology.com/20230427",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_IncreasedecreaseForTheInclusionOfRule402vEquityValuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase/(decrease) for the Inclusion of Rule 402(v) Equity Values [Member]"
       }
      }
     },
     "localname": "IncreasedecreaseForTheInclusionOfRule402vEquityValuesMember",
     "nsuri": "http://www.cardiffoncology.com/20230427",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AdditionalSecurities462b": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities. 462(b)"
       }
      }
     },
     "localname": "AdditionalSecurities462b",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AdditionalSecurities462bFileNumber": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities, 462(b), File Number"
       }
      }
     },
     "localname": "AdditionalSecurities462bFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_AdditionalSecuritiesEffective413b": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities Effective, 413(b)"
       }
      }
     },
     "localname": "AdditionalSecuritiesEffective413b",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.",
        "label": "Address Type [Domain]"
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings.",
        "label": "Approximate Date of Commencement of Proposed Sale to Public"
       }
      }
     },
     "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "dateOrAsapItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r46",
      "r49",
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Line Items]"
       }
      }
     },
     "localname": "AuditorLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "xbrltype": "stringItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r46",
      "r49",
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r46",
      "r49",
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Table]"
       }
      }
     },
     "localname": "AuditorTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_BusinessContactMember": {
     "auth_ref": [
      "r49",
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business contact for the entity",
        "label": "Business Contact [Member]"
       }
      }
     },
     "localname": "BusinessContactMember",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelEmailAddress": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Email address of contact personnel.",
        "label": "Contact Personnel Email Address"
       }
      }
     },
     "localname": "ContactPersonnelEmailAddress",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelFaxNumber": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fax Number of contact personnel.",
        "label": "Contact Personnel Fax Number"
       }
      }
     },
     "localname": "ContactPersonnelFaxNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of contact personnel",
        "label": "Contact Personnel Name"
       }
      }
     },
     "localname": "ContactPersonnelName",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContainedFileInformationFileDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The description of the contained file.",
        "label": "Contained File Information, File Description"
       }
      }
     },
     "localname": "ContainedFileInformationFileDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_ContainedFileInformationFileName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the contained file.",
        "label": "Contained File Information, File Name"
       }
      }
     },
     "localname": "ContainedFileInformationFileName",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContainedFileInformationFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The SEC Document Number of the contained file.",
        "label": "Contained File Information, File Number"
       }
      }
     },
     "localname": "ContainedFileInformationFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_ContainedFileInformationFileType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.).",
        "label": "Contained File Information, File Type"
       }
      }
     },
     "localname": "ContainedFileInformationFileType",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DelayedOrContinuousOffering": {
     "auth_ref": [
      "r73",
      "r74",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Delayed or Continuous Offering"
       }
      }
     },
     "localname": "DelayedOrContinuousOffering",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DividendOrInterestReinvestmentPlanOnly": {
     "auth_ref": [
      "r73",
      "r74",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend or Interest Reinvestment Plan Only"
       }
      }
     },
     "localname": "DividendOrInterestReinvestmentPlanOnly",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r46",
      "r49",
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentCopyrightInformation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The copyright information for the document.",
        "label": "Document Copyright Information"
       }
      }
     },
     "localname": "DocumentCopyrightInformation",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentCreationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different.",
        "label": "Document Creation Date"
       }
      }
     },
     "localname": "DocumentCreationDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The description of the document.",
        "label": "Document Description"
       }
      }
     },
     "localname": "DocumentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards.",
        "label": "Document [Domain]"
       }
      }
     },
     "localname": "DocumentDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_DocumentEffectiveDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases.",
        "label": "Document Effective Date"
       }
      }
     },
     "localname": "DocumentEffectiveDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "auth_ref": [
      "r46",
      "r49",
      "r61",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement",
        "label": "Document Financial Statement Error Correction [Flag]"
       }
      }
     },
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": {
     "auth_ref": [
      "r46",
      "r49",
      "r61",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b).",
        "label": "Document Financial Statement Restatement Recovery Analysis [Flag]"
       }
      }
     },
     "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationDocumentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Document Information, Document [Axis]"
       }
      }
     },
     "localname": "DocumentInformationDocumentAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Text Block]"
       }
      }
     },
     "localname": "DocumentInformationTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_DocumentName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the &lt;FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v105727_8k.txt'.",
        "label": "Document Name"
       }
      }
     },
     "localname": "DocumentName",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentSubtitle": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth'.",
        "label": "Document Subtitle"
       }
      }
     },
     "localname": "DocumentSubtitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentSynopsis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period'",
        "label": "Document Synopsis"
       }
      }
     },
     "localname": "DocumentSynopsis",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentTitle": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report'.",
        "label": "Document Title"
       }
      }
     },
     "localname": "DocumentTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentVersion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The version identifier of the document.",
        "label": "Document Version"
       }
      }
     },
     "localname": "DocumentVersion",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EffectiveAfter60Days486a": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective after 60 Days, 486(a)"
       }
      }
     },
     "localname": "EffectiveAfter60Days486a",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EffectiveOnDate486a": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(a)"
       }
      }
     },
     "localname": "EffectiveOnDate486a",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_EffectiveOnDate486b": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(b)"
       }
      }
     },
     "localname": "EffectiveOnDate486b",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_EffectiveOnSetDate486a": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(a)"
       }
      }
     },
     "localname": "EffectiveOnSetDate486a",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EffectiveOnSetDate486b": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(b)"
       }
      }
     },
     "localname": "EffectiveOnSetDate486b",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EffectiveUponFiling462e": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Upon Filing, 462(e)"
       }
      }
     },
     "localname": "EffectiveUponFiling462e",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EffectiveUponFiling486b": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective upon Filing, 486(b)"
       }
      }
     },
     "localname": "EffectiveUponFiling486b",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EffectiveWhenDeclaredSection8c": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective when Declared, Section 8(c)"
       }
      }
     },
     "localname": "EffectiveWhenDeclaredSection8c",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance",
        "label": "Entities [Table]"
       }
      }
     },
     "localname": "EntitiesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAccountingStandard": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'.  This is distinct from the Document Accounting Standard element.",
        "label": "Entity Accounting Standard"
       }
      }
     },
     "localname": "EntityAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses.",
        "label": "Entity Address, Address Description"
       }
      }
     },
     "localname": "EntityAddressAddressDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses, Address Type [Axis]"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Addresses [Line Items]"
       }
      }
     },
     "localname": "EntityAddressesLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressesTable": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container of address information for the entity",
        "label": "Entity Addresses [Table]"
       }
      }
     },
     "localname": "EntityAddressesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityContactPersonnelLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Contact Personnel [Line Items]"
       }
      }
     },
     "localname": "EntityContactPersonnelLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityHomeCountryISOCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State Country Code' element.",
        "label": "Entity Home Country ISO Code"
       }
      }
     },
     "localname": "EntityHomeCountryISOCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when an entity was incorporated",
        "label": "Entity Incorporation, Date of Incorporation"
       }
      }
     },
     "localname": "EntityIncorporationDateOfIncorporation",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Former Legal or Registered Name of an entity",
        "label": "Entity Information, Former Legal or Registered Name"
       }
      }
     },
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Information [Line Items]"
       }
      }
     },
     "localname": "EntityInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityInvCompanyType": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product).",
        "label": "Entity Inv Company Type"
       }
      }
     },
     "localname": "EntityInvCompanyType",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "invCompanyType"
    },
    "dei_EntityLegalForm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc.",
        "label": "Entity Legal Form"
       }
      }
     },
     "localname": "EntityLegalForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityListingDepositoryReceiptRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'.",
        "label": "Entity Listing, Depository Receipt Ratio"
       }
      }
     },
     "localname": "EntityListingDepositoryReceiptRatio",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "pureItemType"
    },
    "dei_EntityListingDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security.",
        "label": "Entity Listing, Description"
       }
      }
     },
     "localname": "EntityListingDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityListingForeign": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt.",
        "label": "Entity Listing, Foreign"
       }
      }
     },
     "localname": "EntityListingForeign",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityListingParValuePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'.",
        "label": "Entity Listing, Par Value Per Share"
       }
      }
     },
     "localname": "EntityListingParValuePerShare",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "perShareItemType"
    },
    "dei_EntityListingPrimary": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity.",
        "label": "Entity Listing, Primary"
       }
      }
     },
     "localname": "EntityListingPrimary",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityListingSecurityTradingCurrency": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'",
        "label": "Entity Listing, Security Trading Currency"
       }
      }
     },
     "localname": "EntityListingSecurityTradingCurrency",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityListingsExchangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Listings, Exchange [Axis]"
       }
      }
     },
     "localname": "EntityListingsExchangeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityListingsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Listings [Line Items]"
       }
      }
     },
     "localname": "EntityListingsLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityListingsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container for exchange listing information for an entity",
        "label": "Entity Listings [Table]"
       }
      }
     },
     "localname": "EntityListingsTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityNumberOfEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of persons employed by the Entity",
        "label": "Entity Number of Employees"
       }
      }
     },
     "localname": "EntityNumberOfEmployees",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "decimalItemType"
    },
    "dei_EntityPhoneFaxNumbersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Phone Fax Numbers [Line Items]"
       }
      }
     },
     "localname": "EntityPhoneFaxNumbersLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityReportingCurrencyISOCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'.",
        "label": "Entity Reporting Currency ISO Code"
       }
      }
     },
     "localname": "EntityReportingCurrencyISOCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "currencyItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to serve as parent of six Entity related Table concepts.",
        "label": "Entity [Text Block]"
       }
      }
     },
     "localname": "EntityTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_ExchangeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383.",
        "label": "Exchange [Domain]"
       }
      }
     },
     "localname": "ExchangeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_ExhibitsOnly462d": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d)"
       }
      }
     },
     "localname": "ExhibitsOnly462d",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_ExhibitsOnly462dFileNumber": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d), File Number"
       }
      }
     },
     "localname": "ExhibitsOnly462dFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_FormerAddressMember": {
     "auth_ref": [
      "r48",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Former address for entity",
        "label": "Former Address [Member]"
       }
      }
     },
     "localname": "FormerAddressMember",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_FormerFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Former end date of previous fiscal years",
        "label": "Former Fiscal Year End Date"
       }
      }
     },
     "localname": "FormerFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r46",
      "r49",
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_InvestmentCompanyActFileNumber": {
     "auth_ref": [
      "r74",
      "r75",
      "r76",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act File Number"
       }
      }
     },
     "localname": "InvestmentCompanyActFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_InvestmentCompanyActRegistration": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act Registration"
       }
      }
     },
     "localname": "InvestmentCompanyActRegistration",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_InvestmentCompanyRegistrationAmendment": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment"
       }
      }
     },
     "localname": "InvestmentCompanyRegistrationAmendment",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_InvestmentCompanyRegistrationAmendmentNumber": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment Number"
       }
      }
     },
     "localname": "InvestmentCompanyRegistrationAmendmentNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "sequenceNumberItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LegalEntityIdentifier": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI.",
        "label": "Legal Entity Identifier"
       }
      }
     },
     "localname": "LegalEntityIdentifier",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "legalEntityIdentifierItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NameChangeEventDateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them.  The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type.",
        "label": "Name Change Event Date [Axis]"
       }
      }
     },
     "localname": "NameChangeEventDateAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_NameChangeEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table.",
        "label": "Name Change Event [Line Items]"
       }
      }
     },
     "localname": "NameChangeEventLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_NameChangeEventTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period.",
        "label": "Name Change Event [Table]"
       }
      }
     },
     "localname": "NameChangeEventTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_NewEffectiveDateForPreviousFiling": {
     "auth_ref": [
      "r74",
      "r75",
      "r76",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Effective Date for Previous Filing"
       }
      }
     },
     "localname": "NewEffectiveDateForPreviousFiling",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_NoSubstantiveChanges462c": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c)"
       }
      }
     },
     "localname": "NoSubstantiveChanges462c",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_NoSubstantiveChanges462cFileNumber": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c), File Number"
       }
      }
     },
     "localname": "NoSubstantiveChanges462cFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherAddressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other address for entity",
        "label": "Other Address [Member]"
       }
      }
     },
     "localname": "OtherAddressMember",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_ParentEntityLegalName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity",
        "label": "Parent Entity Legal Name"
       }
      }
     },
     "localname": "ParentEntityLegalName",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_PhoneFaxNumberDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of Phone or Fax Number",
        "label": "Phone Fax Number Description"
       }
      }
     },
     "localname": "PhoneFaxNumberDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_PostEffectiveAmendment": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment"
       }
      }
     },
     "localname": "PostEffectiveAmendment",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PostEffectiveAmendmentNumber": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective.",
        "label": "Post-Effective Amendment Number"
       }
      }
     },
     "localname": "PostEffectiveAmendmentNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "sequenceNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreEffectiveAmendment": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment"
       }
      }
     },
     "localname": "PreEffectiveAmendment",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreEffectiveAmendmentNumber": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective.",
        "label": "Pre-Effective Amendment Number"
       }
      }
     },
     "localname": "PreEffectiveAmendmentNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "sequenceNumberItemType"
    },
    "dei_RegistrationStatementAmendmentNumber": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment number to registration statement under the Investment Company Act of 1940.",
        "label": "Registration Statement Amendment Number"
       }
      }
     },
     "localname": "RegistrationStatementAmendmentNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "sequenceNumberItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "localname": "Additional402vDisclosureTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_AdjToCompAmt": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "localname": "AdjToCompAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_AdjToCompAxis": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "localname": "AdjToCompAxis",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "localname": "AdjToPeoCompFnTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_AggtErrCompAmt": {
     "auth_ref": [
      "r53",
      "r65",
      "r81",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "localname": "AggtErrCompAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "auth_ref": [
      "r56",
      "r68",
      "r84",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_AllAdjToCompMember": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "localname": "AllAdjToCompMember",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "ecd_AllExecutiveCategoriesMember": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "localname": "AllExecutiveCategoriesMember",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "ecd_AllIndividualsMember": {
     "auth_ref": [
      "r60",
      "r69",
      "r85",
      "r104",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]"
       }
      }
     },
     "localname": "AllIndividualsMember",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "localname": "ChangedPeerGroupFnTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_CoSelectedMeasureAmt": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "localname": "CoSelectedMeasureAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "decimalItemType"
    },
    "ecd_CoSelectedMeasureName": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "localname": "CoSelectedMeasureName",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "auth_ref": [
      "r53",
      "r65",
      "r81",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "localname": "ErrCompAnalysisTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_ErrCompRecoveryTable": {
     "auth_ref": [
      "r50",
      "r62",
      "r78",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "localname": "ErrCompRecoveryTable",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_ExecutiveCategoryAxis": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]"
       }
      }
     },
     "localname": "ExecutiveCategoryAxis",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "auth_ref": [
      "r57",
      "r69",
      "r85",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "auth_ref": [
      "r57",
      "r69",
      "r85",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "auth_ref": [
      "r57",
      "r69",
      "r85",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "auth_ref": [
      "r57",
      "r69",
      "r85",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_ForgoneRecoveryIndName": {
     "auth_ref": [
      "r57",
      "r69",
      "r85",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "localname": "ForgoneRecoveryIndName",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_IndividualAxis": {
     "auth_ref": [
      "r60",
      "r69",
      "r85",
      "r104",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "localname": "IndividualAxis",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_MeasureAxis": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]"
       }
      }
     },
     "localname": "MeasureAxis",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_MeasureName": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name"
       }
      }
     },
     "localname": "MeasureName",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_NonNeosMember": {
     "auth_ref": [
      "r57",
      "r69",
      "r85",
      "r104",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "localname": "NonNeosMember",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_NonPeoNeoMember": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "localname": "NonPeoNeoMember",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "ecd_OtherPerfMeasureAmt": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure Amount"
       }
      }
     },
     "localname": "OtherPerfMeasureAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "decimalItemType"
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "auth_ref": [
      "r55",
      "r67",
      "r83",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "localname": "OutstandingAggtErrCompAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "auth_ref": [
      "r58",
      "r70",
      "r86",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "localname": "OutstandingRecoveryCompAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_OutstandingRecoveryIndName": {
     "auth_ref": [
      "r58",
      "r70",
      "r86",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "localname": "OutstandingRecoveryIndName",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "localname": "PayVsPerformanceDisclosureLineItems",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "xbrltype": "stringItemType"
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "localname": "PeerGroupIssuersFnTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "localname": "PeoActuallyPaidCompAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_PeoMember": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]"
       }
      }
     },
     "localname": "PeoMember",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "ecd_PeoName": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "localname": "PeoName",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "ecd_PeoTotalCompAmt": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "localname": "PeoTotalCompAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_PvpTable": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "localname": "PvpTable",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_PvpTableTextBlock": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "localname": "PvpTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "auth_ref": [
      "r50",
      "r62",
      "r78",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "xbrltype": "stringItemType"
    },
    "ecd_RestatementDateAxis": {
     "auth_ref": [
      "r51",
      "r63",
      "r79",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "localname": "RestatementDateAxis",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_RestatementDeterminationDate": {
     "auth_ref": [
      "r52",
      "r64",
      "r80",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "localname": "RestatementDeterminationDate",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "dateItemType"
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "auth_ref": [
      "r59",
      "r71",
      "r87",
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "auth_ref": [
      "r54",
      "r66",
      "r82",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_TabularListTableTextBlock": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "localname": "TabularListTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_TotalShareholderRtnAmt": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "localname": "TotalShareholderRtnAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r12",
      "r13",
      "r14",
      "r15",
      "r16",
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r22",
      "r23",
      "r24",
      "r25",
      "r26",
      "r27",
      "r28",
      "r29",
      "r30",
      "r31",
      "r32",
      "r33",
      "r129"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    }
   },
   "unitCount": 1
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r100": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "5",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "ii",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r101": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "5",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "iii",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r102": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "5",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "iv",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r103": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "6",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r104": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "6",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "i",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r105": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r106": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r107": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "i",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r108": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Sentence": "A",
   "Subparagraph": "i",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r109": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Sentence": "B",
   "Subparagraph": "i",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r110": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Sentence": "C",
   "Subparagraph": "i",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r111": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Sentence": "D",
   "Subparagraph": "i",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r112": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Sentence": "E",
   "Subparagraph": "i",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r113": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "ii",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r114": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "iii",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r115": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r116": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "313",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r117": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r118": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r119": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "413",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r120": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r121": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "462",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r122": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "462",
   "Subsection": "c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r123": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "462",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r124": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "462",
   "Subsection": "e",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r125": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "486",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r126": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "486",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r127": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r128": {
   "Name": "Securities Act",
   "Publisher": "SEC",
   "Section": "8",
   "Subsection": "c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r34": {
   "Publisher": "Global LEI Foundation",
   "URI": "www.leiroc.org",
   "URIDate": "2013-08-21",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r35": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r36": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r37": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r38": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r39": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r40": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r41": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r42": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r43": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r44": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r45": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r46": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r47": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r48": {
   "Name": "Form 10-Q",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r49": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r50": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r51": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Subparagraph": "i",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r52": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Sentence": "A",
   "Subparagraph": "i",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r53": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Sentence": "B",
   "Subparagraph": "i",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r54": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Sentence": "C",
   "Subparagraph": "i",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r55": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Sentence": "D",
   "Subparagraph": "i",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r56": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Sentence": "E",
   "Subparagraph": "i",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r57": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Subparagraph": "ii",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r58": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Subparagraph": "iii",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r59": {
   "Name": "Form 20-F",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "6",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r60": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Subparagraph": "ii",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r61": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r62": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r63": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r64": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "Sentence": "i",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r65": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "Sentence": "ii",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r66": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "Sentence": "iii",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r67": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "Sentence": "iv",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r68": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "Sentence": "v",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r69": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "Subparagraph": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r70": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "Subparagraph": "3",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r71": {
   "Name": "Form 40-F",
   "Paragraph": "b",
   "Publisher": "SEC",
   "Section": "19",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r72": {
   "Name": "Form 8-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "308",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r73": {
   "Name": "Form F-3",
   "Publisher": "SEC",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r74": {
   "Name": "Form N-2",
   "Publisher": "SEC",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r75": {
   "Name": "Form N-3",
   "Publisher": "SEC",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r76": {
   "Name": "Form N-4",
   "Publisher": "SEC",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r77": {
   "Name": "Form N-6",
   "Publisher": "SEC",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r78": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r79": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r80": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "Sentence": "i",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r81": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "Sentence": "ii",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r82": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "Sentence": "iii",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r83": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "Sentence": "iv",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r84": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "Sentence": "v",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r85": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "Subparagraph": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r86": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "Subparagraph": "3",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r87": {
   "Name": "Form N-CSR",
   "Paragraph": "b",
   "Publisher": "SEC",
   "Section": "18",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r88": {
   "Name": "Form S-3",
   "Publisher": "SEC",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r89": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r90": {
   "Name": "Investment Company Act",
   "Number": "270",
   "Publisher": "SEC",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r91": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r92": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r93": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "ii",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r94": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "iii",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r95": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "iv",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r96": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "vi",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r97": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "3",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r98": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "4",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r99": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "5",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "i",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001628280-23-013558-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-23-013558-xbrl.zip
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MU)>(_RR0M =FHBE,*F:]$0[+7N ?HB?J.16#_U&:@6A>(U)15-,( V4=7;?
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M2>?RY,J"_ULG9Y?=XT'_TCKKG70ONO ?>&8=LJ86MH[0?7X[ZQ.70!X3J2+
M$;D. NI7)VM4KW6-*AP6K&:U.2$@B3P0^0>-UX&G;X)!$N:CJ<PF_#8(OZD
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M"GK6&Z7Z@?WRH/+RH/.28H@P10K?X0])7/1@^/*@_'()G([(?%2%Y8LQ&98
M9JN(<7[,Q(B4T!=Q&.3]=-C$(*M<$LZ5L*:0RD4CFN-*/2I#N^2*PDJX,'ZH
M?)'<+DIY*]5RI5)IMYVJ4VL-[;;M--O#9JG2+I7;HV;[?VO5>K7YXK?G<F(N
M=?WG.+&W6AA0^9,(ZIM=N')<]2Z90AC&$AYG'7!?[N@2(2<!^9'M]T6%/ZEH
MUV*Q_<I493PSJ3<2?MX#G6J_8IY<N;1/E-N,N?PLI*,'9WOL38L'FQ9X3W*!
MW9&JVD-#@LF6B"+Q]P;L D("-,LAQJX71,%T/-<.8Y7C(QU4B;\QL6+7'0X_
M3WI28!J!3U4F;IPI6129"IA9C):%JN4 VH 2H1W)4ECC;[IL*Z;TB+VOXD?X
M*H21XLTE2L4WD<0B^4WJQ$M9CO+^DJU3GZ@*U6P)S&*=C@?K6EZ*L=_6!V[K
MD$6B/@2S_(3UJ7*UE &@O-+:84U0;A)V"_6OD&>;IBZJ1P5KM4A*I3 9KT..
M68AA)<63^"6RP(0X4752*BO#[(>S9YH?(@O6$P%YI6U9#5QKW_N=^@$[->+<
MP<R0!+37Z <D#1[_FEUK;W3J8SQT$2%$HV<2(<#VF_1DFV0$W45GR[Q"VNP)
M2IT>V11FOR<_2,3)9-F<2$TA"=#%U&_#D^T25KAS@S"Y:E--5,JEPW\7I"="
MEUZ;3HO$)6%NO^F%QR\G3XFYR_S6%,=0AVQ*N]4NZ>$\<;^)7B7N2'\JII6Z
MVT\D4>2%W/&9-T?!@+_M&?$)4P5TB\9YLEEI!DI X_,Y9+$?PFKV-#[-8=$<
M1^M.%'/<X]RC.%UP*\J21&]6T421H(RCV3!)H<WF!6-6.Y:"B.B]!,# PR>;
M.#H<R_D-V(+\:6QWG ?)*Y.)[W'M7H<,0]8KGF"S>"SJR['.FQ+K"C*EKI!P
M/M<);:D<-2YKJ(R194&5C+'!CLQ$7UN%(2+CH"KHFE98,>Z$*"\+#N."^D''
M\S,%6DIV*N!&LF[%7 -I /%%73F9K'9UCU0W3/$"H(3HHRL,I)5^:XS,J%*S
M+,Q*!G6WD&.&F5A5.F60JN[F"=8(XNJH"#,!5Q3,I$9=N,9T[TI9 B56&25]
M+E<?CU7+I(;C5-S(15_'4(ZJ@+C(YDP:49*:K !T'[X&6="R;#8ZN*;RN=(N
M$1Q#M>K)K53540]9:B=+5W-K#:A7*6($4-5M4M63C58(EL.]-H]0LLM<G!LA
MPL0JBZH='!8FKE@N618R0OYN!I)$8U!<88Q"X#K.A@A)IYJ==,C98UL',L (
MOR=-4@C(+%IV*E;R@6Q,F^1)RFGI_+I.4@8E:(>R7_112TD=L::,8(E3;7$5
M#N;2*T6 UP!?PTO_$65J;66DVX]3@5]5-J:Q//4<X0LRFT"$7<>*[LHKTE$P
M#=1GA6&EB"PF'7FN*,U5<-%;GJNQ,J5@R7ZD,@LH50"$,C=J##/I!<O\7/C5
MMWB0/Q6I3#&+I:A3#YX\X"X"ZTL3!!@F"#RJ-F/#"S?6+M?::IY^&"Y5?C1:
M7G J5B-X#U6F?>7'C[3A)*8@4%C6X877S'?_DL:[/-Q8M6IB+YM6O9'YI_+Y
M41FBP53#AKWSYP?L%T4TU]DM P%;E5&:B*?9Y&RS0'3U-U6SQR1VDC" #9^Y
M#JDP2EM?,LJ>.9Z..9+R&@F&* %]03%&'1Y12<",H["9WI5\^S!C%BXF'.VW
M[<FVS12A!FHI_IHY1@9V_D+VI0(!O0;=,)3XBQ)FSM;H.*^M_=WY9/OF\!ON
M(3C=]:(D3(48[VTW(.$=1,8K&7TAQR1U52HI\(R$$,WM^ $BW)V2<SS)794M
MN0TCF3@J$[>)E^ANQOSV1_W)6,;(2)H&L<1V5E9N9)JYV%\B\*@(+YW[:>8^
M*  ><GP8F)=L+AJ<$M"ZJ+@A;XYP^1)[*?\NTZ_?1T=^1.@T,HXL]V_<,/ E
M[CX)Z$ 62*7,(1DSU<@S4RG:E[0#3&':>& M'5)>>PI&6]TQPJ<;&B(*W^6;
MVMYH!M:]$%Q\PD,*NW?-F1>LJT 4[BP#';4.7G2OWKYX:2'LOO0#248D_P%Y
M/$F3%3 Y:@&Z$"A=#%Q(W)L1QBID#\4T3 ]Y3:>S.-6739+JJ2&^?LE<Z/(^
M%WHSYO)\N= ;YBQ=U^.TX#\UG: +OM.U 99PI-\9+K>?0,(MJ]IZ#H?JXZJ.
M?CI(F$/<^49= L"FSLP6A<;=&#26[>ZN]HE+3%G92HU1@!ZNLC46GE'GF;Z8
M)9/H**[,DE.)ZRJZ<_\+P,!$+7"$F$P;CXRUB7W+K ZBC\U57M4Z-)>:=S"4
MD>,,/MD,6P<KB#/,JD%K '9?=WTN++15+5AGOETLK-4+&CUT0>B[3/2$+EIG
M(^S^/,$<$!%$'6( 3R1IH3DKBO1EQOLZZP--C-(D:+A;YE(7#XI9"Y=4E%+0
M[A^/^E#-<WQ4AD>D@&N@4#*"B4XQ8T FJHFX,DAOS%A3[7K5NG (.<,,\Q_L
M6?^>*5$)[ROAC*(>X0(22N09I@% MKN[7P<. _S%04MHMZXB;&E.Q=W6(&3D
MM[K 9C,2V9PN'Y$&(O432N%4ETSF\C$ :],YG_?WF5KT+A>DJP(.\QBLXE@V
MD#-; Y)$F<Y"D)J1P!]3-=>NCXW_A-@Z2.9"Z8JN8]VPT&4RC>A6H%S[,;;(
MQ=RX/V=H@$>W;!IAJHGG,5UR*^O1L75>]+*@TVH(UE+GIZ.5;G22DHTHD'DH
M'P_6%V&/#(QWAIAK@X I(IUKX1F4>0[*?$;8QR"AJ:<(.H<U&I;95*4@\U\B
MZR\>8A8V-3Y)5J"6&S&/O!)RT3FKVQ24Q)6G\I0&M2[36+VPEC[Q5"<,<4$3
M8?!L\:$=D+<.N<4/+/&&+$"QB)"O6R6>C,8,&@FP5JRHP.P=DN"J71TRJWY%
M3I_WU.E/(8)(-%9D9!6Y"'*&@"N8WN^JE#.1"(<2*C+;R>1]]VFOEHWB\"79
M0&?H!/+@P O**PE^P<+8M=TI/;[5''\R"X5 CVR0YG/.0FGU$_:Z0ES7"4P&
MU#I!%&L[9EDJ9H^2HZ4 %4F">6R-=KH<,*>K0E[3(9%;F7URR3;"PY$+U&-A
M$ADOJ/14],C&\AK&>9CIW#E3O1T'F;7G]W=8EO(I""ZJ1!*BBPX8"]Z7K;@=
MD@2%9)GGLA.EJ E!\XK"IUM]5@:YK"@<[B(-57?\XM203*68QN,PF%V/53,=
MVG"*0V(B,CK81? 8>&%BD@W178?S!($;[B#=QB:&A5%4 ?Y?M):>XOS3(YI!
MMY*W&5DI<!M,QX$/QH7Z]'4N A,-4<L\M"S'%9]M&L^JY@</2&1+OV[%DGTI
M<3)]"X@%$7>1WZJV+NW2_]5&ZO5U2*47Z@]Q@&$C?Z:$BR:5[J.=3UEYO(W.
M&/!>ZHHMEWSOP!(U(3<)*"UC?'GGIR*22C8MFXCPCIKH4IG.LWD<CGQ*/"V[
M2F,O5N5),=#I''-N3!T 42BJ4'JHZ>R,BF',P-N2CH(*$,N$!]@BF9@(/G3P
M=40I%37QD!6U"GI3BLNM%H^?<!-O7%DKP'T;[D9TTF?0T);<F&CX$K7,JC-]
M..#1R"!;T8*7.8'91$PZ>J?"IDXJX5BR!>ERS&5CJ\-M'(LEK1/V@<[O#W16
M]H'.S9C+%G='7-X0)VD'3Q[2']L)YV>=&?/^D-#M(HT)6P6@8<J%D7+K1F,)
M$2 )P9.&]'DF%:*,&[?YO0)0&&#88V1:$""720>B93H+B-\D4_+>2^$@Z]UD
M;OB28CH@_$$G 5'M<:E&.$XHBJCBX&CU%N;(O75V?@/$97XL:N.G;;\R(FH;
M/]N<P-[FDS@WZE@08<>MEG8=:0YI41XEISYUZ!<3[%!D:+83 <LA3]K?23TO
M>2+)XT\&O-\XFOD>5S9-9J+H^IWY$:JDA(4-_YE@4Q8*"JBFC:F";3"H@ +B
M0>E8P)]FOFB&IZ>UJM!WZ52WPG ZEA:?)*'K6]TD15\MQ>K):J?-6M&RG-ER
MH_1Z\;\/J^1SHX6R_!00O+*4<S/DC=*&5+)\BI%QR%3&R]B=8LH%QO!X/!?.
M"K#Y'<G8\MBELEU5,77BCE!U:84D2'T=,(IP3AB(6)8@RXUF(9T",]<?!J+<
MWH) =W:Q)EKX&L= 8MWL'LN@\IK;'2<+1ZT!2,)5=D4B*J1[3ONG[U5\$.TG
M&'$"O<$\6<Y"./S8E E/MZF>:3P T?[RH4=PPV3QPSB6!*YFPWL83W;%0K\1
M?$LQ3=+E!I&@5_G=< P]A'S,W DS4*YQ3RF-V82K$VCMD2<=@0M,_,CYL%@X
M0=*>AZSCH9! -"140VHLFX:$:5@Y#]$QQA,V@CM)QKIA-H;P']S==,-8<DGW
M3^U]B@S.,L$%I85$RH4?A^YP)EK-JJI,,^<_P;)-ZH'@WE;X$NN>!Q1 "[Y[
MU70G);)7G!6Z_'E$X$_9EEX"_U[@.3B4X<9LW/4HIDRQ47[:""DN(Z8M.O2S
M.#&A%B4BMV!]\X-;C](FV!#=OB@94\40P NS*,:,.20KC*P_,?I+@VA'E9HY
M_$^Z)H@$='&,1M0@8]G""^8HBUNV^ 7E656;)XMY;[AH6*+<\8AEN-+UO1#<
M*6*[!#X5+53,FQ4Y2OHDR5>>Y!EC7U59%$A< !LB=-&DWP-U<S:*$8V*I<7J
MWCSR/")+FVXH,3VU_Q+@R#.A?+2Y?B^M9(,3BDEMM50Y0S@@QQ6EWB+]6P2Y
M5];N%<S\"=#7\/C84FF/IEP%@#(LGT#^Q '=+-1S*X'V245WEC8U $6-:E1A
MFQ&$9_E$DJBD=+>;?O 5A\ ,22T)/+FQ.EB!$FL:%5&_1?>JAQ7*0TQ];YAS
M(P"7 EEBEX3Z!N.99/ D;":U*I$&J3#)"0G!M*?D'PXD["$(1-2=134G'HAA
MX #M7B8KHJQ9 M?$F+^\;PF-7&J%!#ITR[%57V0&U^1\3+4PNT4%;8*:Q[[C
M1<&#>"PVLXJHRQ+MB(! UA5?0ZX"@1A2U)M4M-X%MZ!>AX4\3"E#_F1A?$=*
M_4B !$.N;M;'2Q_-/"HX^8G+I#NA]Z/ IUBBW.+#6_B>#"ABIRD*_J#$33+^
MM;A:" 4)SM8#/U1$B0XQ]WG'R]473^=W_"5#0M5]2&@SYO*S:M]^*M,M>)W*
M=>"$B\O^1?^J\][Z'F?I!JRC^[Y[/#CK]ZS^J75R=@F_]"^OOGM)7T&Q=T?S
M5!5Z199>_VP90<OLB$0JF5 ADR<*"T:_N' %T&,$MYYO'31?&C9@++.O1&Z?
MA1B.HAE*I52I9D8OFOH09@;*K%FZ7J<>&)MDG0#[HX6#Q5X196^ETQ;.%( H
M^IE(HU$FO? 5BR.$V<'2B!+ IB&F.$2I=*9$EU1][G*(@9B^% Z4B@=.33;B
M4-5';HQFE)Z&R)(W,6BGH,?@;!5FE1YX;BDR*R<#Z6W"L3"G#$UEL R9IS(P
M4HOVV<2HR3+T"^&'T?,KJ/<BDZ05U<2M[\QLJ4IFT%KHX;G';K6.JTK5,Y6B
M/NJM+ I\X6#Q7$Y(F9+8TH4G)PT?![?Z[??MG%ZQ2%M--M(=*4[Z+JS%33VG
M432;"#_NG[,@G%$#0,E0\KCJ8ZE)!*3A[HU*DD4W+Q;E):H_&Z&GE?0?>=;0
MD3:FWIN4R^OIQIH)OQ-KJAU4NV9DOANI:RD627:13@TF!Q]2LB'JV]@?DH(_
M5"[B)#4J!7WRQ&*XDSF"LMCXM'^IBHQ)+!B>JIQS0BRW($.P>$C:JIC_))<H
M[ ,!1^IDO)&1Z0A:/,WH*A1&G/#5B#J_]&J$;)C@:1.%,)@&Z'-B;B%T12NG
ME:OR1)TX+:L@H>;E>+2X0L;]D/9^)GNK2&L4>FO992Q,%.KFNI84RIN( SRP
M-)U>+THZ,_UK%&0,V4ZQ,(MEB>F8.G.3J%7R#D&&;>1R(P.2G$HCYGK*>"?Z
M$[F_"@A:253:*KQSR(02Q9ED')O%F?G1C']@Y9.K ?R%!,0;[\?81XU[[",I
MQ)Y)@3KS*9$PL8DODUX;WQE]W :!_=XXDB1#R!\NXV)IYWE:PBQ3I=PP <1+
M*T[(:SIXIQVR\#QY[1D)XLXTA&$J-2J&J"[/P@#Y>PVF7AQ,CP3MJ*]%8@R'
M</X/J3YO&O$C]<-K.!A3C\V/7)\H05]Z+<>2%C2:C#?H5;>9)S>--DM\G%B3
MQ9*P*.,0_G74F^7'1?KH5>PL?E8K%^OMY1^7BN5'?E:O/F[459,M5XJU=F,_
MV?UDZZ7*NL/":<-3^Z\7U1?J.77NL%3CX4^^HC,6+ON*! @[*EEE$@4K1G^F
M1\OUA6<KTSM\^O6"'R$K?(3<>>K;H77?W5A2&;6JNDLEB"1WX#-O=PX%$2)N
MD^C7 RU^#7(]@M6V@GTZUT^\>GFOXZT/SUJ89^=8N(S7VT47K*Q;@S+W+_?7
MH9E9:+@GW8-(EVO//K<4_[[!]T\^UY/W;"MV&L7Z$-\YE-P-IB ?C5X_ZBSE
MW><PPL\WE>D<Y2(2%JSSXDEQ'8FTC#(/$4A/2MV?*:G6)'&SL?F4_)[1]S/<
M)F[\SW-?DHL4'M$_VR,S$4_&ZH8>PQR#@G4Q?JRPS"S\4>QY/_$VD D;U4VA
MUWZ,!X_Q/+K6UD@'T*A$952V19[0JKY'7CSA=;9E\N+95:CMHM<ZE_R>7)M'
MKLV3OMNGFQD8^GO=[!$4K)?W]/KQPF-[U;]?:-OVFNY*$J9[HNS5VH=[!NN;
M0J]-&6,[]FUC],7M(-?QYHG:;5-K+SE6<%X4#>AJE+@LG.SUVX<*W8W1;S=E
MC.W8MW6DR*:0?*\XKMS*]W__&_9?];CU:>S&Z^13[6_3Q!?:W-/KQ\N-#=6/
MM\?)^(KJ$'Z[K\HA5312+A<K2=7(=U;HM%_DO'P;FH>M2,FQ#JTS V%>E?)L
M WX@KDIW/,4RU2$V"C);]>C^5%,JZW6Q\E66SI0JI:*U;(0+ 5<BAJ!6-SY5
M$#NN32B4OFRBD+01?,<G+";H6='^2>+0JGKD#WZ"VC&"]0]#%GUC8D3LPDDR
M3DZP4BI5"Q:!-R",!T%1Z0XPA/0+E%/E;2?8=R 6701SIEJ !YC1Y]#S^#75
M"2</"(@J C,,9I'$:['9E-D"-5-,ZFL@X AI&#%;^%*YW:H48>U)PPX$A!D'
MT=2EYN("AXUF!X3 FN(E2\_9"C:+QP&B>1%&S:'^E=K/4)N*1JED4;\A#^%?
MRJ66-0R";XCO-8UU-U*' $;%&/*72M/"0XL/1S1[?-T4@7F  -[<H/8%EB(Z
MDKA42SX!5L5VI=A\7&(_'@-GTE+TIA^\Z%P=]U^\%,3-Z<:#'^?",J:HH(M*
MF042>,P]P8^13<ACEL.O0[#@!'+:<AZC*<#[!;G7_%*&,27.T=3C2#]$]YD&
M47QX'3)'H)6%"JWR(>RNH,;23Y\%M\QZ)UE(;**@<&16I<LB= GL8Y+M'Y$Q
M'23]=#R/@->97Z"98Y$UPE(6+%MM')'(F<!OU*X>"TE-A#<!JIFP"#$(%O-E
M&H-A:;ZN+86!$"UWZ 93M*F9S6>DOVAI) %U8>1)4HV?1JZC-T??7,^+4D7S
M!FS19LGI_-LG+[GI1S?U77EQ'/ZDMR\!\EW1BG+;KE^UJ\GEN:K9IKA*SMF<
MKE\IF0R8-/ST]YG/C=M9OX"Z\^FQKU &QE3]K@8GD79.@+.54KF*!R9[U:=F
MF]PCY1:U28K2R(YR8@J#U^.B-ZD2'Z+AH #DI0L."^ZON<^IJAQ+">82V1=Q
MBT+L7#@*[!E!DDT"#TB#'8 <EUW[ >%0%N&VD9APZK)=1+4'$7%+6L 2(H L
M!(F#_169'+9@'3#\VSD8R-7J:UC;[$[)H,)+O!ER)@/WHVCFKH0525DW$DL0
M#=X2Z2G:@VM8ZD#/EK8$U)D6+NH4;H$9AG=P=W"Q^KY=V&=FO<7>"=9[H+D\
M&'LD,!,)K+9' MN,N6QQ<YA\UD)H(83B\&-J:RMEW2GW"/= :'>710S1_AZ,
M?40$NDBK-_H[9[["4#I0C_Z=3::OU1=?DNI-QQV-!X;X*Y%+7=^5MHP'_P($
MDA/@!0&#)_- 3?#*#MWI-,I[I;30TM;1N99T;UR24-E;0=HO;XI71:4HPT#P
M,"C?$]0-Y\L49[.UQ G8;-3*#^SK>P8B7?<J1A4Z&>^UO!B%G@3?Z_%9&"BM
M?XT)O \BJ^-?<X]'F14B7J> @0)=WHW&W-'W&8I>O*VJ%7@JFL$G'W#V4T9\
M2E.JMLR_I>2^-".1>GA1"GM+8A'3#4K6F[C[U+7;+ E31MQ@RI!;K>2KE9AP
MK\EUK*\DXQ972!H1*=KY6G3&4; 52O5B3O!S:M1B*L^I5><D1/_2-@9S,UV"
MA?#=9E^?V.+$U,CZPK1#9='II_L'&X;'2=KP,/73FI";Q@M-#QSJWOTI=6(!
MT:94;WCO8+GK0_H>9]>S*,8W-.]]PX#;8U_XDTP+L1-%@8W=/JV/Z(( &L#
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MZ*?C/[3;Q6:I^1CXAV:YV*@T'X5\L/JS>K7Z]'@*I6*CNOSCQPY;*5::CT/
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M.4YCP50-F=\@E>ZLVPB 'A:/YWY%-SV39/1 5S[EU3-^+773/EY>JRN6[4D
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M7J][@JN#<?4'5A;)+\J"BMR"+K;%J#9,(P6ZK/Z&9ZG5A#I)HF6+ 4XOY4X
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M$UL-T$IL\:DNH?1B!&Y*,O(?>! BW2SV=2172=9_<'>:@6NKXID,.Y07I%2
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MZ22WA5-+,LI*2BW^!+/18@\SU:C-%NYA)I\&1W''8TQ;&<1 (_,Z0@#:L1
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M,4;6\-J1T CP4P!3(V:BQR^JSV.C=_JO$_;B9T@:'X8%M>W@%47 G$3^"8V
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MG$5#DR]@QVK_\*&T47)R2U*H!T*[H_#>%S\2_$);=5].9U0DPS+"=*PRCOV
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ML4+.YY8GP2L5^B/7,11A%EZ+Q;"6KYP@B_ZIUE47Q/4<T)Y^.L&_O/Q=J",
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MC*L(D"K$%2<6;R:Y%@F3S= ^0JDFFS.3+5@0!M%!@/2'OS'IX[_H(H P&KB
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M^_0;=Q#JW:V/,1>ZD.]5I )]V_-NYY)L,)U;9CA^C)Y5=9126&X,0/M_2U\
M2ONA.Y;WY=7?EYK9J?7,>K.]KS<F,V2QG%4IREF5+_?YXNDXU^CB$TG5;RXO
MX-&^O<MV#EZJ^='*S8S6Z?Z[=&.C-1O_/KK^F@.!=C:W0>]2NMK1RHR",J-@
MG8R"##NO5JJU@K!$F6509AF4609EED&99;!S609ZB\$RO>!Y-UZF%^R__[E,
M+R@CLF5Z04G,KX"8FYVNV:O7=I28R_2"?0J!M]L-L]FJEND%>PS;UZ#>E>D%
M9;AT>[=TAX.E97I!>5]>.+V@UJR;C<[3],]=22_86IBMS#0H,PW6RC18,.EH
M1_(,-CHY:<<2#%YE7[!..39G-_;RC"V^=CZ#)AG+LFKZ3)E;4^;6E+DU96Y-
MF5M3YM:4N35E;DV96U/FUI2Y-65NS8YXC/?>(5SFUI3$?##$W*C6S>H32R?+
MW)HRMX8BRT!+G5JOS*W98]B^!O6NS*TI<P6V=TMW.%.@S*TI[\N+0J97;9J=
M=FM?[TN965-FUNQQ9@V/G+M)9@?M8EY-.@'V(-)J%N?<+#=PKM%Y,[/B\Q%<
M<7+"!S<0=N3S!!SAA5:A:W['6I@LO,%?J4$,37WRO1,UL\APU$%M[:!R8!>.
M4_?@Z\4OR,FQ(4_=<FFNVQT.LZ7Y3CP!&^_,) Z JI 0#2^F44TX28=G<A.=
MI5.@^"[A0'+7P;EFM*?(I>E"8YK^1#<%_VP%)(/H/SU7A#0+"&<KRP_3@&X@
M<?$WC6#R//P?UPO!,AKQ#":<5FDT> (R#<I%)L-3?01.'WODU%%FRI3\0 :(
MN-6A&^)]PQ%P<@KG3YL:__/28A@TFDJ5I>FJ<KC6K72ZC<WGCZR_[.+?&MWF
M+FUV6\LN!X0E?9ASW5;/\^B>IL2 N!F[400<9TQC[<*A.RG*C=D@"/<"+J?,
M7P.!P_M$3H;U?1Q4SP!;(NGC8&$4@_Q:X?Q[<:A"_>M@SA9,,"=8&+^@,N*A
MD?+VB\]FC'>WRKT_"+_UV=!RE[G &XG7[;;CZ(=FU80O/ 48*["YUP#06ONI
M #TD8#R9N@X(&-T96*S,; ?T__:*V7Y>5EU:Y[0[B.5V:VV2SYUW+8:ZES";
MO1D'?=SU)<1>'K=9S/?F1B=V?3KU0O?GROX]V*)TZ@E.DMVP;Q/]AX_Z-$]A
M'["E,!Y%)KV!$^[E!N2&^&4/#(:8@@_R("&%)-C["1NMM\UNM2IW(@\@9]J3
MIU1.,/<!;.@0Q:,#%(+0"J8JFN*@H2+_FSYM4E+)T'(05N*["&PWQ/GUKDW/
M_5"OM*K&41CW_X(=4?3$^2L.(RIQ'C"HK0F5"_['DAOB_863D1NI?P I < \
MAU-8\.,C]YLXWN,IZ@OI]#;C5I8>7A&%"+%H:(3Q>(PX<3WX]YC]S(!]&ZQ'
M>AX#893]DW7G6Z"< 0+F>O]#6) C2$A@)K\ M!. Q3S"KQE6$*"CW"3,25=V
MJ-9DBIW^M%Z 1/JB495L%9GL;_:GJK/9JW2JK7TIOVQ66NUVN=FE-UN@"BB2
M@ULEUGIR-0!T-NF1WX-"OB_66#S-Z[>]$RVJY%VZ0'&O_)D?A0CE0!(K\(2C
MBO6,*Q G_ \E9C Y]?^W]^U=;3-)WE]%+S.[DYQC.5)WZY9G-^<XX"1^!ML$
MG&3(/SFM[A:(^,)*-@0^_5O5DJ_88"[&-NC9G0"VU&IU7;NZZE?9;V_^^?8E
M4GB%[[1Y-8'-S"&M7/($_+0)BC[I7$ !.H^J!F3L_N6 KX<='VW*MEU]96GS
ML_KH#F.ZBE4KKIR^\J%G7ZNJ[E]/O&8O*1M9UZEFV:@D'=@YGZB242_OE5>B
M;MWRK+:=-Z]%VI:6YVRU)I0M65[9/OR$BSPACVQ+'56 4;T-+7<LZ/MH^CJT
MY-%-A8I?W0GUTYF:5\@S-B$;S#3/?=BZ-@/^=^^T:WS$4@0N1-Q;$6"*_SBK
M;=]NMNECS/86GI(O%:ZY3:7,>><MT1K4+P7W[M(^G\0K-29;RU6OC)]L6F+V
M?8U0P4\;&N-YF3SJD!)U[UO>_H0\6@2;UG[E<R=:KS6>=-B3775E')6-.D]^
MQ]TLG%0R#DY7%55:M8/*GC"NM#VJ_Q$.Q9QWWA)E;=N/B'6M,=RQ/6SURACJ
M,;&U@I^VR4/=7AZUO4?$\K8H7 ?6?IW.49UW8Z/>.XV[,AELLS_D/&' [D'G
M,-N[&?1HB5"Z=0&+5T:E!QGM#:92$:Q9_EC++04NV]AHS<L)%7S&DH,?9>.
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M5#GZ:%2.=HU6[SP6F9KP;%^CZ>MQ,P AGJ:#3@Y[-4BSH88#P\J-H8/&:Y#
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MC:%RY)5>I/]L:GA9#;""5X]=*HU*G [",VQ9U>]E79-&.+=<G@TRW [PL6"
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MB5R0 >;6ZBR.//'B2+>IKESR1*9YJH5.$LF_;IYG/7FFOH=W&72ZZ3!YY.Y
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MB>@'8_--+@^!DVV3ZH=3"E&FP-\^$M\8Z)?R5_YBK#[5SH_^!5!+ P04
M"  1@)M6O>^3/8$$  #K%P  %0   &-R9&8M,C R,S T,C=?9&5F+GAM;-68
MWU/;.!#'W_DK?+G7$[8E_V0*G1R4&V;HI),"[3TQ:VF=^+"M5+8#_/>5["1-
M+F%*20YR+XDM;U:?77UWI?C=^X<BMZ:HJDR6QSWWT.E96'(ILG)TW+N^.B=1
M[_W)P<&[WPCY^N?PTCJ3O"FPK*U3A5"CL.ZS>FQ]$5C=6:F2A?5%JKML"H2<
MM#\ZE9-'E8W&M44=RO[]5!V)P!$1#T."W'.(%WA(@/J" /.]D">!\ /ZQ^@H
M8A%BJ!\B4)=X8<A()$)!D%*(?9[0E#FMTSPK[X[,1P(56CJXLFIOCWOCNIX<
MV?;]_?WA0Z+R0ZE&-G4<9L^M>S/SAS7[>]9:NW$<V^W3A6F5;3+4;EW[Z\?+
MSWR,!9"LK&HH^8\)]/2B7OQPF<:WNX?:M,J.JO;WEY)#W2[/3T.PGK0P=V1N
M1LP0<2EA[N%#)7HG!Y;590X45S+'(:;6[/)Z>+%.FI6U+;+"GMG8D.>:N/50
M/T[PN%=EQ23'^=A88?HD_3QD ^4;G-^--WMKIK$&4;Q)D.A1+(W =\BXR?OV
MS M?1& *35[OD'C=]TYY90'9+A.\YGH'M*TC4F"1H-HEZHK?)<XYY$;""OGA
M2$YMY,)N\3Y-)WWQ3U/5IK]6@S)_?!YCM<FC[K;TFV<N27?9DFZ88@E7ZR(K
M,]-J+O7M;!Z#MB4X/M18"NSZS'RR7/(5H]QT.;E8EAP2S-O16SW/;3_/]117
M\E06DX\KZ_>B/#SATGX9(%<BO3U#T7"3NW.I^H5L=":&.)%*[Y'7.GAU-<;/
MM>1W_7M0HNJ78C QUMWMJ<R;HJP&J;%JB@+4H\'2!=!V_BM(<NP8;SD5@@D
M FD0$ \\G\3"=PFGJ4-= ;$+T6IN#)X)GCD>#=OP7Q-X-:D_)-97\_3.RO.%
M]6L.'<_122WW?+$ZE>E8>Y94FD&?QK82Y$7)]1&M0H'=MPY5 ^O1O#%M=9 .
MFQP]ATX_?&NR^O$&\@:K&7?@QI13<Q:+8\V-^J0%X :$I@D3@9\D(@Z?);(M
M(/92.*^5U'4QT*W$T.%T^OT;07THQ3EDJN4;I,M/_U)0ZC(X:Y3^"V!,K\90
M#]$DT!3'%"O]M*_5?PE5?0:/@]08S4)$1U W$H($8<J(YS-&XC@)"40^35P
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M9/$[.S/[GYW?S.S_S)Z9W9V;\[R'G.1-/I_W/O>YG^=RWY GR/. BP^T=+0
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MVLP.8KU+4MGWQ^6L-Q(D!,*H;RN/SSXQ%6^QL.HWG<;Z*"U_L.$O"ZF$1]9
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MDTRXA[L3_^.JOJADWM*N1Y_GZ%2:\^9>7D+B?;&<R.>*Z%#X^29^*/^O NQ
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M6*TPS")G-G;<%)M4U;JNO'U8N6NM4Z>9+OM6[#%EY]=)!<%38X(&K-N&?>P
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M[3V7XH!Y?Y)!N,TM<*>^F_O^O5^_>/A$3B+A0E]APQJ!=.UC(,?*^-%,D,R
MA%%\0BY?XU(=D)[H.]AH5P*+4AUR*?D:*'E;P;+"TL6BJ6@U[_YZ"/UP^=8&
M>L'U@ZQ_9GBNZA*2:0-8[!AQ)TAZ0R_)O7P"L><K!/#<O>JUZ,G(U=6'Z'BD
M]<-1=[#R]%;A_N^S[MD\EN%Z_S>CI^Y^OLRKV/!JSZCLX6A7<%OFW0)IYUSC
M[)E4QUZG(I]UVZ'#4Z_J0>O!JSD6GQDX3I\&^.R<V42V?\?K8 E/=>XJB@//
M6['YW1YJJ?M$RI@);K>KZP8LK"!>5]%%*BEYU\'ORWQ0F;V 02FCOQQTL8,4
M_1G5H>8YBQ1 Q#R0:%RD$K&XQ_Y\=I9?Z%?8"VV:$?3)N^->?]8Y=9-* 8O)
MNOEDN567C8+?Z-*13U;)O4+UZAD/[2O?]#T+S ZMRW.Q+1FV'*I.=O<P#<@?
MZTW$!#6";S?Y+=D//9MW9$/:-J)ZX=V,@.GH!2^>=T!6<[TPO@LI+878,QT:
MW3AN%VUQE:>TC9BYV8:]Z_YC)-9!T9J[*3+K+0=WA'9+GV6L9*862J>C&\S3
M!_\<".]/58Z#HZP/!CO,Q9QR(IW5IH5L/>=$\0980I?D5/\2ZFJ7MV#JVYK$
M7B\[O=V$:'J@37SW46[(HGA;FI60_H S$>R2[)\3WES-,,T;_N@BXJG/=+1/
M661DA!WGLRVMRN]8S^28?;4=BQ13IR;I\?PT+O7[O8MJTC8?4M][:V>:Z*C8
M#C6E-)5E>,^L5D*",0QP.:1#T7HSF\;=$JO4J07+WWVY9</)HMH,;K2V#.DT
MB>9D+FQXN-(-UC\J/,.J/^:L9'I_79=R32I//HWH=+O/8Y+$^AR.%FVI7-=_
M+Q;@T2DRKJEHYJTIM)*PKBLDTRL14:+JUW>,D<[=>SW5-*\V;>W<G$65:?>?
MK&<!A,MX^V50N KM<TBG.-.L5:]?1&44_>"7$M'?,?$-J,^))\'EBBQ%N&"Z
M7A!63V_BJ%G029_X%A^?Q[RXHP#?8/,LZ/DV<X>PPE=^ Z3V,O;1=PC2=(%/
MU%V7F54P<7$H,:1QU7:; D@6SR&_QK3-@@::F;#YXI?9TY>X(U,K!7SJ4@XT
MO:&_47A,4BB+ 30"5/?_=O_$_Z_C%:RGU0 6.]Y?0^.R!)TM)U,IBJ0,=HD<
M2C(;3$WG^_:[B@L6Z<)L^A2WL9 Z];JF-CHGA]7K9?!5R2;N3FN&\'8F[FG^
M0EA(R("&,A"310$(]-\56ZOZ4EKVRC:>D9?C10C4Z'W'<,>C+<0W?+K/Q;(K
M>9F%U(XHRZ%:^:W[P?]NBQ4C\#@-9T^\@:(A:A=GD5;JW2O?T[7,RE];"?CF
M,8_E(A+0)9B%[$PQ@M#[1L@"[+O.$3$E\=I,46L:"]-ZYRM$(?3V^.X<[XOF
MTH_UO4Z&.L24>@P+^0"+89+ /.\W9CDL8&EVG4.&0-T,5%E/NEI0DG+$-&0D
M<ML+\EMDK]$S:_T,V D,PZW7OV7+>8M#W>2O,W[R\_[62=Q?IS&5-KM5#D07
M6Z?SG\SG+2JU1P5*US2VP*W1W2<<WP01F4G8^RZ7G@E_4^BN_)9[ZG-L;&<P
M#:U"0,%0J[@!=R6OK7'/9^8ZX\Z>;TA5PD.F)X@N<;F,G?RU()A3.X01SDX7
MXR4>S:757]1?HG.G)G7BB^O-MRQ,S?=[;$/B8WX.$]\N:^(S%ONO6?E9\PW=
MP@ZIYLE6Y:=]+N5PN7W[ 04 WA%(QWU4R<3)A,:T;WB[V[$D=)#+U*/9]+*4
M[[B4[(AGR9Y4E_=R;O%\XP#]'(*S6RVR IVY'VFV[,L(.=1-Y7X:R6MJ&N>&
M!'BD<"^.B6_QM9JFFZ=Z,T<VLHCKWF64F"+O)XTW!( 4'<?8?"B BO%(&64!
M\X >\ [BSDL!;=ER\&D13WO>M#"LZZD-;^V6TK\U9WM<Z%:.PT?SU=68:*8+
MHD4?%WB\";VG*/.CL:JJ-Q>*+=1> 6@X'U;2#$>:U@2K:_*=?QVW*Z&O11V'
M6G#F*UYUQJH(\SLJICEYQJ,^C6F5Z!ZGC=EM.Z-8QV?%?S8:/$V</<6,S27R
MN/<[[]1:I!Z;;M<H*;;4\'$.-MKCQ-O&]:=;D!*USI+ BL7&+):.ZFLJ!I6%
M79P<W\2DP=W(UU &_)YJG$)<V-U<S+O8? D/\BO2/5J0+=I'EDW,PY7KMX#4
M[;%/G7*LA_V61LF7KH,J<H4%6KC/1=ML:*5<,/^TT5=4(_:\<[#">BC7L1/*
MW)@EO)'=G&9A:AHK;L+J, B?.;0#_]X@*!CF":.]S:6BJT:GK?8*PC<4Q#_
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M:0YGYY"I^HUB.#CTX'840O\X$J%..I0'Q9>Y&F%1'Z33J^;2;E-I3DR .^6
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M+W[[^?QA.:(EAN&!R#BB%J1 =PE:.E4-:J?4-[56NQWL:OZR7ARWHS^SI!5
MN['.+AQ%9"QC+ZLI=;N?F?6<";YCZV,343R"OC#1A!!.$LRTH:8G^&3PQK.R
MMCYT\@^-^?82LMZ#[?^Y:(0J5;3;OLW<]0Q^P5)_G!W PU+]GDJ&-P%]]14O
MK8F>7:3<5>W/A$./E2\G[=KS@2HCHG/CR)X&4K#K))+7[?6]L;=P *JVB[SI
M1LRB%QA$[-WX=ORV=L-L@W&+3-W:D5Z+T\+):/M('%<LCM=7,7P_T.(MYX=
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M,AA4TQ(VZ_FU92;(16[W"N+X@M,#&XTXP7@^ZJPZ]R#F*Q; J GPF@7&R<'
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MY_S7C/+_O_[_]9^YA+<F_QM02P,$%     @ $8";5A ,:FQE!0  C2@  !4
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MRVY]QG)> >4QH*P< <H/BX*9:\#7A)<_QZH!G*3[31?&UW+Z31O<OM 'LGG
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MW%^(LIZUSE:_B&U#Q?Y!=TOYSI;<3M@CSQ3V$!TU+T1'Y\WTA<GGMX3DR3*
MZ,SJ.2WJ(>+Q+DP\9\GS.;1S;>W]H->MK";6'RR[E?\!4$L! A0#%     @
M$8";5J:I1+R/$ $ "P\* !$              ( !     &-R9&8M,C R,S T
M,C<N:'1M4$L! A0#%     @ $8";5O2SDQ$3!   4A(  !$
M ( !OA ! &-R9&8M,C R,S T,C<N>'-D4$L! A0#%     @ $8";5KWODSV!
M!   ZQ<  !4              ( ! !4! &-R9&8M,C R,S T,C=?9&5F+GAM
M;%!+ 0(4 Q0    ( !& FU9<+[O6^ZH  /[2   4              "  ;09
M 0!C<F1F+3(P,C,P-#(W7V<Q+FIP9U!+ 0(4 Q0    ( !& FU80#&IL904
M (TH   5              "  >'$ 0!C<F1F+3(P,C,P-#(W7VQA8BYX;6Q0
M2P$"% ,4    "  1@)M6"?[3 \,#  !^%@  %0              @ %YR@$
K8W)D9BTR,#(S,#0R-U]P<F4N>&UL4$L%!@     &  8 B0$  &_. 0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
